<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6073630</article-id><article-id pub-id-type="doi">10.3390/ijms19072072</article-id><article-id pub-id-type="publisher-id">ijms-19-02072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>The Nefarious Nexus of Noncoding RNAs in Cancer </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0212-6734</contrib-id><name><surname>Anastasiadou</surname><given-names>Eleni</given-names></name><xref ref-type="aff" rid="af1-ijms-19-02072">1</xref><xref rid="c1-ijms-19-02072" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Faggioni</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="af2-ijms-19-02072">2</xref></contrib><contrib contrib-type="author"><name><surname>Trivedi</surname><given-names>Pankaj</given-names></name><xref ref-type="aff" rid="af2-ijms-19-02072">2</xref></contrib><contrib contrib-type="author"><name><surname>Slack</surname><given-names>Frank J.</given-names></name><xref ref-type="aff" rid="af1-ijms-19-02072">1</xref></contrib></contrib-group><aff id="af1-ijms-19-02072"><label>1</label>HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; <email>fslack@bidmc.harvard.edu</email></aff><aff id="af2-ijms-19-02072"><label>2</label>Department of Experimental Medicine, La Sapienza University, Viale Regina Elena 324, 0161 Rome, Italy; <email>alberto.faggioni@uniroma1.it</email> (A.F.); <email>pankaj.trivedi@uniroma1.it</email> (P.T.)</aff><author-notes><corresp id="c1-ijms-19-02072"><label>*</label>Correspondence: <email>Eanasta1@bidmc.harvard.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2018</year></pub-date><volume>19</volume><issue>7</issue><elocation-id>2072</elocation-id><history><date date-type="received"><day>04</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>The past decade has witnessed enormous progress, and has seen the noncoding RNAs (ncRNAs) turn from the so-called dark matter RNA to critical functional molecules, influencing most physiological processes in development and disease contexts. </plain></SENT>
<SENT sid="2" pm="."><plain>Many ncRNAs interact with each other and are part of networks that influence the cell transcriptome and proteome and consequently the outcome of biological processes. </plain></SENT>
<SENT sid="3" pm="."><plain>The regulatory circuits controlled by ncRNAs have become increasingly more relevant in cancer. </plain></SENT>
<SENT sid="4" pm="."><plain>Further understanding of these complex network interactions and how ncRNAs are regulated, is paving the way for the identification of better therapeutic strategies in cancer. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>noncoding RNA</kwd><kwd>miRNA</kwd><kwd>lncRNA</kwd><kwd>circRNA</kwd><kwd>ncRNA network in cancer</kwd><kwd>cancer biomarkers</kwd><kwd>RNA aided cancer therapy</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="sec1-ijms-19-02072"><title><text><SENT sid="5" pm="."><plain>1. </plain></SENT>
<SENT sid="6" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="7" pm="."><plain>A few years after the proposal by Watson and Crick of the central dogma of Molecular Biology, which suggested the unidirectional flow of genetic information from DNA to coding RNA to protein, Francis Crick’s “adaptor” hypothesis, suggested the existence of a new RNA class later discovered to be transfer-RNA (tRNA) that connects messenger RNA (mRNA) and the amino acid sequences of a protein [1]. </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, Walter Gilbert’s “The RNA World” hypothesis that describes a world made of RNA molecules, the ribozymes, that synthesize themselves, was inspired by the enzymatic activities of an RNA molecule, a ribonuclease-P (RNP) discovered in prokaryotes—Escherichia coli and the ribosomal RNA that contains a self-splicing exon discovered in eukaryotes—Tetrahymena [2,3,4]. </plain></SENT>
<SENT sid="9" pm="."><plain>Many other discoveries followed, but still most scientific efforts were biased towards coding gene discovery. </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, at that time there were few methodologies to detect the non-coding portion of our genome. </plain></SENT>
</text></p><p><text><SENT sid="11" pm="."><plain>Lineage defective-4 (lin-4) and lethal-7 (let-7) were the first microRNAs (miRNA) identified, both found in Caenorhabditis elegans [5,6]. </plain></SENT>
<SENT sid="12" pm="."><plain>This was followed by a series of studies dealing with the biogenesis and function in physiological and pathological conditions of these tiny non-coding RNA oddities. </plain></SENT>
<SENT sid="13" pm="."><plain>Now functional non-coding RNAs (ncRNAs) have become the scientific penchants since they constitute almost 60% of the transcriptional output in humans [7,8]. </plain></SENT>
<SENT sid="14" pm="."><plain>As the name suggests, the ncRNAs are not transcribed into proteins but they are remarkable regulators of important molecular processes in species ranging from Arabidopsis thaliana and Caenorhabditis elegans, to humans [9]. </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>The ncRNA family is generally divided into two main classes: housekeeping ncRNAs and regulatory RNAs. </plain></SENT>
<SENT sid="16" pm="."><plain>The housekeeping ncRNAs are involved in essential cellular functions such as ribosomal RNA (rRNA), transfer RNA (tRNA), small nucleolar RNAs (snoRNAs) and are generally expressed constitutively. </plain></SENT>
<SENT sid="17" pm="."><plain>Regulatory ncRNAs are involved in gene regulation and include small interfering RNAs (siRNAs), P-element-induced wimpy testes (piwi)-interacting RNAs (piRNAs), enhancer RNAs (eRNAs), miRNAs and the long-noncoding RNAs (lncRNAs), which include the class of circular RNAs (circRNAs) [10]. </plain></SENT>
<SENT sid="18" pm="."><plain>Their length matters when it comes to detecting and distinguishing them by RNA deep sequencing analysis so their classification is based mainly upon the number of nucleotides (nt), i.e., 20–22 nt for miRNAs and more than 200 nt for lncRNAs and the circRNAs. </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>Among the ncRNAs, miRNAs are the most studied, as a post-transcriptional gene regulator involved in many human phenomena and disease states. </plain></SENT>
<SENT sid="20" pm="."><plain>According to the last version of miRBase 21 there are a total of 28,645 hairpin precursor miRNAs that produce 35,828 mature miRNAs in 223 species [11]. </plain></SENT>
<SENT sid="21" pm="."><plain>One gene can be targeted by many miRNAs and one miRNA targets many genes-through RNA base-pairing and the outcome of this interaction is the post transcriptional inhibition of the target, or contrarily, can enhance the expression of a gene under specific cellular conditions and we will examine some paradigms in this review. </plain></SENT>
<SENT sid="22" pm="."><plain>Proteins may also influence expression of miRNAs by interfering with their biogenesis. </plain></SENT>
<SENT sid="23" pm="."><plain>As discussed below, the fact that miRNAs interact with circRNAs and lncRNAs, makes the scenario even more intriguing. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>The discovery of RNA splicing, in 1977 by Phillip A. </plain></SENT>
<SENT sid="25" pm="."><plain>Sharp and Richard J. </plain></SENT>
<SENT sid="26" pm="."><plain>Roberts and one year earlier, of the covalently closed RNA structure of viroids, both became the springboards of discovery of circRNAs, a class of lncRNAs [12,13,14]. </plain></SENT>
<SENT sid="27" pm="."><plain>They were first observed by electron microscopy, 38 years ago, in the cytoplasm of eukaryotic cells [15]. </plain></SENT>
<SENT sid="28" pm="."><plain>Later in 1991, while Janice Nigro et al. were characterizing the tumor suppressor gene Deleted in Colorectal Cancer (DCC) in rats and in humans and in neoplastic and normal cell types, they identified novel products of splicing, named “scrambled exons” derived from a trans-splicing between exons that contain complementary sequences in distant regions of their introns [16]. </plain></SENT>
<SENT sid="29" pm="."><plain>Subsequently, Capel et al. in 1993 found that Sex determining region Y (SRY) c-DNA and 5′-Rapid Amplification of cDNA Ends (RACE) clones, isolated from mouse testis had an unusual circular structure and were abundant, reaching a whopping 90% of all transcripts [17]. </plain></SENT>
<SENT sid="30" pm="."><plain>In the same year, another group identified mis-spliced, highly stable, circRNAs of the human proto-oncogene transcription factor ETS-1 [18]. </plain></SENT>
<SENT sid="31" pm="."><plain>A few years later, Zaphiropoulos et al., hypothesized that circRNAs may be formed also through an exon skipping mechanism [19]. </plain></SENT>
<SENT sid="32" pm="."><plain>In other words, the crossover point of the covalently closed loop brings together alternate 5′ donor splice sites with the 3′ splice acceptor sites of non-sequential exons, forming circRNAs. </plain></SENT>
<SENT sid="33" pm="."><plain>Their length may vary from more than 200 nt to less than 100 nt. </plain></SENT>
<SENT sid="34" pm="."><plain>Only in the last few years have we started to understand their biogenesis. </plain></SENT>
<SENT sid="35" pm="."><plain>The main reason behind this “neglect” being that they were considered cytoplasmic byproducts of splicing. </plain></SENT>
<SENT sid="36" pm="."><plain>Additionally, their identification was missed due to molecular techniques of those days, such as RNA sequencing analysis, which enriched only poly(A) RNA samples and excluded the “back spliced” circRNAs because they don’t have poly(A) tail. </plain></SENT>
<SENT sid="37" pm="."><plain>More recently, thousands of circRNAs in different species, Drosophila Melanogaster, Caenorabditis elegans, mouse and humans have been identified but little is known about their biogenesis, function and biological significance [20,21,22]. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>Overall, the previously mentioned classes of ncRNAs have critical functions in post-transcriptional oncogene and tumor suppressor regulation. </plain></SENT>
<SENT sid="39" pm="."><plain>Also, they may interact or compete with one another. </plain></SENT>
<SENT sid="40" pm="."><plain>These interactions are part of the competitive endogenous RNAs (ceRNAs) hypothesis, that includes pseudogenes which lack coding potential and can include lncRNAs, circRNA that compete for the same group of miRNA responsive elements (MRE) in the transcriptome and may have implications in tumorigenesis [23,24,25]. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>The review will start with a comparison between miRNA, circRNA and lncRNA biogenesis. </plain></SENT>
<SENT sid="42" pm="."><plain>Subsequently, we will focus on the function and regulation of the three classes of ncRNAs in cancer. </plain></SENT>
<SENT sid="43" pm="."><plain>In addition, recent insights into how interactions between the various classes of ncRNAs drive or suppress oncogenesis will be examined. </plain></SENT>
<SENT sid="44" pm="."><plain>An exploration of these topics is timely, given the flood of new publications analyzing the role of miRNAs, lncRNAs, and circRNAs in cancer [26,27]. </plain></SENT>
<SENT sid="45" pm="."><plain>Since, novel RNA based therapeutics have started to become an intergral part of clinical applications, it becomes imperative to understand the complexity of ncRNA networks to ensure that such technologies are applied to cancer treatment [28]. </plain></SENT>
</text></p></sec></SecTag><sec id="sec2-ijms-19-02072"><title><text><SENT sid="46" pm="."><plain>2. </plain></SENT>
<SENT sid="47" pm="."><plain>Comparison of the Biogenesis of Noncoding RNAs </plain></SENT>
</text></title><p><text><SENT sid="48" pm="."><plain>The exploration of different steps involved in ncRNAs biogenesis is necessary because the deregulation of the biogenesis may have implications in oncogenic pathways. </plain></SENT>
<SENT sid="49" pm="."><plain>Here, we compare the biogenesis of miRNAs (Figure 1A), circular RNAs (Figure 1B) and lncRNAs (Figure 1C), highlighting the common aspects, differences as well as some exceptions of noncanonical ncRNAs, that may follow different pathways during their final maturation. </plain></SENT>
<SENT sid="50" pm="."><plain>A broader understanding of biogenetic mechanisms will provide also the right tools to understand ncRNA dependent tumorigenesis better and consequently devise better therapeutic tools. </plain></SENT>
</text></p><sec id="sec2dot1-ijms-19-02072"><title><text><SENT sid="51" pm="."><plain>2.1. </plain></SENT>
<SENT sid="52" pm="."><plain>Similarities and Differences in Biogenesis of ncRNAs </plain></SENT>
</text></title><sec id="sec2dot1dot1-ijms-19-02072"><title><text><SENT sid="53" pm="."><plain>2.1.1. </plain></SENT>
<SENT sid="54" pm="."><plain>Transcription, Capping and Adenylation </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>Similarities: Generally, ncRNAs are generated in the nucleus, transcribed by polymerase II (Pol II) giving rise to a long, usually hundreds of kilobases 5′ capped and 3′ polyadenylated transcript, the precursor mRNA (pre-mRNA) (Figure 1A–C). </plain></SENT>
<SENT sid="56" pm="."><plain>But within the lncRNAs the predominant form may be monoexonic and nonpolyadenylated, particularly in the case of eRNAs and the promoter-associated upstream antisense lncRNAs (uaRNAs) [29]. </plain></SENT>
<SENT sid="57" pm="."><plain>The ncRNA genes are interspersed throughout the genome, and can be intergenic, or intronic. </plain></SENT>
</text></p><p><text><SENT sid="58" pm="."><plain>miRNAs: Intergenic miRNAs (i.e., lin-4 and let-7) are independently transcribed, in contrast with the intronic miRNAs (i.e., miR-26) that reside in their host gene and are transcribed from the same promoter as the host gene itself [30,31]. </plain></SENT>
<SENT sid="59" pm="."><plain>Furthermore, intronic miRNAs need RNA splicing components to be spliced out from the transcript of their host gene and become mature miRNA. </plain></SENT>
<SENT sid="60" pm="."><plain>Whether miRNAs are intergenic or intronic, they can be co-transcribed from a single transcription unit, named polycistron. </plain></SENT>
<SENT sid="61" pm="."><plain>A known example is the polycistronic miR-17-92 cluster, which contains six precursor miRNAs within about 1 kb on chromosome 13 [32]. </plain></SENT>
</text></p><p><text><SENT sid="62" pm="."><plain>CircRNAs: They are divided in intronic (ciRNAs), exonic circRNAs and exonic-intronic, (ElciRNAs) in which exons are circularized with introns (Figure 1B). </plain></SENT>
<SENT sid="63" pm="."><plain>[33,34,35]. </plain></SENT>
<SENT sid="64" pm="."><plain>It is not yet completely clear whether circRNAs are generated co-transcriptionally (while the introns are being spliced out from the pre-mRNA) or post-transcriptionally [36]. </plain></SENT>
<SENT sid="65" pm="."><plain>But experimental evidence in the yeast Saccharomyces cerevisiae and in the nuclear extract of the human cell line HeLa suggest that circRNAs are generated by an inverse splicing mechanism of the introns mediated by the spliceosome, giving rise to 3′-5′ back splice circRNA [37]. </plain></SENT>
<SENT sid="66" pm="."><plain>The latter may be also formed through an exon skipping mechanism as it has been demonstrated in cytochrome P-450 2C18 transcript, which is expressed in the human epidermis and in the Androgen-binding protein (ABP) gene in rat testis [19]. </plain></SENT>
<SENT sid="67" pm="."><plain>ElciRNAs are also derived from a backsplice mechanism driven by intron-pairing. </plain></SENT>
<SENT sid="68" pm="."><plain>The ciRNAs instead, have a 2′-5′ junction and form a lariat RNA [38]. </plain></SENT>
<SENT sid="69" pm="."><plain>All three classes of circRNAs are derived from the non-polyadenylated fraction of RNA (poly(A)−). </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>LncRNAs: Based on their location in the genome, lncRNAs are long intergenic (lincRNAs), between two adjacent genes or intronic, within the intron of a protein-coding gene (Figure 1C). </plain></SENT>
<SENT sid="71" pm="."><plain>Generally, a very common characteristic of lncRNAs is the bidirectional or divergent transcription generated by Pol II, from shared protein-coding gene promoters [39]. </plain></SENT>
<SENT sid="72" pm="."><plain>Divergent transcription of lncRNAs is enhanced by the chromatin remodeling complex, SWItch/Sucrose Non-Fermentable (SWI/SNF) and is inhibited by chromatin assembly factor-1 (CAF1) (further details of lncRNA biogenesis are reviewed by Quinn et al. [40]). </plain></SENT>
<SENT sid="73" pm="."><plain>It is also worthy to mention that DICER1, a protein that aids miRNA biogenesis, along with the transcription factor c-myc, induces lncRNA transcription from divergently transcribed protein-coding genes [41]. </plain></SENT>
<SENT sid="74" pm="."><plain>Contrarily, four chromatin remodeling factors inhibit lncRNA transcription and this inhibition consequently regulates mRNA gene expression [42]. </plain></SENT>
</text></p><p><text><SENT sid="75" pm="."><plain>Exceptions within the group of miRNAs: Recently published reports suggest that some intronic miRNAs, like miR-93, may also have their own promoters [43]. </plain></SENT>
<SENT sid="76" pm="."><plain>Contrarily, intergenic or exonic miRNAs, like let-7c, are transcribed from promoters that are in the opposite direction of the gene. </plain></SENT>
<SENT sid="77" pm="."><plain>Not only Pol II but also RNA polymerase III (Pol III) can transcribe almost 20% of the human miRNAs because of the presence of Arthrobacter luteus restriction endonuclease (Alu) transposable elements upstream of miRNA promoters. </plain></SENT>
<SENT sid="78" pm="."><plain>A genomic analysis of 42 miRNAs, in almost 100 kilobase pairs (kbp) long fragment in the human chromosome 19 miRNA cluster (C19MC), had Alu sequences upstream of their promoters and were transcribed by Pol III [44]. </plain></SENT>
</text></p></sec><sec id="sec2dot1dot2-ijms-19-02072"><title><text><SENT sid="79" pm="."><plain>2.1.2. </plain></SENT>
<SENT sid="80" pm="."><plain>Processing of ncRNAs </plain></SENT>
</text></title><p><text><SENT sid="81" pm="."><plain>Similarities: The pre-mRNA transcript is processed by the spliceosome. </plain></SENT>
<SENT sid="82" pm="."><plain>While for circRNAs and lncRNAs, this is the main processing mechanism, it is not the case for every miRNA. </plain></SENT>
<SENT sid="83" pm="."><plain>There are non-canonical miRNAs, the mirtrons [45], which are found in introns at the exon junction site of the pre-mRNA, and are spliceosome-dependent. </plain></SENT>
<SENT sid="84" pm="."><plain>In this section, we will also describe some exemptions to the canonical processing of lncRNAs. </plain></SENT>
</text></p><p><text><SENT sid="85" pm="."><plain>miRNAs: In the nucleus, the microprocessor complex of the RNA-binding protein Di George Syndrome Critical Region Gene 8 (DGCR8) together with the RNase III enzyme Drosha, binds and cleaves the basal stem of pri-miRNAs to liberate the stem-loop precursor miRNA (pre-miRNA) of about 65 nucleotides (nt). </plain></SENT>
<SENT sid="86" pm="."><plain>Drosha contains a tandem of RNase III domains (RIIIDs) and a double strand (ds)-RNA binding domain and each domain has a specialized action to cleave accurately at the 11th bp of the hairpin away from the basal single strand junction of the 5′ strand and 22 bp from the apical junction. </plain></SENT>
<SENT sid="87" pm="."><plain>Also, the 3′ strand side of the hairpin is cleaved. </plain></SENT>
<SENT sid="88" pm="."><plain>These Drosha cleavages create a precise 2nt overhang from the 3′ side of the stem loop (Figure 1A). </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>Pri-miRNA, after being processed into a pre-miRNA is exported from the nucleus into the cytoplasm by Exportin 5 (EXP5) (encoded from XPO5 gene), supported by a Ran-GTP-dependent mechanism. </plain></SENT>
<SENT sid="90" pm="."><plain>Furthermore, EXP5 protects pre-miRNA from nucleolytic attack in the nucleus and enables the interaction between the stem loop and the inner surface. </plain></SENT>
<SENT sid="91" pm="."><plain>Once in the cytoplasm, the Pre-miRNA loop is cleaved by the RNase III Dicer and HIV-1 TAR RNA binding protein (TRBP) to form a mature RNA duplex of almost 22 nucleotides (nt) long with a 3′-end having a two nucleotides overhang. </plain></SENT>
<SENT sid="92" pm="."><plain>The 5′ strand of the RNA duplex or rarely the 3′ strand which contains thermodynamically unstable nucleotides, will be selected as the guide strand, which will become the mature miRNA [46]. </plain></SENT>
<SENT sid="93" pm="."><plain>This thermodynamic instability can facilitate the unwinding of the duplex by helicases, such as Gemin3 or RCK/p54 [47,48]. </plain></SENT>
<SENT sid="94" pm="."><plain>The guide strand is selected by one of the four Argonaute (AGO) proteins due to the presence of Uracil (U) at nucleotide position 1 or Adenosine (A) at the 5′ end of the RNA duplex and loaded together with the passenger strand in the RNA induced silencing complex (RISC) [49,50]. </plain></SENT>
<SENT sid="95" pm="."><plain>Subsequently, the passenger strand is cleaved and generally degraded, but may also be maintained or activated [51]. </plain></SENT>
<SENT sid="96" pm="."><plain>The 22 nt long mature miRNA contains the “seed sequence” (2 to 7 nucleotides) at the 5′ end for target recognition. </plain></SENT>
<SENT sid="97" pm="."><plain>Likewise, for the target recognition, complementarity at position 8 and conserved adenosines flanking the seed complementary sites in mRNAs are critical [52,53]. </plain></SENT>
<SENT sid="98" pm="."><plain>The interaction between the seed sequence and the 3′UTR of the target mRNA impair the translation and stability of the mRNA transcripts and this interaction occurs not only in the cytoplasm but occasionally also in the nucleus [54,55]. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>Exceptions in processing of miRNAs: In a Drosha-deleted human cell line, the canonical miRNA production was completely abolished except for a few non-canonical miRNAs (mirtrons) that were Drosha-independent and located in the introns of the mRNA encoding host genes [56]. </plain></SENT>
<SENT sid="100" pm="."><plain>This indicates that Drosha processing of the canonical miRNAs is indispensable for their maturation. </plain></SENT>
<SENT sid="101" pm="."><plain>The pre-miR-451 is the only exception so far of a pre-miRNA that escapes Dicer processing, by binding directly to Ago2 [57]. </plain></SENT>
<SENT sid="102" pm="."><plain>miRNAs not associated with RISC are detected in the cytoplasm as miRNA-mRNA duplexes not bound to Agos. </plain></SENT>
<SENT sid="103" pm="."><plain>Another exception is that also the 3′-end of a mature miRNA contributes to target recognition [58,59,60]. </plain></SENT>
</text></p><p><text><SENT sid="104" pm="."><plain>CircRNAs: A chromatin-bound RNA nascent sequencing dataset showed that circRNA and canonical splicing pre-mRNA antagonize each other and this event is tissue specific and conserved in Drosophila and humans [20]. </plain></SENT>
<SENT sid="105" pm="."><plain>The canonical spliceosomal machinery produces backspliced pre-mRNA using cis regulating mechanisms such as long bordering intronic complementary sequences, the Alu repeats in humans [61,62]. </plain></SENT>
<SENT sid="106" pm="."><plain>An example of a human gene locus that contains Alu repeats is the Homeodomain Interacting Protein Kinase 3 (HIPK3) locus circularization. </plain></SENT>
<SENT sid="107" pm="."><plain>Trans regulating factors, are also involved, like the splicing factor Muscleblind (MBL), that promotes circRNA biogenesis in Drosophila and it is conserved also in mice and in humans [20]. </plain></SENT>
<SENT sid="108" pm="."><plain>Interestingly, MBL not only binds to its own exon but also regulates its own circularization. </plain></SENT>
<SENT sid="109" pm="."><plain>The circularization efficiency seems to be inversely correlated with the exon length and the intronic complementary sequences which promote circularization [63]. </plain></SENT>
</text></p><p><text><SENT sid="110" pm="."><plain>Importantly, ciRNAs processing depends on consensus RNA sequences next to the 5′ splice site and branch point that probably makes them resistant to debranching enzymes [64]. </plain></SENT>
<SENT sid="111" pm="."><plain>They are localized in the nucleus and enhance transcription of their parental genes [38]. </plain></SENT>
<SENT sid="112" pm="."><plain>ElciRNAs are also localized in the nucleus and interact with small nuclear RNA (snRNA), like U1, that both interact with Pol II at the promoters of parental genes and activate their transcription [33]. </plain></SENT>
<SENT sid="113" pm="."><plain>CircRNAs are transported in the cytoplasm and are very stable because they lack 3′ and 5′ ends and consequently are protected from any exonuclease activity [35]. </plain></SENT>
</text></p><p><text><SENT sid="114" pm="."><plain>LncRNAs: The processing of lncRNAs is similar to the pre-mRNAs processing but there are some exceptions: Upon Pol II transcription, some of the newly formed lncRNAs, like MALAT1 (metastasis- associated lung adenocarcinoma transcript 1) and NEAT (nuclear enriched abundant transcript 1), undergo a particular type of the tRNA-like structure processing at their 3′-ends. </plain></SENT>
<SENT sid="115" pm="."><plain>The tRNA-like structure at the 3′-end is cleaved by the ribonuclease P (RNaseP) and generates tRNA-like smallRNA products and a stable 3’ triple helix containing lncRNAs. </plain></SENT>
<SENT sid="116" pm="."><plain>The tRNA-like smallRNAs cleaved from NEAT are unstable whereas those derived from MALAT1 are stable and cytoplasmic [65]. </plain></SENT>
<SENT sid="117" pm="."><plain>Another exception is the formation of hybrid molecules such as lnc-pri-miRNA and sno-lncRNAs. </plain></SENT>
<SENT sid="118" pm="."><plain>It has been estimated that 17.5% of miRNAs are located in lncRNAs. </plain></SENT>
<SENT sid="119" pm="."><plain>Examples of these hybrids are: lnc-pri-miR-21 and lnc-pri-miR-122 [66]. </plain></SENT>
<SENT sid="120" pm="."><plain>The microprocessor complex, that generates the pre-miRNAs, cleaves the lnc-pri-miRNA molecule and gives rise to an unstable non polyA lncRNA and a pre-miRNA so the cell can express high levels of miRNA without competing with the transcription of the host gene, the polyA lncRNA [66]. </plain></SENT>
<SENT sid="121" pm="."><plain>The sno-RNA related lncRNAs (sno-lncRNAs) are generated from introns between two sno-RNAs [67]. </plain></SENT>
<SENT sid="122" pm="."><plain>After splicing sno-lncRNAs can be produced by either box C/D or box H/ACA snoRNAs and contain snoRNA flanking sequences but deprived of a 3′ poly(A) tail and 5′ cap [68]. </plain></SENT>
<SENT sid="123" pm="."><plain>Their functional role in cancer is discussed in Section 3.3, dealing with lncRNAs in cancer. </plain></SENT>
</text></p></sec></sec></sec><sec id="sec3-ijms-19-02072"><title><text><SENT sid="124" pm="."><plain>3. </plain></SENT>
<SENT sid="125" pm="."><plain>Functions of ncRNAs in Cancer </plain></SENT>
</text></title><sec id="sec3dot1-ijms-19-02072"><title><text><SENT sid="126" pm="."><plain>3.1. </plain></SENT>
<SENT sid="127" pm="."><plain>Deregulation of miRNA Expression in Cancer </plain></SENT>
</text></title><sec id="sec3dot1dot1-ijms-19-02072"><title><text><SENT sid="128" pm="."><plain>3.1.1. </plain></SENT>
<SENT sid="129" pm="."><plain>miRNA Signatures in Cancer </plain></SENT>
</text></title><p><text><SENT sid="130" pm="."><plain>Many types of cancers are characterized by a specific miRNA signature [69,70,71]. </plain></SENT>
<SENT sid="131" pm="."><plain>For example, miR-155/BIC precursor was found to be highly expressed in pediatric Burkitt lymphoma (BL), while reduced levels of miR-143 and miR-145 were found in the adenomatous and cancer stages of colorectal neoplasia [72,73]. </plain></SENT>
<SENT sid="132" pm="."><plain>Two different miRNA signatures characterize Chronic Lymphocytic Leukemia (CLL) samples and were associated with the presence or absence of mutations. </plain></SENT>
<SENT sid="133" pm="."><plain>In addition, significant differences were observed in miRNA expression in CLL versus normal CD5+ B cells [74]. </plain></SENT>
<SENT sid="134" pm="."><plain>Furthermore, increased levels of oncomiRs miR-21, miR-155 and the miR-17-92 were found in several lymphomas and leukemia and conversely the expression of tumor suppressors let-7 and miR-34 is frequently decreased [75,76,77,78,79,80,81,82]. </plain></SENT>
<SENT sid="135" pm="."><plain>Profiling of 217 mammalian miRNAs differentially expressed in 334 human samples across different types of cancers through a bead-based flow cytometric method and validated by Northern blots, showed that miRNAs not merely characterize a type of cancer, but their expression pattern reflects the developmental history of human cancers [70]. </plain></SENT>
<SENT sid="136" pm="."><plain>Furthermore, miRNA expression seems higher in normal rather than in tumor tissues. </plain></SENT>
<SENT sid="137" pm="."><plain>This suggests that the impaired cellular differentiation associates with a decrease in miRNA expression. </plain></SENT>
<SENT sid="138" pm="."><plain>miRNA signature in multiple human cancers reveal the possibility to classify many tumor types and their differentiation stage based on a specific miRNA expression and their potential use in cancer diagnosis and eventually also in cancer treatment. </plain></SENT>
</text></p><p><text><SENT sid="139" pm="."><plain>One of the known miRNA signatures is the high expression of miR-155 and miR-21 in hematological malignancies and especially in lymphomagenesis. </plain></SENT>
<SENT sid="140" pm="."><plain>In the Eμ-miR155 transgenic mice, under the control of a VH promoter-Ig heavy chain Eμ enhancer, miR-155 activated the pre-B stage of differentiation [83]. </plain></SENT>
<SENT sid="141" pm="."><plain>When its expression was induced, the mice developed leukemia and high-grade lymphoma. </plain></SENT>
<SENT sid="142" pm="."><plain>In another study, two mice lymphoma models, miR-21 and miR-155 causes recombination- locus of X-over P1 (Cre-loxP) tetracycline-controlled knock-in mouse, were developed [76]. </plain></SENT>
<SENT sid="143" pm="."><plain>These mice upon induction of miR-21 and miR-155, after three months rearing in the absence of doxycycline food, developed acute lymphadenopathy and splenomegaly. </plain></SENT>
<SENT sid="144" pm="."><plain>The same mice when fed back with doxycycline food, completely recovered from all disease symptoms and the lymphadenopathy regressed. </plain></SENT>
<SENT sid="145" pm="."><plain>Anti-miR-21 and anti-miR-155 were placed in nanoparticles composed of (polylactic-co-glycolicacid) (PLGA) and the Peptide nucleic acid (PNA) with a low pH-induced transmembrane structure (pHLIP) and were successfully delivered to the mice and reduced the tumor growth. </plain></SENT>
<SENT sid="146" pm="."><plain>This study opened a new field of RNA-based therapeutic treatment of lymphoma. </plain></SENT>
<SENT sid="147" pm="."><plain>In a recent study, miR-21 encapsulated in tumor-penetrating nanocomplexes (TPN) was successfully delivered to the tumor site for pancreatic ductal adenocarcinoma (PDAC), on patient-derived-xenograft (PDX) samples and patient-derived-organoids (PDO) [84]. </plain></SENT>
<SENT sid="148" pm="."><plain>These findings demonstrate a new paradigm that paves the way in the use of antimiRs as anticancer drugs. </plain></SENT>
</text></p></sec><sec id="sec3dot1dot2-ijms-19-02072"><title><text><SENT sid="149" pm="."><plain>3.1.2. </plain></SENT>
<SENT sid="150" pm="."><plain>Cellular miRNAs Interact with Viral Proteins </plain></SENT>
</text></title><p><text><SENT sid="151" pm="."><plain>miRNAs interact with viral proteins in diverse types of virally associated cancers. </plain></SENT>
<SENT sid="152" pm="."><plain>Interestingly, about 15–20% of cancers have infectious etiology. </plain></SENT>
<SENT sid="153" pm="."><plain>Indeed, a broad miRNA profiling of different viral serotypes suggested that Human Papilloma virus (HPV)-16 and -18 can both upregulate certain common miRNAs like miR-25, -92a, -93, -106b, both in tumor tissues as well as in, in vitro infected foreskin derived and vaginal keratinocytes [85]. </plain></SENT>
<SENT sid="154" pm="."><plain>Furthermore, miR-122 is highly expressed in hepatocytes, targets the 5′ end of the genomic RNA of Hepatitis C Virus (HCV) and induce the stability and proliferation of HCV [86]. </plain></SENT>
<SENT sid="155" pm="."><plain>Many viruses also have evolved viral orthologues of oncogenic cellular miRNA with identical seed sequences. </plain></SENT>
<SENT sid="156" pm="."><plain>Oncogenic miR-155 is a case in point, viral orthologues of which, are found in genomes of KSHV and Marek’s disease virus (MDV) [87]. </plain></SENT>
<SENT sid="157" pm="."><plain>Epstein-Barr virus (EBV) is associated with a wide variety of cancers and contributes to cellular transformation in two ways, either by employing its own miRNA (V-miRNAs) or by altering cellular miRNA expression through virally encoded latent growth transformation proteins, EBNA2 and LMP1 [88,89,90]. </plain></SENT>
<SENT sid="158" pm="."><plain>The virally encoded nuclear protein, EBNA2, essential for EBV’s transforming potential, was shown to simultaneously increase miR-21, a noted oncomiR and downregulate miR-146a, which is considered a tumor suppressive miRNA [91,92]. </plain></SENT>
<SENT sid="159" pm="."><plain>LMP1 on the other hand, induces miR-155 expression [93]. </plain></SENT>
<SENT sid="160" pm="."><plain>The same viral protein, when expressed at high level increases expression of miR-29b to downregulate TCL1 expression [94]. </plain></SENT>
<SENT sid="161" pm="."><plain>miR-21 is consistently increased by EBV across several different types of tumors like BL and plasma cell derived malignancies [95,96]. </plain></SENT>
<SENT sid="162" pm="."><plain>We have recently shown that EBNA2 can increase immune checkpoint protein PD-L1 by downregulating miR-34a [28]. </plain></SENT>
<SENT sid="163" pm="."><plain>Cellular miRNA alteration can also be used as a biomarker of EBV. </plain></SENT>
<SENT sid="164" pm="."><plain>For example, the expression of specific miRNAs was either increased or decreased in the context of EBV’s presence in DLBCLs [97]. </plain></SENT>
<SENT sid="165" pm="."><plain>Overall, virus interaction with host cell miRNA indicate another level of viral manipulation that helps the propagation and survival of the virus and the knowledge of this interaction has implications in virally associated tumor therapies. </plain></SENT>
</text></p></sec><sec id="sec3dot1dot3-ijms-19-02072"><title><text><SENT sid="166" pm="."><plain>3.1.3. </plain></SENT>
<SENT sid="167" pm="."><plain>Defective Biogenesis of miRNAs </plain></SENT>
</text></title><p><text><SENT sid="168" pm="."><plain>Deregulated expression of miRNAs in different cancer types may also reflect a defective miRNA biogenesis mechanism and maturation. </plain></SENT>
<SENT sid="169" pm="."><plain>Dicer knock-out mouse embryonic cells failed to differentiate and low levels of Dicer and Drosha expression are associated with advanced tumor stage of ovarian cancer and poor response to chemotherapy [98,99]. </plain></SENT>
<SENT sid="170" pm="."><plain>Contrarily, overexpression of Dicer was detected in prostate and lung cancer [100,101]. </plain></SENT>
<SENT sid="171" pm="."><plain>Likewise, high expression of Drosha was found in cervical squamous cell carcinoma (SCC) which, consequently altered the miRNA profile, and the cell proliferation, invasion and metastasis were enhanced [102]. </plain></SENT>
<SENT sid="172" pm="."><plain>A whole exome sequencing of 44 Wilms tumors, identified missense mutations in the RNase IIIB domains of Dicer1 and Drosha [103]. </plain></SENT>
<SENT sid="173" pm="."><plain>These mutations impaired the expression of let-7 family as well as other tumor suppressor miRNAs, which derived from the 5′ arm of the miRNA hairpins and this finding could explain one of the main mechanisms that induce the formation of Wilms tumors. </plain></SENT>
<SENT sid="174" pm="."><plain>Additionally, the role of Exportin 5 (XPO5) in tumor progression has been under investigation. </plain></SENT>
<SENT sid="175" pm="."><plain>Decreased levels of XPO5 protein expression has been linked with a worst prognosis of renal and esophageal tumors, whereas a better prognosis has been seen in multiple myeloma, liver cancer and in non-small-cell lung cancer [104,105]. </plain></SENT>
<SENT sid="176" pm="."><plain>Recently, the role of XPO5 has been investigated in liver cancer [106]. </plain></SENT>
<SENT sid="177" pm="."><plain>Phosphorylation of XPO5 by ERK inhibits nuclear export of pre-miR-122 in the cytoplasm. </plain></SENT>
<SENT sid="178" pm="."><plain>Therefore, maturation of miR-122 is impaired and cannot target septin-9 (SEPT9) oncogene. </plain></SENT>
<SENT sid="179" pm="."><plain>Expression of this oncogene was found increased and caused Taxol resistance, a drug used in liver cancer therapy. </plain></SENT>
<SENT sid="180" pm="."><plain>The discovery of ERK-XPO5 pathway implies a novel therapeutic strategy towards XPO5 activation. </plain></SENT>
<SENT sid="181" pm="."><plain>Besides the evidence that miRNA biogenesis perturbation leads to tumorigenesis, a plethora of other mechanisms are involved as well. </plain></SENT>
<SENT sid="182" pm="."><plain>Importantly, it has been shown that 98 of 186 miRNA genes are found in fragile sites and in cancer associated genomic regions [107]. </plain></SENT>
</text></p></sec></sec><sec id="sec3dot2-ijms-19-02072"><title><text><SENT sid="183" pm="."><plain>3.2. </plain></SENT>
<SENT sid="184" pm="."><plain>circRNAs in Cancer </plain></SENT>
</text></title><p><text><SENT sid="185" pm="."><plain>Thousands of circRNAs, 2000 in human, 1900 in mouse and 700 in Caenorhabditis elegans, are detected and conserved in different tissues and developmental stages [108]. </plain></SENT>
<SENT sid="186" pm="."><plain>Furthermore, 25 thousand circRNAs were identified in human fibroblasts, by high-throughput sequencing analysis of ribosome-depleted and exonuclease treated RNA libraries [109]. </plain></SENT>
<SENT sid="187" pm="."><plain>Interestingly, they are very stable in the intracellular milieu exhibiting a half-life of more than 48 h, comparing to that of mRNAs of only 10 h or less and are also resistant to RNA exonucleases [110,111]. </plain></SENT>
</text></p><p><text><SENT sid="188" pm="."><plain>Because of the broad expression of circRNAs in various tissues and developmental stages in diverse species, a computational analysis of circRNAs, miRNAs and mRNAs interactions has been performed in different diseases, that brought to the development of Circ2Traits database [112]. </plain></SENT>
<SENT sid="189" pm="."><plain>This database comprises 1953 predicted human circRNAs datasets, the miR2disease dataset and human miRNAs associated with 174 different human diseases [113]. </plain></SENT>
<SENT sid="190" pm="."><plain>The authors of Circ2Traits database not only identified 49 circRNAs, containing one or more single-nucleotide polymorphism (SNP) in their Ago-binding sites, but they have also included the genome-wide association study (GWAS) to create a link between circRNAs associated with disease related SNPs and have predicted the circRNA interaction with disease associated miRNAs. </plain></SENT>
<SENT sid="191" pm="."><plain>From their study and Circ2Traits database, a circRNAs association with gastric and prostate cancer and with other diseases was unraveled. </plain></SENT>
</text></p><p><text><SENT sid="192" pm="."><plain>Another algorithm, circRNADb, includes 32,914 human exonic circRNAs collected from the literature and gives genomic information about circRNAs as well as internal ribosome entry site (IRES), open reading frame (ORF) and references [114]. </plain></SENT>
<SENT sid="193" pm="."><plain>CircBase, provides scripts to identify circRNAs in sequencing data [115]. </plain></SENT>
<SENT sid="194" pm="."><plain>The development of such algorithms reveals an increasing interest to explore interacting networks of circRNAs with miRNAs in disease and particularly in cancer. </plain></SENT>
</text></p><p><text><SENT sid="195" pm="."><plain>A ribosomal-depleted RNA sequencing analysis identified 27,000 circRNAs in six human normal tissues and seven human cancers tissues [116]. </plain></SENT>
<SENT sid="196" pm="."><plain>The most abundant circRNA identified in these tumors was circHIPK3 produced from exon 2 of the HIPK3 gene, that can bind and inhibit nine tumor suppressor miRNAs, among them miR-124. </plain></SENT>
<SENT sid="197" pm="."><plain>When circHIPK3 was overexpressed in HEK-293T cells, the growth inhibitory effect of miR-124 was alleviated. </plain></SENT>
<SENT sid="198" pm="."><plain>The above findings indicate that circRNAs act as oncogenes, by sequestering tumor suppressor miRNAs. </plain></SENT>
</text></p><p><text><SENT sid="199" pm="."><plain>A computational analysis of ribo-minus RNA extracted from human umbilical venous endothelial cells (HUVEC) under hypoxic conditions, identified endothelial circRNAs [117]. </plain></SENT>
<SENT sid="200" pm="."><plain>One of these circRNAs is cZNF292. </plain></SENT>
<SENT sid="201" pm="."><plain>When this circRNA was silenced, the tube formation and spheroid sprouting were reduced in HUVEC cells, indicating that cZNF292 has proangiogenic activities in vitro. </plain></SENT>
<SENT sid="202" pm="."><plain>Moreover, no sponging effect for any miRNA was reported by high-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation (HITS-CLIP). </plain></SENT>
<SENT sid="203" pm="."><plain>This is the first study, which links a circRNA with one of the hallmarks of tumorigenesis, namely hypoxia. </plain></SENT>
</text></p></sec><sec id="sec3dot3-ijms-19-02072"><title><text><SENT sid="204" pm="."><plain>3.3. </plain></SENT>
<SENT sid="205" pm="."><plain>lncRNA in Cancer </plain></SENT>
</text></title><p><text><SENT sid="206" pm="."><plain>The expression of lncRNAs seems to be more specific than mRNAs in different cell types, tissues in developmental stages as well as in diseases including cancer [118,119,120,121]. </plain></SENT>
<SENT sid="207" pm="."><plain>As it was previously mentioned for miRNAs, also lncRNAs may act either as tumor-suppressors or promote carcinogenesis [122]. </plain></SENT>
<SENT sid="208" pm="."><plain>The lncRNAs are localized in the nucleus and in cytoplasm. </plain></SENT>
<SENT sid="209" pm="."><plain>They act in trans or in cis with transcription factors, miRNAs or other ncRNAs (sno-RNAs) and chromatin DNA. </plain></SENT>
<SENT sid="210" pm="."><plain>For example, enhancer-associated lncRNAs (eRNAs) regulate in trans other neighboring genes, in the nucleus, during their transcription or post transcriptionally. </plain></SENT>
<SENT sid="211" pm="."><plain>One known example is the regulation of HOX genes (HOTAIR and HOXA), a group of genes which controls the body orientation, that is, head-to-tail axis of animals, by the antisense RNA, HOXA transcript at the distal tip, (HOTTIP), which in turn is transcribed by the 5′ end of the HOXA gene. </plain></SENT>
<SENT sid="212" pm="."><plain>The lincRNA, HOTTIP forms a chromosomal loop, which brings together HOXA distant genes and activates their transcription [123]. </plain></SENT>
<SENT sid="213" pm="."><plain>This lincRNA is also known to be highly expressed across different types of cancers and associated with distal metastasis, high tumor stage and therefore may serve as a novel biomarker of poor prognosis [124]. </plain></SENT>
</text></p><p><text><SENT sid="214" pm="."><plain>A cis acting lncRNA in the nucleus is CCAT1-L (Colorectal Cancer Associated Transcript 1-the long isoform). </plain></SENT>
<SENT sid="215" pm="."><plain>It is transcribed upstream of the oncogene MYC enhancer region and promotes chromosome looping that brings into proximity the super enhancer to the MYC promoter and induces enhanced transcription of MYC [125]. </plain></SENT>
<SENT sid="216" pm="."><plain>Furthermore, CCAT1-L specifically interacts with the chromatin CCCTC-binding factor (CTCF) to maintain and promote the chromatin interaction between the MYC promoter and its enhancers in CRC cell lines (Figure 2A). </plain></SENT>
</text></p><p><text><SENT sid="217" pm="."><plain>LncRNAs also deregulate the expression of transcriptional regulators through interaction with the Polycomb Repressive complex 1 and -2 (PRC1,-2) which modifies chromatin histones by promoting histone H3 lysine 27 trimethylation (H3K27me3) [126,127]. </plain></SENT>
<SENT sid="218" pm="."><plain>An example is the highly expressed lincRNA Up-regulated in bladder cancer 1 (linc-UBC1), which is associated with lymph node metastasis and poor prognosis in bladder cancer (BC) patients. </plain></SENT>
<SENT sid="219" pm="."><plain>Linc-UBC1 resides in the nucleus where it interacts with two proteins of the PRC2 complex, Enhancer of Zeste Homolog 2 (EZH2) and Suppressor of Zeste 12 Homolog (SUZ12). </plain></SENT>
<SENT sid="220" pm="."><plain>It suppresses in trans, the PRC2 target genes BMP2, KLF4 and HOXA5 leading to increased proliferation of BC human cell lines [128]. </plain></SENT>
<SENT sid="221" pm="."><plain>Like linc-UBC1, lincRNA HOTAIR also interacts with PRC2 components SUZ12 and EZH2 to promote tumor progression in breast cancer, gastrointestinal cancer and hepatocellular carcinoma [129,130,131]. </plain></SENT>
</text></p><p><text><SENT sid="222" pm="."><plain>Another lncRNA that works as molecular scaffold in the nucleus, bringing together regulatory proteins, is X-inactive specific transcript (XIST). </plain></SENT>
<SENT sid="223" pm="."><plain>It is required for the transcriptional silencing of one X-chromosome in female mammals, but its high expression also promotes invasion and cell proliferation in human glioblastoma stem cells, gastric cancer (GC) tissues and human GC cell lines [132,133,134]. </plain></SENT>
<SENT sid="224" pm="."><plain>Recently, a box H/ACA small nucleolar RNA (snoRNA)-ended lncRNA SLERT (snoRNA-ended lncRNA enhances pre-ribosomal RNA transcription) has been identified [135]. </plain></SENT>
<SENT sid="225" pm="."><plain>The presence of sno-RNAs at both ends of SLERT is necessary for the biogenesis and translocation for SLERT to the nucleolus, where it controls rRNA transcription by Pol I and promotes the pre-rRNA transcription through interaction with DDX21, a DEAD-box RNA helicase involved in the ribosome biogenesis. </plain></SENT>
<SENT sid="226" pm="."><plain>SLERT inhibits the inhibitory effect of DDX1 on Pol I, leading to enhanced transcription of rRNA, which is associated with uncontrolled transformed mammalian cell proliferation [136]. </plain></SENT>
<SENT sid="227" pm="."><plain>Deletion of SLERT impairs pre-rRNA transcription and rRNA production, leading to decreased tumorigenesis [135]. </plain></SENT>
<SENT sid="228" pm="."><plain>Among the nuclear lncRNAs, MALAT1 (also known as NEAT-2) is evolutionary highly conserved in mammals. </plain></SENT>
<SENT sid="229" pm="."><plain>It regulates gene expression and alternative splicing and has been linked to lung cancer metastasis and to other types of human cancers [137]. </plain></SENT>
<SENT sid="230" pm="."><plain>As mentioned before, there are lncRNAs, which reside in the cytoplasm where they exert their regulatory roles. </plain></SENT>
<SENT sid="231" pm="."><plain>One of these cytoplasmic lncRNAs is the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) Interacting LncRNA (NKILA). </plain></SENT>
<SENT sid="232" pm="."><plain>It binds to NF-κB/IκB complex and inhibits NF-κB activation, known to be involved in development and progression of human cancer. </plain></SENT>
<SENT sid="233" pm="."><plain>A negative feedback loop mechanism explains the initial induction of NKILA by NF-κB followed by NKILA inhibition of NF-κB. </plain></SENT>
<SENT sid="234" pm="."><plain>Therefore, NKILA acts as a tumor suppressor against breast cancer progression and metastasis, tongue squamous cell carcinoma cells and in non-small cell lung cancer (NSCLC) [138,139,140]. </plain></SENT>
</text></p><p><text><SENT sid="235" pm="."><plain>As expected after the discovery of the first lncRNAs in cancer like H19, MALAT1, PCA3, the list of lncRNAs involved in tumor progression and metastasis is growing and their role as prognostic biomarkers and as prominent therapeutic targets in tumor patients is becoming increasingly more evident [141,142,143]. </plain></SENT>
</text></p></sec></sec><sec id="sec4-ijms-19-02072"><title><text><SENT sid="236" pm="."><plain>4. </plain></SENT>
<SENT sid="237" pm="."><plain>Interaction Networks of ncRNAs in Cancer </plain></SENT>
</text></title><sec id="sec4dot1-ijms-19-02072"><title><text><SENT sid="238" pm="."><plain>4.1. </plain></SENT>
<SENT sid="239" pm="."><plain>Regulation through Competitive Interactions </plain></SENT>
</text></title><sec id="sec4dot1dot1-ijms-19-02072"><title><text><SENT sid="240" pm="."><plain>4.1.1. </plain></SENT>
<SENT sid="241" pm="."><plain>Competing lncRNAs </plain></SENT>
</text></title><p><text><SENT sid="242" pm="."><plain>The function of lncRNAs as ceRNAs for miRNAs, transcription factors, RNA-binding proteins (RBPs), or DNAs and the fact that lncRNAs can be transcribed from pseudogenes, is a subject of intense ongoing research by several groups and these functions are important in metastasis and in tumor progression [144,145]. </plain></SENT>
<SENT sid="243" pm="."><plain>The exemplary interaction between a lncRNA and a miRNA in cancer is provided by the known lncRNA, XIST. </plain></SENT>
<SENT sid="244" pm="."><plain>As mentioned earlier, XIST is highly expressed in GC tissues compared with the normal tissues. </plain></SENT>
<SENT sid="245" pm="."><plain>Upon knockdown of XIST by antisense oligos in human GC cell lines, proliferation and apoptosis were also decreased. </plain></SENT>
<SENT sid="246" pm="."><plain>The mechanism behind the effect of XIST on cell growth and invasion in GC, involves sequestration of the tumor suppressor miR-497, which targets the oncogene Metastasis Associated in Colon Cancer 1 (MACC1) (Figure 2B) [134,146]. </plain></SENT>
<SENT sid="247" pm="."><plain>LncRNA cancer susceptibility candidate 2 (CASC2) sequesters and suppresses onco-miR-21 responsible for the malignant progression of human gliomas and on the other hand, miR-21 targets CASC2 [147]. </plain></SENT>
<SENT sid="248" pm="."><plain>In gastric cancer, HOTAIR is highly expressed, and de-represses the expression of HER2 through competition for miR-331-3p binding in Ago2-containing ribonucleoprotein complex (Figure 2A) [148]. </plain></SENT>
<SENT sid="249" pm="."><plain>Another lncRNA, Loc285194, regulated by p53, binds and inhibits miR-211 in RISC complex in colon carcinoma cell lines [149]. </plain></SENT>
<SENT sid="250" pm="."><plain>LncRNA growth arrest-specific transcript 5 (GAS5) promoted proliferation, metastasis and inhibited apoptosis by regulation of miR-301a in esophageal cancer (EC) [150]. </plain></SENT>
<SENT sid="251" pm="."><plain>It has been recently reported that HOTTIP functions as an oncogene in small cell lung cancer (SCLC) by sponging the tumor suppressor miR-216a and consequently increases the expression of BCL-2, a target of miR-216a. </plain></SENT>
<SENT sid="252" pm="."><plain>By regulating BCL-2 expression, HOTTIP enhanced chemoresistance of SCLC [151]. </plain></SENT>
<SENT sid="253" pm="."><plain>However, lncRNAs may not only sequester miRNAs but also transcription factors, as it is described in Figure 2B [152]. </plain></SENT>
<SENT sid="254" pm="."><plain>This is the case of the P21 associated ncRNA DNA damage activated (PANDA) lncRNA, which is transcribed antisense of the transcription start site of the cell cycle gene CDKN1A. </plain></SENT>
<SENT sid="255" pm="."><plain>Upon DNA damage by doxorubicin treatment of human fetal ling fibroblasts, PANDA was one of the five lncRNAs transcribed from CDKN1A. </plain></SENT>
<SENT sid="256" pm="."><plain>PANDA antisense transcription was found to be exclusively induced by p53 and this lncRNA sequesters the transcription factor NF-YA, which binds the promoter of apoptotic activators such as APAF1, BIK, FAS and LRDD (Figure 2C) [153]. </plain></SENT>
<SENT sid="257" pm="."><plain>Hence, PANDA counteracts CDKN1 inhibitory effect on the cell cycle and this may have implications in cancerous cell growth. </plain></SENT>
<SENT sid="258" pm="."><plain>The importance of untangling the networking mechanisms by which lncRNAs act as ceRNAs for miRNAs, proteins and DNA in cancer will provide novel and more precise therapeutic targets for cancer therapy. </plain></SENT>
</text></p></sec><sec id="sec4dot1dot2-ijms-19-02072"><title><text><SENT sid="259" pm="."><plain>4.1.2. </plain></SENT>
<SENT sid="260" pm="."><plain>Pseudogenes Derived-lncRNAs </plain></SENT>
</text></title><p><text><SENT sid="261" pm="."><plain>Pseudogenes represent duplicative, homologous sequence regions of their parental genes. </plain></SENT>
<SENT sid="262" pm="."><plain>For a long time, they were considered “junk DNA” non-coding genes defined also as a relic of evolution, without any function. </plain></SENT>
<SENT sid="263" pm="."><plain>Since the discovery in 1977 of the first pseudogene, identified in the 3′-end of its parental gene, 5S DNA of Xenopus laevis, the field of pseudogenes is finally starting to be important in malignancy pathways [154]. </plain></SENT>
<SENT sid="264" pm="."><plain>Pseudogenes may also have their origin through a retrotransposition of processed mRNAs back into the genome. </plain></SENT>
<SENT sid="265" pm="."><plain>There are different types of pseudogenes depending on their origin in the genome and are reviewed elsewhere [155]. </plain></SENT>
<SENT sid="266" pm="."><plain>Here we will highlight some examples of pseudogenes derived-lncRNAs in cancer. </plain></SENT>
<SENT sid="267" pm="."><plain>Pseudogenes act like “endogenous competitors” and affect miRNA binding on all their gene targets. </plain></SENT>
<SENT sid="268" pm="."><plain>Poliseno and co-workers identified the first pseudogene derived-lncRNA in an oncogenic networking, the tumor-suppressor gene phosphatase and tensin homolog pseudogene1 (PTENpg1) that sequesters numerous PTEN-targeting miRNAs by acting as a miRNA sponge [156]. </plain></SENT>
<SENT sid="269" pm="."><plain>They found that expression of PTENpg1 and PTEN was higher in normal human tissues compared to prostate tumor samples. </plain></SENT>
<SENT sid="270" pm="."><plain>Later, another study revealed that PTENpg1 transcribes two anti-sense RNA isoforms -α and -β (PTENpg1 asRNA-α, and -β) and that they function in an opposite way. </plain></SENT>
<SENT sid="271" pm="."><plain>The PTENpg1 asRNA α negatively regulates PTEN expression and the asRNA β is required for PTENpg1 (sense) to act as a miRNA decoy [157]. </plain></SENT>
<SENT sid="272" pm="."><plain>Depletion of PTENpg1 asRNA α in human osteosarcoma cell lines arrested their growth and sensitized cells to the DNA-damaging agent doxorubicin. </plain></SENT>
<SENT sid="273" pm="."><plain>The knowledge of this PTENpg1 and other pseudogene ncRNA regulatory pathways may prove therapeutically relevant in order to control gene expression and simultaneously provide valuable general information of tumor biology. </plain></SENT>
<SENT sid="274" pm="."><plain>Another pseudogene derived-lncRNA is the small ubiquitin-like modifier 1 pseudogene 3, (SUMO1P3). </plain></SENT>
<SENT sid="275" pm="."><plain>It was found to be upregulated in human gastric cancer tissues compared with paired-adjacent non-tumorous tissues thus, SUMO1P3 could be useful as a biomarker and a therapeutic target for GC [144]. </plain></SENT>
<SENT sid="276" pm="."><plain>Additionally, the Double Homeobox A Pseudogene 8 (DUXAP8) expressed-lncRNA, enhances gastric cancer cell proliferation and tumorigenesis through silencing PLEKHO1 transcription epigenetically, by binding to EZH2 and SUZ12 [158]. </plain></SENT>
<SENT sid="277" pm="."><plain>The same pseudogene was highly expressed in colorectal cancer (CRC) and its expression was positively associated with tumor size, pathological stage and lymphatic metastasis and was exerting its oncogenic function through epigenetically silencing the tumor suppressors p21 and PTEN expression [159]. </plain></SENT>
<SENT sid="278" pm="."><plain>Such observations are critical to our current understanding of gene regulation and highlight a biological role for pseudogene-expressed lncRNAs in human cells. </plain></SENT>
</text></p></sec><sec id="sec4dot1dot3-ijms-19-02072"><title><text><SENT sid="279" pm="."><plain>4.1.3. </plain></SENT>
<SENT sid="280" pm="."><plain>Decoying Role of circRNAs </plain></SENT>
</text></title><p><text><SENT sid="281" pm="."><plain>A combination of computational, functional and biochemical analyses revealed that the antisense Cerebellar Degeneration-Related protein 1 (CDR1as), a known human circRNA, is conserved from annelids to humans, and contains 74 miR-7 seed matches [108,160]. </plain></SENT>
<SENT sid="282" pm="."><plain>Additionally, miR-671 cleaves CDR1as in an Ago2-slicer-dependent manner reducing CDR1 mRNA levels [161]. </plain></SENT>
<SENT sid="283" pm="."><plain>These studies reveal the sponging-sequestering effect of circRNAs on miRNAs. </plain></SENT>
<SENT sid="284" pm="."><plain>The biological significance of circRNAs decoying effect on miRNAs in cancer was further strengthened by an interesting study which unraveled that ciRS-7 (CDR1as) sequesters the tumor suppressor miR-7. </plain></SENT>
<SENT sid="285" pm="."><plain>This miRNA, suppresses EGF receptor in glioblastoma, IRS-1 and IRS-2, Raf1 and other oncogenes [162]. </plain></SENT>
<SENT sid="286" pm="."><plain>The ciRS-7/miR-7/miR-671 axis is quite intriguing and gives new insights of circRNA and miRNAs interaction in cancer. </plain></SENT>
<SENT sid="287" pm="."><plain>CiRS-7 inhibits miR-7 repression of its target genes and the miR-671 may liberate miR-7, upon cleavage of ciRS-7 (Figure 2D). </plain></SENT>
</text></p><p><text><SENT sid="288" pm="."><plain>Recently, a small number of circRNAs, which sequester miRNAs have been reported but their functional role needs further investigation. </plain></SENT>
<SENT sid="289" pm="."><plain>The SRY circRNA was discovered to harbor complementary sequences for miRNAs and contains 16 binding sites for miR-138 [17,160]. </plain></SENT>
<SENT sid="290" pm="."><plain>More recently, another study identified circRNA-ZNF91 derived from a gene encoding a primate-specific zing-finger protein, ZNF91, with 39 additional sites for miR-296. </plain></SENT>
<SENT sid="291" pm="."><plain>CDR1as has 22 binding sites for miR-876-5p/3167 family [163]. </plain></SENT>
<SENT sid="292" pm="."><plain>In addition, the circular isoform of the coding gene Itchy E3 Ubiquitin Protein Ligase (ITCH), cir-ITCH functions as a sponge for miR-7, miR-17, and miR-214 in esophageal squamous cell carcinoma (ESCC). </plain></SENT>
<SENT sid="293" pm="."><plain>The same miRNAs bind to the 3′UTR of mRNA ITCH. </plain></SENT>
<SENT sid="294" pm="."><plain>Consequently, cir-ITCH increases the level of ITCH mRNA and promotes ubiquitination and degradation of phosphorylated Dvl2, thereby inhibiting the Wnt/β-catenin pathway and this reveals the anti-tumoral property of cir-ITCH [164]. </plain></SENT>
<SENT sid="295" pm="."><plain>Furthermore, decreased cir-ITCH level was associated with poor survival of glioma patients, by sponging miR-214 and regulating ITCH-Wnt/β-catenin pathway [165]. </plain></SENT>
<SENT sid="296" pm="."><plain>Therefore, restoration of cir-ITCH expression could be a future direction to develop a novel treatment strategy in ESCC and glioma. </plain></SENT>
<SENT sid="297" pm="."><plain>CircRNAs can also interact with proteins and an example comes from a study in which the circ-forkhead box O3 (circ-Foxo3) forms a ternary complex with two cell cycle regulatory proteins, p21 and CDK2 and blocks the cell cycle progression in NIH3T3 cells (Figure 2E) [166]. </plain></SENT>
<SENT sid="298" pm="."><plain>An analysis of Foxo3 gene revealed that a pseudogene with high homology to Foxo3 mRNA as well as a circ-Foxo3, was generated from the same Foxo3 gene [167]. Foxo3 pseudogene (Foxo3P), mRNA and circ-Foxo3 had the same potential binding sites for 8 miRNAs (three of them are miR-22, miR-138, miR-433) and they could sponge these miRNAs and increase the tumor suppressor gene Foxo3 translation [168]. </plain></SENT>
<SENT sid="299" pm="."><plain>Over-expression of Foxo3P, Foxo3 and circ-Foxo3 in a breast cancer cell line decreased cell proliferation and induced extensive cell death due to apoptosis in tumors formed by the same cell line in nude mice. </plain></SENT>
<SENT sid="300" pm="."><plain>Among the aforementioned Foxo3 molecules, circ-Foxo3 demonstrated to have a more potent miRNA sponging effect and on cell survival. </plain></SENT>
<SENT sid="301" pm="."><plain>This may be due to the stability of the circ- Foxo3. </plain></SENT>
<SENT sid="302" pm="."><plain>As previously mentioned, circRNAs have a longer half-life than the linear mRNAs and are also resistant to RNA exonucleases. </plain></SENT>
<SENT sid="303" pm="."><plain>Nevertheless, the intense investigations on function of circRNAs as a miRNA trap are hampered, mainly because of the missing loss-of function experiments due to an overlapping of the linear and circular isoforms. </plain></SENT>
<SENT sid="304" pm="."><plain>It has been also speculated that the small “free” circRNAs could be carried by exosomes outside of the cells and this could explain the low abundance of circRNAs [169]. </plain></SENT>
<SENT sid="305" pm="."><plain>There is ample evidence that the quantity of circRNAs may exceed their linear isoforms, depending of the cell type and tissue and may play important role either in progression of cancer or tumor suppression. </plain></SENT>
<SENT sid="306" pm="."><plain>This may have therapeutic implications for some types of cancer and although this field is still in its infancy, a future circRNA-based cancer therapy could become realistic. </plain></SENT>
</text></p></sec><sec id="sec4dot1dot4-ijms-19-02072"><title><text><SENT sid="307" pm="."><plain>4.1.4. </plain></SENT>
<SENT sid="308" pm="."><plain>Progenitor miRNA </plain></SENT>
</text></title><p><text><SENT sid="309" pm="."><plain>A novel paradigm of a miRNA post-transcriptional mechanism is the discovery of an intermediate progenitor miRNA described in the biogenesis of the polycistronic onco-miR-17-92 [170]. </plain></SENT>
<SENT sid="310" pm="."><plain>During the Emryonic Stem Cell (ESC) differentiation, Gregory and his colleagues noticed that there is an accumulation of the miR-17-92 cluster, but the levels of miR-92a, one of the members of the cluster, were stable. </plain></SENT>
<SENT sid="311" pm="."><plain>They discovered that the reason behind this accumulation was the presence of an inhibitory domain at the 5′ part of the pri-miR-17-92 that brought it to a higher-order RNA conformation. </plain></SENT>
<SENT sid="312" pm="."><plain>Therefore, the microprocessor complex was unable to process the primary transcript into the precursors. </plain></SENT>
<SENT sid="313" pm="."><plain>When the 5′ inhibitory domain was cleaved at 9nt before pri-miR-17a loop by the endonuclease CPSF3 aided by the spliceosome-associated ISY1, enabled the formation of a novel intermediate structure, named the progenitor miR-17-18a-19a-20a-19a except miR-92a. </plain></SENT>
<SENT sid="314" pm="."><plain>The latter was processed by Drosha, creating the 3′-end of pro-miR-17-19a. </plain></SENT>
<SENT sid="315" pm="."><plain>Importantly, the pro-miR formation was a necessary intermediate step for the miR-17-92 maturation. </plain></SENT>
<SENT sid="316" pm="."><plain>The same group proposed the biological relevance of this additional post-transcriptional step that could explain the opposite anti-tumoral effect of one of the members of this family, miR-92a, observed in mouse lymphoma [171]. </plain></SENT>
<SENT sid="317" pm="."><plain>Expression of the miR-17-92 cluster is increased in B cell lymphoma, T cell acute lymphoblastic leukemia (T-ALL) and other tumors. </plain></SENT>
<SENT sid="318" pm="."><plain>Interestingly, miR-92a inhibits oncogenic miR-19, which belongs to the same family, and promotes proteosomal degradation of c-Myc. </plain></SENT>
<SENT sid="319" pm="."><plain>In contrast, when miR-19 is more expressed, it overcomes the inhibitory action of miR-92 and promotes tumor progression. </plain></SENT>
<SENT sid="320" pm="."><plain>Overall, the processing of the cluster pri-miR-17-92 by CPSF3 and ISY1, gives rise to a pro-miRNA that omits miR-92a from the cluster. </plain></SENT>
<SENT sid="321" pm="."><plain>This could explain the antagonism between miRNAs belonging in the same cluster with a high impact on tumor formation. </plain></SENT>
</text></p></sec></sec></sec><sec id="sec5-ijms-19-02072"><title><text><SENT sid="322" pm="."><plain>5. </plain></SENT>
<SENT sid="323" pm="."><plain>Disruption of ncRNA Networks in Cancer </plain></SENT>
</text></title><sec id="sec5dot1-ijms-19-02072"><title><text><SENT sid="324" pm="."><plain>5.1. </plain></SENT>
<SENT sid="325" pm="."><plain>miRNA Editing </plain></SENT>
</text></title><p><text><SENT sid="326" pm="."><plain>Adenosine to inosine (A-to-I) editing catalyzed by adenosine deaminases acting on RNAs (ADARs) affects miRNA biogenesis and reprograms miRNA targeting [172]. </plain></SENT>
<SENT sid="327" pm="."><plain>Thousands of hitherto unknown A-to-I RNA editing sites in human transcripts, in normal tissues and in various cancers have been identified thanks to the advanced deep sequencing technology and bioinformatics analysis [173]. </plain></SENT>
<SENT sid="328" pm="."><plain>Editing sites are typically found in introns and in 3′UTRs where inverted Alu repeats form double stranded RNAs (dsRNAs) [174,175,176]. </plain></SENT>
<SENT sid="329" pm="."><plain>Therefore, Alu elements are the substrates of RNA editing. </plain></SENT>
<SENT sid="330" pm="."><plain>A-to-I RNA editing by ADAR of pri- and pre-miRNAs may regulate expression and function of their mature counterparts. </plain></SENT>
<SENT sid="331" pm="."><plain>ADAR enzymes form a heterodimer complex with Dicer to promote miRNA processing or inhibit the microprocessor complex cleavage of pri-miRNAs and therefore suppress miRNA maturation [172,177]. </plain></SENT>
<SENT sid="332" pm="."><plain>In turn, these enzymes are regulated by CREB and c-Jun transcription factors. </plain></SENT>
<SENT sid="333" pm="."><plain>In glioblastomas, editing within miRNA is decreased or lost because the activity of ADAR2 is impaired compared with the normal brain tissue [178]. </plain></SENT>
<SENT sid="334" pm="."><plain>Upon reconstitution of ADAR2 activity, miRNA editing was recovered and the expression of onco-miRs and onco-suppressors miRNAs became balanced as seen in the normal brain tissue. </plain></SENT>
<SENT sid="335" pm="."><plain>Surprisingly, ADAR2 edited the precursors of miR-222/221 and miR-21 and decreased the expression of the corresponding oncomiRs in vitro and in vivo (Figure 3A). </plain></SENT>
<SENT sid="336" pm="."><plain>In another study, in situ analysis of melanoma samples in microarrays tissue was performed [179]. </plain></SENT>
<SENT sid="337" pm="."><plain>This study reported that expression of ADAR1 was frequently reduced during the metastatic transition. </plain></SENT>
<SENT sid="338" pm="."><plain>Moreover, knockdown of ADAR1 changed the cell phenotype of 131 cancer regulators miRNAs and microarray analysis revealed that ADAR1 controls the expression of miRNAs that target genes associated with these phenotypic changes. </plain></SENT>
<SENT sid="339" pm="."><plain>Furthermore, overexpression of the onco-miR, miR-17-5p and a newly identified miR-432 silenced both isoforms of ADAR1 in melanoma cells. </plain></SENT>
<SENT sid="340" pm="."><plain>A recent study in melanoma identified that miR-455-5p has two A-to-I editing sites in low metastatic melanomas and this changed its inhibitory effect on its target, the tumor suppressor gene, CPEB1 [180]. </plain></SENT>
<SENT sid="341" pm="."><plain>In other words, A-to-I editing of miR-455-5p changed completely its biological effect and inhibited melanoma growth and metastasis. </plain></SENT>
<SENT sid="342" pm="."><plain>In addition, a study revealed that overexpression of ADAR1 in chordoma, a rare neoplasm of the axial skeleton, accompanied reduced levels of miR-10a and miR-125a, caused by enhanced pre-miR-10a and pri-miR-125a A-to-I editing [181]. </plain></SENT>
<SENT sid="343" pm="."><plain>This phenomenon might contribute to the pathogenesis of chordoma. </plain></SENT>
</text></p><p><text><SENT sid="344" pm="."><plain>In summary, ADAR enzymes seem to have both anti-tumoral or a pro-tumoral effect in different types of cancer by reducing the expression of onco-miRs or tumor suppressors miRs. </plain></SENT>
<SENT sid="345" pm="."><plain>These enzymes thus represent promising targets for tumor therapy. </plain></SENT>
</text></p></sec><sec id="sec5dot2-ijms-19-02072"><title><text><SENT sid="346" pm="."><plain>5.2. </plain></SENT>
<SENT sid="347" pm="."><plain>Epigenetic Regulation of miRNAs </plain></SENT>
</text></title><p><text><SENT sid="348" pm="."><plain>It is estimated that 40% of the human genes promoter contain Cytosine-phosphodiester bond-Guanosine (CpG) islands, at the 5′ end of regulatory genes [182]. </plain></SENT>
<SENT sid="349" pm="."><plain>Many studies have reported that the 5-carbon of cytosine pyrimidine ring can be methylated and methylation of tumor suppressor genes may lead to cancer. </plain></SENT>
<SENT sid="350" pm="."><plain>Since many miRNA promoters are embedded in (CpG) islands of their host genes involved in neoplastic development, it is reasonable that methylation of these DNA regions of tumor suppressive miRNAs may lead to the development and progression of cancers. </plain></SENT>
<SENT sid="351" pm="."><plain>Furthermore, another epigenetic modification of miRNA promoters is the histone H3 and H4 hypo-acetylation by Histone Deacetylation (HDAC) enzymes [183]. </plain></SENT>
<SENT sid="352" pm="."><plain>Evidence that miRNA expression is regulated through epigenetic modifications of their promoter came from studies of cancerous and healthy cells treated with DNA-demethylating agents, like 5-Aza-2′-deoxycytidine (5-Aza-CdR) and histone deacetylase inhibitor, 4-phenylbutyric acid (PBA). </plain></SENT>
<SENT sid="353" pm="."><plain>It has been reported that the promoter of miR-127 is inserted in CpG islands and it is silenced in primary tumors of prostate, bladder, and colon [184]. </plain></SENT>
<SENT sid="354" pm="."><plain>After a combinatorial treatment of these cell lines with 5-Aza-CdR and PBA, miR-127 expression was restored and its target, the proto-oncogene B-cell lymphoma-6 (BCL-6) was repressed (Figure 3B) [185]. </plain></SENT>
<SENT sid="355" pm="."><plain>Chromatin immunoprecipitation (ChIP) showed that activation of miR-127 expression after treatment was due to decreased cytosine methylation, H3 acetylation and methylation of H3 at lysine 4 (H3-K4), around the transcriptional start sites of this gene. </plain></SENT>
<SENT sid="356" pm="."><plain>Another study has examined the miRNA methylation profile of human metastatic cancer cells of colon, melanoma and head and neck cancer [186]. </plain></SENT>
<SENT sid="357" pm="."><plain>Among other miRNAs, it was found that the CpG islands in the promoter of miR-34b/c, miR-148 and miR-9 were hypermethylated, therefore underexpressed and their target genes expression, c-myc and CDK6 were consequently highly expressed. </plain></SENT>
<SENT sid="358" pm="."><plain>Surprisingly, it was observed that hypermethylation of these miRNAs was associated with the metastatic cancer cells in the corresponding lymph nodes. </plain></SENT>
<SENT sid="359" pm="."><plain>This finding highlights a promising application of the miRNA methylation profile as a metastatic marker. </plain></SENT>
<SENT sid="360" pm="."><plain>Recently, a high-throughput sequencing analysis investigated how chemoresistance of a breast cancer cell line to adriamycin (ADM) and paclitaxel (PTX) can influence gene expression, methylation status and miRNA expression in comparison to chemosensitive controls [187]. </plain></SENT>
<SENT sid="361" pm="."><plain>This study reported that highly expressed miRNAs in the chemoresistant cells were less methylated around their transcriptional start site (TSS) and vice versa. </plain></SENT>
<SENT sid="362" pm="."><plain>Furthermore, investigators have analyzed genes with Kyoto Encyclopedia Of Genes and Genomes (KEGG) database, that were regulated by methylation and miRNAs. </plain></SENT>
<SENT sid="363" pm="."><plain>Seventeen genes were identified to be associated with methylation and dysregulation of miRNAs and generally they were involved in the cell motility and EMT pathways. </plain></SENT>
<SENT sid="364" pm="."><plain>Overall, these studies indicate that epigenetic mechanisms may control transcription of tumor suppressor miRNAs. </plain></SENT>
<SENT sid="365" pm="."><plain>Methylation profile of miRNAs can be engaged as a prognostic marker as well as for metastatic propensity. </plain></SENT>
<SENT sid="366" pm="."><plain>Moreover, treatment of tumors with drugs that interrupt this control may have therapeutic implications for cancer cure. </plain></SENT>
</text></p></sec><sec id="sec5dot3-ijms-19-02072"><title><text><SENT sid="367" pm="."><plain>5.3. </plain></SENT>
<SENT sid="368" pm="."><plain>Uridylation of the 3′-End of ncRNAs </plain></SENT>
</text></title><p><text><SENT sid="369" pm="."><plain>Several studies in plants and animal models indicate that uridylation regulates ncRNAs whereas longer mRNAs are degraded after addition of uridines [188,189]. </plain></SENT>
<SENT sid="370" pm="."><plain>The only known substrate in the nucleus of uridylation is the small nucleolar (snοRNA) RNA U6, operated by the U6 Terminal Uridylyl Transferase (TUTase), an essential enzyme for cell survival in mammals [190]. </plain></SENT>
<SENT sid="371" pm="."><plain>The addition of four Uridine residues in the 3′-end of U6 is essential for its splicing function. </plain></SENT>
<SENT sid="372" pm="."><plain>In the cytoplasm, polyuridylation occurs on polyadenylated and non-polyadenylated RNA such as miRNAs and has been shown to regulate miRNA biogenesis and activity [191]. </plain></SENT>
</text></p><p><text><SENT sid="373" pm="."><plain>Deep sequencing analysis with strand specific RNA linker ligation to identify and examine the 3′-ends of small RNAs in human embryonic stem cells, suggested that the largest non-template modification was uridylation, especially in mature miRNAs, such as miR-302-367 cluster [192]. </plain></SENT>
<SENT sid="374" pm="."><plain>A further high-throughput sequencing analysis specifically for miRNA precursors was performed to better understand the mechanism and function of oligo-uridylation in the 3′-end of miRNAs [193]. </plain></SENT>
<SENT sid="375" pm="."><plain>Many pre-microRNAs were found to be uridylated and this modification was increased in differentiated adult mouse tissues. </plain></SENT>
<SENT sid="376" pm="."><plain>Among pre-miRNAs, pre-let-7 family was identified. </plain></SENT>
<SENT sid="377" pm="."><plain>It is known from previous studies that let-7 precursor is uridylated at the 3′-end by the uridylyl transferase, TUTase4 (TUT4) (Figure 3C) [194]. </plain></SENT>
<SENT sid="378" pm="."><plain>In this mechanism, Lin28 binds the conserved sequence motif GGAG in the terminal loop of pre-let-7 and triggers the Terminal Uridylyl Transferases 4 and 7 (TUT4/7). </plain></SENT>
<SENT sid="379" pm="."><plain>This finally inhibits let-7 maturation in embryonic stem cells affecting their maintenance. </plain></SENT>
<SENT sid="380" pm="."><plain>Dis3L2, an RNase II/3′-5′exonuclease, which is the catalytic subunit of the RNA exosome recognizes and degrades the oligo-uridylated pre-let-7 [195,196]. </plain></SENT>
<SENT sid="381" pm="."><plain>This enzyme is mutated in the Perlman syndrome and in Wilms tumors and its role in tumorigenesis is only recently unraveled after the discovery of the Dis3L2-Mediated Decay (DMD) pathway [197,198]. </plain></SENT>
<SENT sid="382" pm="."><plain>An analysis of Dis3L2 targets in mouse embryonic stem cells after an RNA immunoprecipitation assay identified lncRNAs and pseudogenes in DMD pathway. </plain></SENT>
<SENT sid="383" pm="."><plain>A series of in vitro Dis3L2 loss-of- function experiments helped to determine that some of the lncRNAs were 3′ uridylated and as expected they were accumulated in the cytoplasm (Figure 3C). </plain></SENT>
<SENT sid="384" pm="."><plain>Deep sequencing of the 3′-ends particularly of the RNA Component of Mitochondrial RNA Processing Endoribonuclease lncRNA (Rmrp), identified that the uridine tail was added to those which contained CAC nucleotides after the 3′-end and thereby were degraded by Dis3L2. </plain></SENT>
<SENT sid="385" pm="."><plain>DMD pathway is a guardian sentinel of the aberrant oligo-uridylated RNA species that should be degraded especially when these RNAs are cancer-related. </plain></SENT>
<SENT sid="386" pm="."><plain>The ncRNAs and the subsequent degradation of oligo-Uridine tails through Dis3L2 enzyme unified in the DMD pathway may explain the reduced expression of let-7 and other tumor suppressor miRNAs as well as lncRNAs deregulated in cancer [199]. </plain></SENT>
</text></p></sec><sec id="sec5dot4-ijms-19-02072"><title><text><SENT sid="387" pm="."><plain>5.4. </plain></SENT>
<SENT sid="388" pm="."><plain>Phosphorylation of the 5′ End of miRNAs </plain></SENT>
</text></title><p><text><SENT sid="389" pm="."><plain>The mere presence and detection of a miRNA in the cytoplasm does not imply its activity. </plain></SENT>
<SENT sid="390" pm="."><plain>Indeed, a miRNA is active when it is able to repress its target genes unless its activity is compromised by various alterations, as described earlier. </plain></SENT>
</text></p><p><text><SENT sid="391" pm="."><plain>A novel paradigm of a miRNA modification that enhances its activation has been recently discovered and it is the phosphorylation of the 5′ end in the mature tumor suppressor miR-34 [200]. </plain></SENT>
<SENT sid="392" pm="."><plain>This miRNA is usually methylated thereby under-expressed in human malignancies or because miR-34 gene locus, 1p36, is frequently deleted in human tumors [201]. </plain></SENT>
<SENT sid="393" pm="."><plain>Although in some instances, it can also be present abundantly in human cancer cell lines [202]. </plain></SENT>
<SENT sid="394" pm="."><plain>It is also known that p53 binds to the promoter of miR-34 and enhances the transcription thereof, especially when a DNA damage external signal is triggered. </plain></SENT>
<SENT sid="395" pm="."><plain>Furthermore, many miRNAs when knocked down, do not influence important biological functions but might respond to external stimulus, such as irradiation. </plain></SENT>
<SENT sid="396" pm="."><plain>In fact, in this study a pool of mature and inactive miR-34 was detected in cancer cell lines. </plain></SENT>
<SENT sid="397" pm="."><plain>But when the same cells underwent ionizing irradiation (IR) to induce DNA damage, this pool became activated. </plain></SENT>
<SENT sid="398" pm="."><plain>The activation was through the human RNA 5′-kinase (hClp1) and Ataxia telangiectasia (ATM)-dependent 5′ phosphorylation of the mature miR-34. </plain></SENT>
<SENT sid="399" pm="."><plain>Interestingly, 5′ phosphorylated miR-34a suppressed its targets genes, Cyclin Dependent Kinase 4 (CDK4) and B-cell Lymphoma 2 (BCL2). </plain></SENT>
<SENT sid="400" pm="."><plain>This surprising finding may explain why regardless of a high expression of miRNAs, sometimes they might not be functionally active. </plain></SENT>
<SENT sid="401" pm="."><plain>More importantly, this innovative modification could be further explored in other tumor suppressor miRNAs as a rapid cellular defense to external stimuli. </plain></SENT>
<SENT sid="402" pm="."><plain>This study provides an interesting perspective for a cancer therapy based on the activation of the existing inactive tumor suppressor pool inside the cytoplasm rather than injecting miRNAs intravenously in human patients. </plain></SENT>
</text></p></sec><sec id="sec5dot5-ijms-19-02072"><title><text><SENT sid="403" pm="."><plain>5.5. </plain></SENT>
<SENT sid="404" pm="."><plain>Alterations and Regulatory Sequences within 3′UTRs </plain></SENT>
</text></title><p><text><SENT sid="405" pm="."><plain>The 3′ untranslated regions (3′UTRs) of mRNAs is defined as the sequence between the STOP codon and the poly(A) tail. </plain></SENT>
<SENT sid="406" pm="."><plain>It is important for their transportation into the cytoplasm, the stability and translational efficiency of mRNAs. </plain></SENT>
<SENT sid="407" pm="."><plain>These regions are targeted by miRNAs, therefore length variations of 3′UTRs of many genes affect their regulation by miRNAs. </plain></SENT>
<SENT sid="408" pm="."><plain>These alterations derive from the alternative polyadenylation mechanism (APA) present in more than 70% of the mammalian genes. </plain></SENT>
<SENT sid="409" pm="."><plain>This leads to formation of isoforms with multiple 3′UTRs derived from a single gene. </plain></SENT>
<SENT sid="410" pm="."><plain>The length of a 3′UTR is dictated by alternative splicing and more frequently by the cleavage and polyadenylation of the pre-mRNA at defined sequences, 10–30 nt after the canonical sequence AAUAAA or its variants known as polyadenylation sites (PAS) [203,204]. </plain></SENT>
<SENT sid="411" pm="."><plain>Moreover, short 3′UTRs are more stable therefore more abundant because they are no longer recognized by miRNAs to suppress the translation. </plain></SENT>
<SENT sid="412" pm="."><plain>This phenomenon is frequently observed in actively proliferating cells and in cancer [205]. </plain></SENT>
</text></p><p><text><SENT sid="413" pm="."><plain>Equally important and well connected to APA mechanism is the presence of regulatory sequences within 3′UTRs. </plain></SENT>
<SENT sid="414" pm="."><plain>An example is the ubiquity of Adenosine-Uracil elements (ARES), which are conserved sequences within mRNA 3′UTRs. </plain></SENT>
<SENT sid="415" pm="."><plain>ARES interact with micro-ribonucleoproteins (microRNPs) such as AGO2 in complex with other proteins to regulate the stability and translation of mRNAs in response to external or internal stimuli [206]. </plain></SENT>
<SENT sid="416" pm="."><plain>A seminal observation that miRNAs may induce mRNA translation demonstrated that miR-369-3, interact with AGO2 and fragile X mental retardation-related protein 1 (FXR1) complex to induce translation of TNFα, in serum starved HEK293 and HeLa cell lines (Figure 3D). </plain></SENT>
<SENT sid="417" pm="."><plain>Therefore, upon cell cycle arrest, the interaction between the seed sequence of the miRNA within the minimal TNFα ARE 3′UTR induces TNFα translation but in proliferating cells, miRNA had exactly the opposite inhibitory effect [207]. </plain></SENT>
<SENT sid="418" pm="."><plain>Similarly, let-7 enhanced translation of its target mRNA in quiescent cells and repressed it when the cells were proliferating. </plain></SENT>
</text></p><p><text><SENT sid="419" pm="."><plain>In another study, a translational control element (TCE) within the Kruppel Like Factor (KLF4) 3′UTR interacted with miR-206 and miR-344-1 to promote or inhibit KLF4 expression respectively, in proliferating normal human mammary epithelial cells [208]. </plain></SENT>
<SENT sid="420" pm="."><plain>miR-206 induced translation of KLF4 to enhance the malignant phenotype in human mammary epithelial cells. </plain></SENT>
</text></p><p><text><SENT sid="421" pm="."><plain>Overall, trans-factors such as RNA binding proteins (RBP) and miRNAs act to contend or cooperate with each other in order to regulate cis-regulatory sequences within mRNAs involved in cancer [209,210,211]. </plain></SENT>
<SENT sid="422" pm="."><plain>Another example of this mechanism includes the RBP Human antigen R (HuR), a member of the human embryonic lethal abnormal visual (Elav) gene family that stabilizes and regulates translation of mRNA [212,213]. </plain></SENT>
<SENT sid="423" pm="."><plain>Recently, a dissecting study of the KRAS 3′UTR oncogene in HeLa cells identified two 49-nt cis-regulatory sequences and miR-185 was able to bind one, while the other contained a stabilizing element [210]. </plain></SENT>
<SENT sid="424" pm="."><plain>Furthermore, knocking down of HuR and Dicer has increased mRNA and protein levels of KRAS. </plain></SENT>
<SENT sid="425" pm="."><plain>These results indicate that miRNA and HuR cooperatively bind the same sequence in the 3′UTR of this oncogene and repress its expression. </plain></SENT>
<SENT sid="426" pm="."><plain>Moreover, in the same repressive 49-nt sequence there was a single nucleotide polymorphism (SNP) at the first nucleotide of the predicted miR-185 target site but its role in the tumorigenesis has yet to be determined in the above context. </plain></SENT>
</text></p><p><text><SENT sid="427" pm="."><plain>Other RBP reported to be involved in human malignancies, is the human Pumilio protein complex, which upon binding to cis-regulatory sequences within 3′UTRs, induces a conformational change in the RNA structure and regulates miRNAs activity towards their target genes [214,215,216]. </plain></SENT>
<SENT sid="428" pm="."><plain>Bladder carcinomas selectively down-regulate miR-503 and miR-125b that cooperate with Pumilio to target E2F3, and multiple tumor cell lines shorten the 3′-end of the E2F3 mRNA, removing the Pumilio regulatory elements (Figure 3E) [217]. </plain></SENT>
<SENT sid="429" pm="."><plain>These observations indicate one of the ways how oncogenes escape the inhibitory effect of tumor suppressor miRNAs. </plain></SENT>
<SENT sid="430" pm="."><plain>Among the RBPs that regulate miRNA targeting on mRNAs in the nucleoplasm and cytoplasm, the Splicing factor proline/glutamine-rich protein (Sfpq) promotes let-7a-mediated degradation on Lin28 3′UTR mRNA through a nuclear mechanism in human and mice cell lines [54]. </plain></SENT>
<SENT sid="431" pm="."><plain>The multitude of actions of many other RBP proteins known to interfere with binding sites within 3′UTRs of genes involved in tumorigenesis and influence miRNAs seed sequences still need to be explored [218]. </plain></SENT>
<SENT sid="432" pm="."><plain>Altogether, interactive networks between 3′UTRs, RBP, miRNAs and specific cellular conditions entail a new window of opportunity for cancer therapy, by repressing or enhancing important interactions within these networks. </plain></SENT>
</text></p><p><text><SENT sid="433" pm="."><plain>As mentioned above, in the general view of 3′UTR aberrations are the single nucleotide polymorphism (SNPs) that interrupt cis-acting regulatory elements embedded in the 3′UTR as well as chromosomal translocations that involve the 3′UTR resulting in the loss of miRNA complementary sites [219]. </plain></SENT>
</text></p><p><text><SENT sid="434" pm="."><plain>The SNPs are involved in many types of cancers and they occur frequently in the human genome, at about every hundred base pairs (bp) [220]. </plain></SENT>
<SENT sid="435" pm="."><plain>Interestingly, SNPs are usually silent mutations of a single nucleotide, which do not alter the amino acid sequence, however, there are nonsynonymous SNPs that change the amino acid sequence to create a new protein and gene function. </plain></SENT>
<SENT sid="436" pm="."><plain>The silent polymorphisms may reside in non-coding genomic regions like miRNAs and 3′UTRs. </plain></SENT>
<SENT sid="437" pm="."><plain>When polymorphisms fall into an important region of the miRNA seed sequence the regulation of its target genes will be abrogated. </plain></SENT>
<SENT sid="438" pm="."><plain>Since the first study of a wide-genome analysis DNA sequencing of tumor tissues whereby 12 miRNA-binding SNPs were identified to be associated with human cancer, many more studies have emerged [221]. </plain></SENT>
<SENT sid="439" pm="."><plain>For example, in lung cancer, a germline SNP in the 3′UTR of KRAS proto-oncogene abrogated the binding site of let-7, thus increasing KRAS protein levels and promoted tumor progression [222]. </plain></SENT>
<SENT sid="440" pm="."><plain>Moreover, a somatic SNP was found in the 3′UTR of the oncogene Mouse Double Minute 4 (MDM4) known to decrease p53 tumor suppressor function, which created a new binding site for miR-191. </plain></SENT>
<SENT sid="441" pm="."><plain>This miRNA suppressed only the MDM4-C allelic variant expression and retarded ovarian cancer progression and the tumor became chemosensitive (Figure 3F) [223]. </plain></SENT>
<SENT sid="442" pm="."><plain>A wide-genome analysis for SNPs associated with breast cancer within 3′UTRs that modify miRNA binding sites identified two SNPs, one in the BRCA1 3′UTR that created a binding site for the miR-638 and decreased the levels of BRCA1 protein in breast cancer cells whereas the other was in the TGFBR1 3′UTR and created a binding site for miR-268 [224]. </plain></SENT>
<SENT sid="443" pm="."><plain>These findings show that SNPs may turn out to be valuable as cancer biomarkers which affect prognosis as well as response to therapy. </plain></SENT>
</text></p></sec><sec id="sec5dot6-ijms-19-02072"><title><text><SENT sid="444" pm="."><plain>5.6. </plain></SENT>
<SENT sid="445" pm="."><plain>Genetic Alterations </plain></SENT>
</text></title><p><text><SENT sid="446" pm="."><plain>Since tumorigenesis involves genomic alterations, such as chromosomal translocations that may influence or produce proto-oncogenes and onco-suppressors as well as “fusion genes”, a recent pioneering study investigated the impact these genomic alterations may have on non-coding RNAs and specifically on circRNAs [225]. </plain></SENT>
<SENT sid="447" pm="."><plain>One example of fusion genes is the breakpoint cluster region protein-Abelson murine leukemia viral oncogene (BCR-ABL) gene on chromosome 22 or Philadelphia chromosome, discovered in leukemia patients. </plain></SENT>
<SENT sid="448" pm="."><plain>The investigators showed that upon chromosomal translocation, the two genes bring complementary repetitive intronic sequences (Alu), which generally favors back-splicing events to generate aberrant circRNAs, called fusion (f)-circRNAs. </plain></SENT>
<SENT sid="449" pm="."><plain>They demonstrated that many recurrent chromosomal translocations, of PML/RARα observed in Acute Promyelocytic Leukemia (APL), MLL/AF9 in Acute Myeloid Leukemia (AML), EWSR1/FLI1 in Ewing Sarcoma and EML4/ALK1 associated with lung cancer could form f-circRNAs [226,227]. </plain></SENT>
<SENT sid="450" pm="."><plain>Interestingly, the f-circM9 derived from MLL/AF9 fusion and f-circPR (derived from PML/RARα fusion), enhance proliferation of leukemia cells in vitro (Figure 2F). </plain></SENT>
<SENT sid="451" pm="."><plain>But the f-circRNAs failed to induce leukemia in mice. </plain></SENT>
<SENT sid="452" pm="."><plain>When both the f-circRNA and the fusion protein (f-protein) were overexpressed in leukemia cells and introduced in mice, they enhanced leukemia progression and resistance to chemotherapy. </plain></SENT>
</text></p><p><text><SENT sid="453" pm="."><plain>The intriguing role of circRNAs in tumorigenesis has only started to be uncovered and the number of circRNAs involved in cancer is progressively increasing. </plain></SENT>
<SENT sid="454" pm="."><plain>Computational identification of these remarkable ncRNAs as well as an accurate estimation of their abundance and function in every type of cancer will aid potential therapeutic approaches based on them. </plain></SENT>
</text></p></sec><sec id="sec5dot7-ijms-19-02072"><title><text><SENT sid="455" pm="."><plain>5.7. </plain></SENT>
<SENT sid="456" pm="."><plain>lncRNA Modifications in Cancer </plain></SENT>
</text></title><p><text><SENT sid="457" pm="."><plain>Dysregulated lncRNAs due to methylation or mutation in single nucleotides may occur in cancer. </plain></SENT>
<SENT sid="458" pm="."><plain>For example, the reason behind the low expression of lncRNA LOC100130476 in the pathogenesis of esophageal squamous cell carcinoma (ESCC) has been investigated in 123 ESCC patients comparing with the normal tissues. </plain></SENT>
<SENT sid="459" pm="."><plain>Low expression was due to hypermethylation of the CpG sites in exon 1 closing to the transcription start site of LOC100130476 [228]. </plain></SENT>
<SENT sid="460" pm="."><plain>The ESCC patients with low expression or hypermethylation of this lncRNA had a poor prognosis. </plain></SENT>
<SENT sid="461" pm="."><plain>The aberrant hypermethylation within the three CpG islands regions around the transcription start site of another lncRNA CTC-276P9 was identified in esophageal cancer cells and ESCC tissues and was also related with poor survival of ESCC patients [229]. </plain></SENT>
<SENT sid="462" pm="."><plain>In another study, the promoter region of maternally expressed gene 3 (MEG3) lncRNA was methylated in ESCC. </plain></SENT>
<SENT sid="463" pm="."><plain>Interestingly, this lncRNA has ceRNA functions. </plain></SENT>
<SENT sid="464" pm="."><plain>It sequesters the onco-miR-9 so that it does not target FOXO1 and E-cadherin in ESCC human cell lines, eventually leading to inhibition of tumor cell proliferation (Figure 3G1) [230]. </plain></SENT>
<SENT sid="465" pm="."><plain>The above examples identify three lncRNA as prognostic biomarkers and therapeutic targets for ESCC patients. </plain></SENT>
<SENT sid="466" pm="."><plain>Three lncRNA PTENP1 tagSNPs, namely, rs7853346 C&gt;G, rs865005 C&gt;T, and rs10971638 G&gt;A were genotyped in 768 GC patients and 768 cancer-free controls in a Chinese population [231]. </plain></SENT>
<SENT sid="467" pm="."><plain>Those patients with rs7853346 G allele had significantly reduced risk of GC, compared with those carrying C allele and was more obvious in older subjects (≥60 years), nonsmokers, nondrinkers, and subjects without family history of GC. </plain></SENT>
<SENT sid="468" pm="."><plain>Through bioinformatics analyses, it was found that rs7853346 might change the local folding structure of lncPTENP1 abolishing its sponging effect on miR-106b and miR-93 with a consequent reduction of the tumor suppressor PTEN gene expression (Figure 3G2). </plain></SENT>
<SENT sid="469" pm="."><plain>These data suggest that GC susceptibility can be predicted by lncRNA PTENP1 polymorphism rs7853346 [231]. </plain></SENT>
<SENT sid="470" pm="."><plain>In another study it was found that the lncRNA H19 SNPs may contribute to susceptibility to GC resulting in gain and loss of function of miRNA-lncRNA interactions [232]. </plain></SENT>
</text></p></sec></sec><SecTag type="DISCUSS"><sec id="sec6-ijms-19-02072"><title><text><SENT sid="471" pm="."><plain>6. </plain></SENT>
<SENT sid="472" pm="."><plain>Perspectives </plain></SENT>
</text></title><p><text><SENT sid="473" pm="."><plain>As the so-called dark matter ncRNAs gets more and more elucidated, we have started to uncover some fascinating concepts and paradigms showing how they interact with each other, both in normal and diseased circumstances. </plain></SENT>
<SENT sid="474" pm="."><plain>The role of miRNAs is definitely the most studied among ncRNAs, mainly because they have the advantage of having been discovered earlier than their longer kins. </plain></SENT>
<SENT sid="475" pm="."><plain>In order to broaden the knowledge of how lncRNAs contribute to cancer development, besides studying their networking ability to act as ceRNA for miRNA, proteins and DNA, the development of suitable animal model systems will be critical. </plain></SENT>
<SENT sid="476" pm="."><plain>Revelation of pseudogene-derived lncRNAs is an exciting new development and how these lncRNAs interact with miRNAs will provide novel biomarkers and prognostic tools for cancer. </plain></SENT>
<SENT sid="477" pm="."><plain>The relatively younger protagonists, namely circRNAs which act as miRNA traps and the fusion circRNAs generated during chromosomal translocation further emphasize how the complex network of ncRNAs is perturbed in cancer. </plain></SENT>
<SENT sid="478" pm="."><plain>A better individual and collective understanding of the members of this nefarious nexus will set the stage for RNA aided cancer therapy. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="479" pm="."><plain>This work was supported by Ludwig Center at Harvard grant to F.J.S. and E.A. </plain></SENT>
<SENT sid="480" pm="."><plain>P.T. was supported by a grant from UICC, Switzerland. </plain></SENT>
<SENT sid="481" pm="."><plain>We thank members of the Trivedi group and the Slack group for comments. </plain></SENT>
</text></text4fund></p></ack></SecTag><notes><title>Author Contributions</title><p>E.A., A.F., P.T. and F.J.S. analyzed the data, scanned literature and wrote the paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-ijms-19-02072"><text><SENT sid="482" pm="."><plain>1.EddyS.R.Non-coding RNA genes and the modern RNA worldNat. </plain></SENT>
<SENT sid="483" pm="."><plain>Rev. </plain></SENT>
<SENT sid="484" pm="."><plain>Genet.2001291992910.1038/35103511<?supplied-pmid 11733745?>11733745 </plain></SENT>
</text></ref><ref id="B2-ijms-19-02072"><text><SENT sid="485" pm="."><plain>2.GilbertW.Origin of life: The RNA worldNature198631961810.1038/319618a0 </plain></SENT>
</text></ref><ref id="B3-ijms-19-02072"><text><SENT sid="486" pm="."><plain>3.AltmanS.A view of RNase PMol. </plain></SENT>
<SENT sid="487" pm="."><plain>BioSyst.2007360460710.1039/b707850c<?supplied-pmid 17700860?>17700860 </plain></SENT>
</text></ref><ref id="B4-ijms-19-02072"><text><SENT sid="488" pm="."><plain>4.CechT.R.Nobel lecture. </plain></SENT>
<SENT sid="489" pm="."><plain>Self-splicing and enzymatic activity of an intervening sequence RNA from TetrahymenaBiosci. </plain></SENT>
<SENT sid="490" pm="."><plain>Rep.19901023926110.1007/BF01117241<?supplied-pmid 1699616?>1699616 </plain></SENT>
</text></ref><ref id="B5-ijms-19-02072"><text><SENT sid="491" pm="."><plain>5.LeeR.C.FeinbaumR.L.AmbrosV.The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14Cell19937584385410.1016/0092-8674(93)90529-Y8252621 </plain></SENT>
</text></ref><ref id="B6-ijms-19-02072"><text><SENT sid="492" pm="."><plain>6.ReinhartB.J.SlackF.J.BassonM.PasquinelliA.E.BettingerJ.C.RougvieA.E.HorvitzH.R.RuvkunG.The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegansNature200040390190610.1038/35002607<?supplied-pmid 10706289?>10706289 </plain></SENT>
</text></ref><ref id="B7-ijms-19-02072"><text><SENT sid="493" pm="."><plain>7.DjebaliS.DavisC.A.MerkelA.DobinA.LassmannT.MortazaviA.TanzerA.LagardeJ.LinW.SchlesingerF.Landscape of transcription in human cellsNature201248910110810.1038/nature11233<?supplied-pmid 22955620?>22955620 </plain></SENT>
</text></ref><ref id="B8-ijms-19-02072"><text><SENT sid="494" pm="."><plain>8.ENCODE Project ConsortiumThe ENCODE (ENCyclopedia of DNA Elements) ProjectScience200430663664015499007 </plain></SENT>
</text></ref><ref id="B9-ijms-19-02072"><text><SENT sid="495" pm="."><plain>9.RajagopalanR.VaucheretH.TrejoJ.BartelD.P.A diverse and evolutionarily fluid set of microRNAs in Arabidopsis thalianaGenes Dev.2006203407342510.1101/gad.1476406<?supplied-pmid 17182867?>17182867 </plain></SENT>
</text></ref><ref id="B10-ijms-19-02072"><text><SENT sid="496" pm="."><plain>10.EspinosaJ.M.Revisiting lncRNAs: How Do You Know Yours Is Not an eRNA?Mol. </plain></SENT>
<SENT sid="497" pm="."><plain>Cell2016621210.1016/j.molcel.2016.03.022<?supplied-pmid 27058782?>27058782 </plain></SENT>
</text></ref><ref id="B11-ijms-19-02072"><text><SENT sid="498" pm="."><plain>11.KozomaraA.Griffiths-JonesS.miRBase: Annotating high confidence microRNAs using deep sequencing dataNucleic Acids Res.201442D68D7310.1093/nar/gkt1181<?supplied-pmid 24275495?>24275495 </plain></SENT>
</text></ref><ref id="B12-ijms-19-02072"><text><SENT sid="499" pm="."><plain>12.BergetS.M.MooreC.SharpP.A.Spliced segments at the 5′ terminus of adenovirus 2 late mRNAProc. </plain></SENT>
<SENT sid="500" pm="."><plain>Natl. </plain></SENT>
<SENT sid="501" pm="."><plain>Acad. </plain></SENT>
<SENT sid="502" pm="."><plain>Sci. </plain></SENT>
<SENT sid="503" pm="."><plain>USA1977743171317510.1073/pnas.74.8.3171<?supplied-pmid 269380?>269380 </plain></SENT>
</text></ref><ref id="B13-ijms-19-02072"><text><SENT sid="504" pm="."><plain>13.ChowL.T.GelinasR.E.BrokerT.R.RobertsR.J.An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNACell1977121810.1016/0092-8674(77)90180-5902310 </plain></SENT>
</text></ref><ref id="B14-ijms-19-02072"><text><SENT sid="505" pm="."><plain>14.SangerH.L.KlotzG.RiesnerD.GrossH.J.KleinschmidtA.K.Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structuresProc. </plain></SENT>
<SENT sid="506" pm="."><plain>Natl. </plain></SENT>
<SENT sid="507" pm="."><plain>Acad. </plain></SENT>
<SENT sid="508" pm="."><plain>Sci. </plain></SENT>
<SENT sid="509" pm="."><plain>USA1976733852385610.1073/pnas.73.11.3852<?supplied-pmid 1069269?>1069269 </plain></SENT>
</text></ref><ref id="B15-ijms-19-02072"><text><SENT sid="510" pm="."><plain>15.HsuM.T.Coca-PradosM.Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cellsNature197928033934010.1038/280339a0<?supplied-pmid 460409?>460409 </plain></SENT>
</text></ref><ref id="B16-ijms-19-02072"><text><SENT sid="511" pm="."><plain>16.NigroJ.M.ChoK.R.FearonE.R.KernS.E.RuppertJ.M.OlinerJ.D.KinzlerK.W.VogelsteinB.Scrambled exonsCell19916460761310.1016/0092-8674(91)90244-S1991322 </plain></SENT>
</text></ref><ref id="B17-ijms-19-02072"><text><SENT sid="512" pm="."><plain>17.CapelB.SwainA.NicolisS.HackerA.WalterM.KoopmanP.GoodfellowP.Lovell-BadgeR.Circular transcripts of the testis-determining gene Sry in adult mouse testisCell1993731019103010.1016/0092-8674(93)90279-Y7684656 </plain></SENT>
</text></ref><ref id="B18-ijms-19-02072"><text><SENT sid="513" pm="."><plain>18.CocquerelleC.MascrezB.HetuinD.BailleulB.Mis-splicing yields circular RNA moleculesFASEB J.1993715516010.1096/fasebj.7.1.7678559<?supplied-pmid 7678559?>7678559 </plain></SENT>
</text></ref><ref id="B19-ijms-19-02072"><text><SENT sid="514" pm="."><plain>19.ZaphiropoulosP.G.Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testisMol. </plain></SENT>
<SENT sid="515" pm="."><plain>Cell. </plain></SENT>
<SENT sid="516" pm="."><plain>Biol.1997172985299310.1128/MCB.17.6.2985<?supplied-pmid 9154796?>9154796 </plain></SENT>
</text></ref><ref id="B20-ijms-19-02072"><text><SENT sid="517" pm="."><plain>20.Ashwal-FlussR.MeyerM.PamudurtiN.R.IvanovA.BartokO.HananM.EvantalN.MemczakS.RajewskyN.KadenerS.circRNA biogenesis competes with pre-mRNA splicingMol. </plain></SENT>
<SENT sid="518" pm="."><plain>Cell201456556610.1016/j.molcel.2014.08.019<?supplied-pmid 25242144?>25242144 </plain></SENT>
</text></ref><ref id="B21-ijms-19-02072"><text><SENT sid="519" pm="."><plain>21.IvanovA.MemczakS.WylerE.TortiF.PorathH.T.OrejuelaM.R.PiechottaM.LevanonE.Y.LandthalerM.DieterichC.Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animalsCell Rep.20151017017710.1016/j.celrep.2014.12.019<?supplied-pmid 25558066?>25558066 </plain></SENT>
</text></ref><ref id="B22-ijms-19-02072"><text><SENT sid="520" pm="."><plain>22.Rybak-WolfA.StottmeisterC.GlazarP.JensM.PinoN.GiustiS.HananM.BehmM.BartokO.Ashwal-FlussR.Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically ExpressedMol. </plain></SENT>
<SENT sid="521" pm="."><plain>Cell20155887088510.1016/j.molcel.2015.03.027<?supplied-pmid 25921068?>25921068 </plain></SENT>
</text></ref><ref id="B23-ijms-19-02072"><text><SENT sid="522" pm="."><plain>23.SalmenaL.PolisenoL.TayY.KatsL.PandolfiP.P.A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language?Cell201114635335810.1016/j.cell.2011.07.014<?supplied-pmid 21802130?>21802130 </plain></SENT>
</text></ref><ref id="B24-ijms-19-02072"><text><SENT sid="523" pm="."><plain>24.TayY.RinnJ.PandolfiP.P.The multilayered complexity of ceRNA crosstalk and competitionNature201450534435210.1038/nature12986<?supplied-pmid 24429633?>24429633 </plain></SENT>
</text></ref><ref id="B25-ijms-19-02072"><text><SENT sid="524" pm="."><plain>25.PeiB.SisuC.FrankishA.HowaldC.HabeggerL.MuX.J.HarteR.BalasubramanianS.TanzerA.DiekhansM.The GENCODE pseudogene resourceGenome Biol.201213R5110.1186/gb-2012-13-9-r51<?supplied-pmid 22951037?>22951037 </plain></SENT>
</text></ref><ref id="B26-ijms-19-02072"><text><SENT sid="525" pm="."><plain>26.AnastasiadouE.JacobL.S.SlackF.J.Non-coding RNA networks in cancerNat. </plain></SENT>
<SENT sid="526" pm="."><plain>Rev. </plain></SENT>
<SENT sid="527" pm="."><plain>Cancer20181851810.1038/nrc.2017.99<?supplied-pmid 29170536?>29170536 </plain></SENT>
</text></ref><ref id="B27-ijms-19-02072"><text><SENT sid="528" pm="."><plain>27.AdamsB.D.AnastasiadouE.EstellerM.HeL.SlackF.J.The Inescapable Influence of Noncoding RNAs in CancerCancer Res.2015755206521010.1158/0008-5472.CAN-15-1989<?supplied-pmid 26567137?>26567137 </plain></SENT>
</text></ref><ref id="B28-ijms-19-02072"><text><SENT sid="529" pm="."><plain>28.AnastasiadouE.StroopinskyD.AlimpertiS.JiaoA.L.PyzerA.R.CippitelliC.PepeG.SeveraM.RosenblattJ.EtnaM.P.Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomasLeukemia201810.1038/s41375-018-0178-x<?supplied-pmid 29946193?>29946193 </plain></SENT>
</text></ref><ref id="B29-ijms-19-02072"><text><SENT sid="530" pm="."><plain>29.BonasioR.ShiekhattarR.Regulation of transcription by long noncoding RNAsAnnu. </plain></SENT>
<SENT sid="531" pm="."><plain>Rev. </plain></SENT>
<SENT sid="532" pm="."><plain>Genet.20144843345510.1146/annurev-genet-120213-092323<?supplied-pmid 25251851?>25251851 </plain></SENT>
</text></ref><ref id="B30-ijms-19-02072"><text><SENT sid="533" pm="."><plain>30.SainiH.K.Griffiths-JonesS.EnrightA.J.Genomic analysis of human microRNA transcriptsProc. </plain></SENT>
<SENT sid="534" pm="."><plain>Natl. </plain></SENT>
<SENT sid="535" pm="."><plain>Acad. </plain></SENT>
<SENT sid="536" pm="."><plain>Sci. </plain></SENT>
<SENT sid="537" pm="."><plain>USA2007104177191772410.1073/pnas.0703890104<?supplied-pmid 17965236?>17965236 </plain></SENT>
</text></ref><ref id="B31-ijms-19-02072"><text><SENT sid="538" pm="."><plain>31.AmbrosV.LeeR.C.LavanwayA.WilliamsP.T.JewellD.MicroRNAs and other tiny endogenous RNAs in C. elegansCurr. </plain></SENT>
<SENT sid="539" pm="."><plain>Biol.20031380781810.1016/S0960-9822(03)00287-212747828 </plain></SENT>
</text></ref><ref id="B32-ijms-19-02072"><text><SENT sid="540" pm="."><plain>32.OliveV.LiQ.HeL.mir-17-92: A polycistronic oncomir with pleiotropic functionsImmunol. </plain></SENT>
<SENT sid="541" pm="."><plain>Rev.201325315816610.1111/imr.12054<?supplied-pmid 23550645?>23550645 </plain></SENT>
</text></ref><ref id="B33-ijms-19-02072"><text><SENT sid="542" pm="."><plain>33.LiZ.HuangC.BaoC.ChenL.LinM.WangX.ZhongG.YuB.HuW.DaiL.Exon-intron circular RNAs regulate transcription in the nucleusNat. </plain></SENT>
<SENT sid="543" pm="."><plain>Struct. </plain></SENT>
<SENT sid="544" pm="."><plain>Mol. </plain></SENT>
<SENT sid="545" pm="."><plain>Biol.20152225626410.1038/nsmb.2959<?supplied-pmid 25664725?>25664725 </plain></SENT>
</text></ref><ref id="B34-ijms-19-02072"><text><SENT sid="546" pm="."><plain>34.GreeneJ.BairdA.M.BradyL.LimM.GrayS.G.McDermottR.FinnS.P.Circular RNAs: Biogenesis, Function and Role in Human DiseasesFront. </plain></SENT>
<SENT sid="547" pm="."><plain>Mol. </plain></SENT>
<SENT sid="548" pm="."><plain>Biosci.201743810.3389/fmolb.2017.00038<?supplied-pmid 28634583?>28634583 </plain></SENT>
</text></ref><ref id="B35-ijms-19-02072"><text><SENT sid="549" pm="."><plain>35.LasdaE.ParkerR.Circular RNAs: Diversity of form and functionRNA2014201829184210.1261/rna.047126.114<?supplied-pmid 25404635?>25404635 </plain></SENT>
</text></ref><ref id="B36-ijms-19-02072"><text><SENT sid="550" pm="."><plain>36.BrugioloM.HerzelL.NeugebauerK.M.Counting on co-transcriptional splicingF1000Prime Rep.20135910.12703/P5-9<?supplied-pmid 23638305?>23638305 </plain></SENT>
</text></ref><ref id="B37-ijms-19-02072"><text><SENT sid="551" pm="."><plain>37.BraunS.DomdeyH.WiebauerK.Inverse splicing of a discontinuous pre-mRNA intron generates a circular exon in a HeLa cell nuclear extractNucleic Acids Res.1996244152415710.1093/nar/24.21.4152<?supplied-pmid 8932365?>8932365 </plain></SENT>
</text></ref><ref id="B38-ijms-19-02072"><text><SENT sid="552" pm="."><plain>38.ZhangY.ZhangX.O.ChenT.XiangJ.F.YinQ.F.XingY.H.ZhuS.YangL.ChenL.L.Circular intronic long noncoding RNAsMol. </plain></SENT>
<SENT sid="553" pm="."><plain>Cell20135179280610.1016/j.molcel.2013.08.017<?supplied-pmid 24035497?>24035497 </plain></SENT>
</text></ref><ref id="B39-ijms-19-02072"><text><SENT sid="554" pm="."><plain>39.SigovaA.A.MullenA.C.MolinieB.GuptaS.OrlandoD.A.GuentherM.G.AlmadaA.E.LinC.SharpP.A.GiallourakisC.C.Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cellsProc. </plain></SENT>
<SENT sid="555" pm="."><plain>Natl. </plain></SENT>
<SENT sid="556" pm="."><plain>Acad. </plain></SENT>
<SENT sid="557" pm="."><plain>Sci. </plain></SENT>
<SENT sid="558" pm="."><plain>USA20131102876288110.1073/pnas.1221904110<?supplied-pmid 23382218?>23382218 </plain></SENT>
</text></ref><ref id="B40-ijms-19-02072"><text><SENT sid="559" pm="."><plain>40.QuinnJ.J.ChangH.Y.Unique features of long non-coding RNA biogenesis and functionNat. </plain></SENT>
<SENT sid="560" pm="."><plain>Rev. </plain></SENT>
<SENT sid="561" pm="."><plain>Genet.201617476210.1038/nrg.2015.10<?supplied-pmid 26666209?>26666209 </plain></SENT>
</text></ref><ref id="B41-ijms-19-02072"><text><SENT sid="562" pm="."><plain>41.ZhengG.X.DoB.T.WebsterD.E.KhavariP.A.ChangH.Y.Dicer-microRNA-Myc circuit promotes transcription of hundreds of long noncoding RNAsNat. </plain></SENT>
<SENT sid="563" pm="."><plain>Struct. </plain></SENT>
<SENT sid="564" pm="."><plain>Mol. </plain></SENT>
<SENT sid="565" pm="."><plain>Biol.20142158559010.1038/nsmb.2842<?supplied-pmid 24929436?>24929436 </plain></SENT>
</text></ref><ref id="B42-ijms-19-02072"><text><SENT sid="566" pm="."><plain>42.AlcidE.A.TsukiyamaT.ATP-dependent chromatin remodeling shapes the long noncoding RNA landscapeGenes Dev.2014282348236010.1101/gad.250902.114<?supplied-pmid 25367034?>25367034 </plain></SENT>
</text></ref><ref id="B43-ijms-19-02072"><text><SENT sid="567" pm="."><plain>43.RamalingamP.PalanichamyJ.K.SinghA.DasP.BhagatM.KassabM.A.SinhaS.ChattopadhyayP.Biogenesis of intronic miRNAs located in clusters by independent transcription and alternative splicingRNA201420768710.1261/rna.041814.113<?supplied-pmid 24226766?>24226766 </plain></SENT>
</text></ref><ref id="B44-ijms-19-02072"><text><SENT sid="568" pm="."><plain>44.BorchertG.M.LanierW.DavidsonB.L.RNA polymerase III transcribes human microRNAsNat. </plain></SENT>
<SENT sid="569" pm="."><plain>Struct. </plain></SENT>
<SENT sid="570" pm="."><plain>Mol. </plain></SENT>
<SENT sid="571" pm="."><plain>Biol.2006131097110110.1038/nsmb1167<?supplied-pmid 17099701?>17099701 </plain></SENT>
</text></ref><ref id="B45-ijms-19-02072"><text><SENT sid="572" pm="."><plain>45.SibleyC.R.SeowY.SaaymanS.DijkstraK.K.El AndaloussiS.WeinbergM.S.WoodM.J.The biogenesis and characterization of mammalian microRNAs of mirtron originNucleic Acids Res.20124043844810.1093/nar/gkr722<?supplied-pmid 21914725?>21914725 </plain></SENT>
</text></ref><ref id="B46-ijms-19-02072"><text><SENT sid="573" pm="."><plain>46.BartelD.P.Metazoan MicroRNAsCell2018173205110.1016/j.cell.2018.03.006<?supplied-pmid 29570994?>29570994 </plain></SENT>
</text></ref><ref id="B47-ijms-19-02072"><text><SENT sid="574" pm="."><plain>47.MourelatosZ.DostieJ.PaushkinS.SharmaA.CharrouxB.AbelL.RappsilberJ.MannM.DreyfussG.miRNPs: A novel class of ribonucleoproteins containing numerous microRNAsGenes Dev.20021672072810.1101/gad.974702<?supplied-pmid 11914277?>11914277 </plain></SENT>
</text></ref><ref id="B48-ijms-19-02072"><text><SENT sid="575" pm="."><plain>48.ChuC.Y.RanaT.M.Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54PLoS Biol.20064e21010.1371/journal.pbio.0040210<?supplied-pmid 16756390?>16756390 </plain></SENT>
</text></ref><ref id="B49-ijms-19-02072"><text><SENT sid="576" pm="."><plain>49.HuH.Y.YanZ.XuY.HuH.MenzelC.ZhouY.H.ChenW.KhaitovichP.Sequence features associated with microRNA strand selection in humans and fliesBMC Genom.20091041310.1186/1471-2164-10-413<?supplied-pmid 19732433?>19732433 </plain></SENT>
</text></ref><ref id="B50-ijms-19-02072"><text><SENT sid="577" pm="."><plain>50.NakanishiK.Anatomy of RISC: How do small RNAs and chaperones activate Argonaute proteins?Wiley Interdiscip. </plain></SENT>
<SENT sid="578" pm="."><plain>Rev. </plain></SENT>
<SENT sid="579" pm="."><plain>RNA2016763766010.1002/wrna.1356<?supplied-pmid 27184117?>27184117 </plain></SENT>
</text></ref><ref id="B51-ijms-19-02072"><text><SENT sid="580" pm="."><plain>51.WinterJ.DiederichsS.Argonaute-3 activates the let-7a passenger strand microRNARNA Biol.2013101631164310.4161/rna.26424<?supplied-pmid 24100239?>24100239 </plain></SENT>
</text></ref><ref id="B52-ijms-19-02072"><text><SENT sid="581" pm="."><plain>52.LewisB.P.BurgeC.B.BartelD.P.Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targetsCell2005120152010.1016/j.cell.2004.12.035<?supplied-pmid 15652477?>15652477 </plain></SENT>
</text></ref><ref id="B53-ijms-19-02072"><text><SENT sid="582" pm="."><plain>53.GrimsonA.FarhK.K.JohnstonW.K.Garrett-EngeleP.LimL.P.BartelD.P.MicroRNA targeting specificity in mammals: Determinants beyond seed pairingMol. </plain></SENT>
<SENT sid="583" pm="."><plain>Cell2007279110510.1016/j.molcel.2007.06.017<?supplied-pmid 17612493?>17612493 </plain></SENT>
</text></ref><ref id="B54-ijms-19-02072"><text><SENT sid="584" pm="."><plain>54.BottiniS.Hamouda-TekayaN.MategotR.ZaragosiL.E.AudebertS.PisanoS.GrandjeanV.MauduitC.BenahmedM.BarbryP.Post-transcriptional gene silencing mediated by microRNAs is controlled by nucleoplasmic SfpqNat. </plain></SENT>
<SENT sid="585" pm="."><plain>Commun.20178118910.1038/s41467-017-01126-x<?supplied-pmid 29084942?>29084942 </plain></SENT>
</text></ref><ref id="B55-ijms-19-02072"><text><SENT sid="586" pm="."><plain>55.GagnonK.T.LiL.ChuY.JanowskiB.A.CoreyD.R.RNAi factors are present and active in human cell nucleiCell Rep.2014621122110.1016/j.celrep.2013.12.013<?supplied-pmid 24388755?>24388755 </plain></SENT>
</text></ref><ref id="B56-ijms-19-02072"><text><SENT sid="587" pm="."><plain>56.KimY.K.KimB.KimV.N.Re-evaluation of the roles of DROSHA, Export in 5, and DICER in microRNA biogenesisProc. </plain></SENT>
<SENT sid="588" pm="."><plain>Natl. </plain></SENT>
<SENT sid="589" pm="."><plain>Acad. </plain></SENT>
<SENT sid="590" pm="."><plain>Sci. </plain></SENT>
<SENT sid="591" pm="."><plain>USA2016113E1881E188910.1073/pnas.1602532113<?supplied-pmid 26976605?>26976605 </plain></SENT>
</text></ref><ref id="B57-ijms-19-02072"><text><SENT sid="592" pm="."><plain>57.YangJ.S.MaurinT.RobineN.RasmussenK.D.JeffreyK.L.ChandwaniR.PapapetrouE.P.SadelainM.O’CarrollD.LaiE.C.Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesisProc. </plain></SENT>
<SENT sid="593" pm="."><plain>Natl. </plain></SENT>
<SENT sid="594" pm="."><plain>Acad. </plain></SENT>
<SENT sid="595" pm="."><plain>Sci. </plain></SENT>
<SENT sid="596" pm="."><plain>USA2010107151631516810.1073/pnas.1006432107<?supplied-pmid 20699384?>20699384 </plain></SENT>
</text></ref><ref id="B58-ijms-19-02072"><text><SENT sid="597" pm="."><plain>58.JanasM.M.WangB.HarrisA.S.AguiarM.ShafferJ.M.SubrahmanyamY.V.BehlkeM.A.WucherpfennigK.W.GygiS.P.GagnonE.Alternative RISC assembly: Binding and repression of microRNA-mRNA duplexes by human Ago proteinsRNA2012182041205510.1261/rna.035675.112<?supplied-pmid 23019594?>23019594 </plain></SENT>
</text></ref><ref id="B59-ijms-19-02072"><text><SENT sid="598" pm="."><plain>59.HelwakA.KudlaG.DudnakovaT.TollerveyD.Mapping the human miRNA interactome by CLASH reveals frequent noncanonical bindingCell201315365466510.1016/j.cell.2013.03.043<?supplied-pmid 23622248?>23622248 </plain></SENT>
</text></ref><ref id="B60-ijms-19-02072"><text><SENT sid="599" pm="."><plain>60.BottiniS.Hamouda-TekayaN.TanasaB.ZaragosiL.E.GrandjeanV.RepettoE.TrabucchiM.From benchmarking HITS-CLIP peak detection programs to a new method for identification of miRNA-binding sites from Ago2-CLIP dataNucleic Acids Res.201745e7110.1093/nar/gkx007<?supplied-pmid 28108660?>28108660 </plain></SENT>
</text></ref><ref id="B61-ijms-19-02072"><text><SENT sid="600" pm="."><plain>61.JeckW.R.SharplessN.E.Detecting and characterizing circular RNAsNat. </plain></SENT>
<SENT sid="601" pm="."><plain>Biotechnol.20143245346110.1038/nbt.2890<?supplied-pmid 24811520?>24811520 </plain></SENT>
</text></ref><ref id="B62-ijms-19-02072"><text><SENT sid="602" pm="."><plain>62.HaslerJ.SamuelssonT.StrubK.Useful ‘junk’: Alu RNAs in the human transcriptomeCell. </plain></SENT>
<SENT sid="603" pm="."><plain>Mol. </plain></SENT>
<SENT sid="604" pm="."><plain>Life Sci.2007641793180010.1007/s00018-007-7084-0<?supplied-pmid 17514354?>17514354 </plain></SENT>
</text></ref><ref id="B63-ijms-19-02072"><text><SENT sid="605" pm="."><plain>63.PasmanZ.BeenM.D.Garcia-BlancoM.A.Exon circularization in mammalian nuclear extractsRNA19962603610<?supplied-pmid 8718689?>8718689 </plain></SENT>
</text></ref><ref id="B64-ijms-19-02072"><text><SENT sid="606" pm="."><plain>64.ZhangY.YangL.ChenL.L.Characterization of Circular RNAsMethods Mol. </plain></SENT>
<SENT sid="607" pm="."><plain>Biol.2016140221522710.1007/978-1-4939-3378-5_17<?supplied-pmid 26721494?>26721494 </plain></SENT>
</text></ref><ref id="B65-ijms-19-02072"><text><SENT sid="608" pm="."><plain>65.WiluszJ.E.Long noncoding RNAs: Re-writing dogmas of RNA processing and stabilityBiochim. </plain></SENT>
<SENT sid="609" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="610" pm="."><plain>Acta2016185912813810.1016/j.bbagrm.2015.06.003<?supplied-pmid 26073320?>26073320 </plain></SENT>
</text></ref><ref id="B66-ijms-19-02072"><text><SENT sid="611" pm="."><plain>66.DhirA.DhirS.ProudfootN.J.JoplingC.L.Microprocessor mediates transcriptional termination of long noncoding RNA transcripts hosting microRNAsNat. </plain></SENT>
<SENT sid="612" pm="."><plain>Struct. </plain></SENT>
<SENT sid="613" pm="."><plain>Mol. </plain></SENT>
<SENT sid="614" pm="."><plain>Biol.20152231932710.1038/nsmb.2982<?supplied-pmid 25730776?>25730776 </plain></SENT>
</text></ref><ref id="B67-ijms-19-02072"><text><SENT sid="615" pm="."><plain>67.McMahonM.ContrerasA.RuggeroD.Small RNAs with big implications: New insights into H/ACA snoRNA function and their role in human diseaseWiley Interdiscip. </plain></SENT>
<SENT sid="616" pm="."><plain>Rev. </plain></SENT>
<SENT sid="617" pm="."><plain>RNA2015617318910.1002/wrna.1266<?supplied-pmid 25363811?>25363811 </plain></SENT>
</text></ref><ref id="B68-ijms-19-02072"><text><SENT sid="618" pm="."><plain>68.YinQ.F.YangL.ZhangY.XiangJ.F.WuY.W.CarmichaelG.G.ChenL.L.Long noncoding RNAs with snoRNA endsMol. </plain></SENT>
<SENT sid="619" pm="."><plain>Cell20124821923010.1016/j.molcel.2012.07.033<?supplied-pmid 22959273?>22959273 </plain></SENT>
</text></ref><ref id="B69-ijms-19-02072"><text><SENT sid="620" pm="."><plain>69.CalinG.A.FerracinM.CimminoA.Di LevaG.ShimizuM.WojcikS.E.IorioM.V.VisoneR.SeverN.I.FabbriM.A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemiaN. </plain></SENT>
<SENT sid="621" pm="."><plain>Engl. </plain></SENT>
<SENT sid="622" pm="."><plain>J. </plain></SENT>
<SENT sid="623" pm="."><plain>Med.20053531793180110.1056/NEJMoa050995<?supplied-pmid 16251535?>16251535 </plain></SENT>
</text></ref><ref id="B70-ijms-19-02072"><text><SENT sid="624" pm="."><plain>70.LuJ.GetzG.MiskaE.A.Alvarez-SaavedraE.LambJ.PeckD.Sweet-CorderoA.EbertB.L.MakR.H.FerrandoA.A.MicroRNA expression profiles classify human cancersNature200543583483810.1038/nature03702<?supplied-pmid 15944708?>15944708 </plain></SENT>
</text></ref><ref id="B71-ijms-19-02072"><text><SENT sid="625" pm="."><plain>71.RamkissoonS.H.MainwaringL.A.OgasawaraY.KeyvanfarK.McCoyJ.P.Jr.SloandE.M.KajigayaS.YoungN.S.Hematopoietic-specific microRNA expression in human cellsLeuk. </plain></SENT>
<SENT sid="626" pm="."><plain>Res.20063064364710.1016/j.leukres.2005.09.001<?supplied-pmid 16226311?>16226311 </plain></SENT>
</text></ref><ref id="B72-ijms-19-02072"><text><SENT sid="627" pm="."><plain>72.MetzlerM.WildaM.BuschK.ViehmannS.BorkhardtA.High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphomaGenes Chromosomes Cancer20043916716910.1002/gcc.10316<?supplied-pmid 14695998?>14695998 </plain></SENT>
</text></ref><ref id="B73-ijms-19-02072"><text><SENT sid="628" pm="."><plain>73.MichaelM.Z.SMO.C.van Holst PellekaanN.G.YoungG.P.JamesR.J.Reduced accumulation of specific microRNAs in colorectal neoplasiaMol. </plain></SENT>
<SENT sid="629" pm="."><plain>Cancer Res.20031882891<?supplied-pmid 14573789?>14573789 </plain></SENT>
</text></ref><ref id="B74-ijms-19-02072"><text><SENT sid="630" pm="."><plain>74.CalinG.A.LiuC.G.SevignaniC.FerracinM.FelliN.DumitruC.D.ShimizuM.CimminoA.ZupoS.DonoM.MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemiasProc. </plain></SENT>
<SENT sid="631" pm="."><plain>Natl. </plain></SENT>
<SENT sid="632" pm="."><plain>Acad. </plain></SENT>
<SENT sid="633" pm="."><plain>Sci. </plain></SENT>
<SENT sid="634" pm="."><plain>USA2004101117551176010.1073/pnas.0404432101<?supplied-pmid 15284443?>15284443 </plain></SENT>
</text></ref><ref id="B75-ijms-19-02072"><text><SENT sid="635" pm="."><plain>75.MedinaP.P.NoldeM.SlackF.J.OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphomaNature2010467869010.1038/nature09284<?supplied-pmid 20693987?>20693987 </plain></SENT>
</text></ref><ref id="B76-ijms-19-02072"><text><SENT sid="636" pm="."><plain>76.BabarI.A.ChengC.J.BoothC.J.LiangX.WeidhaasJ.B.SaltzmanW.M.SlackF.J.Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphomaProc. </plain></SENT>
<SENT sid="637" pm="."><plain>Natl. </plain></SENT>
<SENT sid="638" pm="."><plain>Acad. </plain></SENT>
<SENT sid="639" pm="."><plain>Sci. </plain></SENT>
<SENT sid="640" pm="."><plain>USA2012109E1695E170410.1073/pnas.1201516109<?supplied-pmid 22685206?>22685206 </plain></SENT>
</text></ref><ref id="B77-ijms-19-02072"><text><SENT sid="641" pm="."><plain>77.XiaoC.SrinivasanL.CaladoD.P.PattersonH.C.ZhangB.WangJ.HendersonJ.M.KutokJ.L.RajewskyK.Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytesNat. </plain></SENT>
<SENT sid="642" pm="."><plain>Immunol.2008940541410.1038/ni1575<?supplied-pmid 18327259?>18327259 </plain></SENT>
</text></ref><ref id="B78-ijms-19-02072"><text><SENT sid="643" pm="."><plain>78.HeL.ThomsonJ.M.HemannM.T.Hernando-MongeE.MuD.GoodsonS.PowersS.Cordon-CardoC.LoweS.W.HannonG.J.A microRNA polycistron as a potential human oncogeneNature200543582883310.1038/nature03552<?supplied-pmid 15944707?>15944707 </plain></SENT>
</text></ref><ref id="B79-ijms-19-02072"><text><SENT sid="644" pm="."><plain>79.BeachyS.H.OnozawaM.ChungY.J.SlapeC.BilkeS.FrancisP.PinedaM.WalkerR.L.MeltzerP.AplanP.D.Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphomaBlood20121201048105910.1182/blood-2012-01-401760<?supplied-pmid 22723554?>22723554 </plain></SENT>
</text></ref><ref id="B80-ijms-19-02072"><text><SENT sid="645" pm="."><plain>80.AsslaberD.PinonJ.D.SeyfriedI.DeschP.StocherM.TinhoferI.EgleA.MerkelO.GreilR.microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemiaBlood20101154191419710.1182/blood-2009-07-234823<?supplied-pmid 20089965?>20089965 </plain></SENT>
</text></ref><ref id="B81-ijms-19-02072"><text><SENT sid="646" pm="."><plain>81.Esquela-KerscherA.SlackF.J.Oncomirs—Micrornas with a role in cancerNat. </plain></SENT>
<SENT sid="647" pm="."><plain>Rev. </plain></SENT>
<SENT sid="648" pm="."><plain>Cancer2006625926910.1038/nrc1840<?supplied-pmid 16557279?>16557279 </plain></SENT>
</text></ref><ref id="B82-ijms-19-02072"><text><SENT sid="649" pm="."><plain>82.PyzerA.R.StroopinskyD.RosenblattJ.AnastasiadouE.RajabiH.WashingtonA.TagdeA.ChuJ.H.CollM.JiaoA.L.MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAsLeukemia2017312780279010.1038/leu.2017.163<?supplied-pmid 28555079?>28555079 </plain></SENT>
</text></ref><ref id="B83-ijms-19-02072"><text><SENT sid="650" pm="."><plain>83.CostineanS.ZanesiN.PekarskyY.TiliE.VoliniaS.HeeremaN.CroceC.M.Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic miceProc. </plain></SENT>
<SENT sid="651" pm="."><plain>Natl. </plain></SENT>
<SENT sid="652" pm="."><plain>Acad. </plain></SENT>
<SENT sid="653" pm="."><plain>Sci. </plain></SENT>
<SENT sid="654" pm="."><plain>USA20061037024702910.1073/pnas.0602266103<?supplied-pmid 16641092?>16641092 </plain></SENT>
</text></ref><ref id="B84-ijms-19-02072"><text><SENT sid="655" pm="."><plain>84.GillesM.E.HaoL.HuangL.RupaimooleR.Lopez-CasasP.P.PulverE.JeongJ.C.MuthuswamyS.K.HidalgoM.BhatiaS.N.Personalized RNA Medicine for Pancreatic CancerClin. </plain></SENT>
<SENT sid="656" pm="."><plain>Cancer Res.2018241734174710.1158/1078-0432.CCR-17-2733<?supplied-pmid 29330203?>29330203 </plain></SENT>
</text></ref><ref id="B85-ijms-19-02072"><text><SENT sid="657" pm="."><plain>85.WangX.WangH.K.LiY.HafnerM.BanerjeeN.S.TangS.BriskinD.MeyersC.ChowL.T.XieX.microRNAs are biomarkers of oncogenic human papillomavirus infectionsProc. </plain></SENT>
<SENT sid="658" pm="."><plain>Natl. </plain></SENT>
<SENT sid="659" pm="."><plain>Acad. </plain></SENT>
<SENT sid="660" pm="."><plain>Sci. </plain></SENT>
<SENT sid="661" pm="."><plain>USA20141114262426710.1073/pnas.1401430111<?supplied-pmid 24591631?>24591631 </plain></SENT>
</text></ref><ref id="B86-ijms-19-02072"><text><SENT sid="662" pm="."><plain>86.JoplingC.L.SchutzS.SarnowP.Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genomeCell Host Microbe20084778510.1016/j.chom.2008.05.013<?supplied-pmid 18621012?>18621012 </plain></SENT>
</text></ref><ref id="B87-ijms-19-02072"><text><SENT sid="663" pm="."><plain>87.CullenB.R.MicroRNAs as mediators of viral evasion of the immune systemNat. </plain></SENT>
<SENT sid="664" pm="."><plain>Immunol.20131420521010.1038/ni.2537<?supplied-pmid 23416678?>23416678 </plain></SENT>
</text></ref><ref id="B88-ijms-19-02072"><text><SENT sid="665" pm="."><plain>88.Di NapoliA.Al-JadiriM.F.TalericoC.DurantiE.PilozziE.TrivediP.AnastasiadouE.AlsaadawiA.R.Al-DarrajiA.F.Al-HadadS.A.Epstein-Barr virus (EBV) positive classical Hodgkin lymphoma of Iraqi children: An immunophenotypic and molecular characterization of Hodgkin/Reed-Sternberg cellsPediatr. </plain></SENT>
<SENT sid="666" pm="."><plain>Blood Cancer2013602068207210.1002/pbc.24654<?supplied-pmid 24000236?>24000236 </plain></SENT>
</text></ref><ref id="B89-ijms-19-02072"><text><SENT sid="667" pm="."><plain>89.FarinaA.PeruzziG.LacconiV.LennaS.QuartaS.RosatoE.VestriA.R.YorkM.DreyfusD.H.FaggioniA.Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytesArthritis Res. </plain></SENT>
<SENT sid="668" pm="."><plain>Ther.2017193910.1186/s13075-017-1237-9<?supplied-pmid 28245863?>28245863 </plain></SENT>
</text></ref><ref id="B90-ijms-19-02072"><text><SENT sid="669" pm="."><plain>90.FarinaA.FarinaG.A.Fresh Insights into Disease Etiology and the Role of Microbial PathogensCurr. </plain></SENT>
<SENT sid="670" pm="."><plain>Rheumatol. </plain></SENT>
<SENT sid="671" pm="."><plain>Rep.201618110.1007/s11926-015-0552-x<?supplied-pmid 26700911?>26700911 </plain></SENT>
</text></ref><ref id="B91-ijms-19-02072"><text><SENT sid="672" pm="."><plain>91.AnastasiadouE.BoccellatoF.CironeM.KisL.L.KleinE.FratiL.FaggioniA.TrivediP.Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virusLeukemia2005191854185610.1038/sj.leu.2403895<?supplied-pmid 16079894?>16079894 </plain></SENT>
</text></ref><ref id="B92-ijms-19-02072"><text><SENT sid="673" pm="."><plain>92.RosatoP.AnastasiadouE.GargN.LenzeD.BoccellatoF.VincentiS.SeveraM.CocciaE.M.BigiR.CironeM.Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2Leukemia2012262343235210.1038/leu.2012.108<?supplied-pmid 22614176?>22614176 </plain></SENT>
</text></ref><ref id="B93-ijms-19-02072"><text><SENT sid="674" pm="."><plain>93.GattoG.RossiA.RossiD.KroeningS.BonattiS.MallardoM.Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-κB pathwayNucleic Acids Res.2008366608661910.1093/nar/gkn666<?supplied-pmid 18940871?>18940871 </plain></SENT>
</text></ref><ref id="B94-ijms-19-02072"><text><SENT sid="675" pm="."><plain>94.AnastasiadouE.BoccellatoF.VincentiS.RosatoP.BozzoniI.FratiL.FaggioniA.PresuttiC.TrivediP.Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29bOncogene2010291316132810.1038/onc.2009.439<?supplied-pmid 19966860?>19966860 </plain></SENT>
</text></ref><ref id="B95-ijms-19-02072"><text><SENT sid="676" pm="."><plain>95.CameronJ.E.FewellC.YinQ.McBrideJ.WangX.LinZ.FlemingtonE.K.Epstein-Barr virus growth/latency III program alters cellular microRNA expressionVirology200838225726610.1016/j.virol.2008.09.018<?supplied-pmid 18950829?>18950829 </plain></SENT>
</text></ref><ref id="B96-ijms-19-02072"><text><SENT sid="677" pm="."><plain>96.AnastasiadouE.GargN.BigiR.YadavS.CampeseA.F.LapentaC.SpadaM.CuomoL.BottaA.BelardelliF.Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cellsInt. </plain></SENT>
<SENT sid="678" pm="."><plain>J. </plain></SENT>
<SENT sid="679" pm="."><plain>Cancer20151371491149710.1002/ijc.29489<?supplied-pmid 25704079?>25704079 </plain></SENT>
</text></ref><ref id="B97-ijms-19-02072"><text><SENT sid="680" pm="."><plain>97.ImigJ.MotschN.ZhuJ.Y.BarthS.OkoniewskiM.ReinekeT.TinguelyM.FaggioniA.TrivediP.MeisterG.microRNA profiling in Epstein-Barr virus-associated B-cell lymphomaNucleic Acids Res.2011391880189310.1093/nar/gkq1043<?supplied-pmid 21062812?>21062812 </plain></SENT>
</text></ref><ref id="B98-ijms-19-02072"><text><SENT sid="681" pm="."><plain>98.MerrittW.M.LinY.G.HanL.Y.KamatA.A.SpannuthW.A.SchmandtR.UrbauerD.PennacchioL.A.ChengJ.F.NickA.M.Dicer, Drosha, and outcomes in patients with ovarian cancerN. </plain></SENT>
<SENT sid="682" pm="."><plain>Engl. </plain></SENT>
<SENT sid="683" pm="."><plain>J. </plain></SENT>
<SENT sid="684" pm="."><plain>Med.20083592641265010.1056/NEJMoa0803785<?supplied-pmid 19092150?>19092150 </plain></SENT>
</text></ref><ref id="B99-ijms-19-02072"><text><SENT sid="685" pm="."><plain>99.VaksmanO.HetlandT.E.TropeC.G.ReichR.DavidsonB.Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinomaHum. </plain></SENT>
<SENT sid="686" pm="."><plain>Pathol.2012432062206910.1016/j.humpath.2012.02.016<?supplied-pmid 22647351?>22647351 </plain></SENT>
</text></ref><ref id="B100-ijms-19-02072"><text><SENT sid="687" pm="."><plain>100.ChioseaS.JelezcovaE.ChandranU.AcquafondataM.McHaleT.SobolR.W.DhirR.Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinomaAm. </plain></SENT>
<SENT sid="688" pm="."><plain>J. </plain></SENT>
<SENT sid="689" pm="."><plain>Pathol.20061691812182010.2353/ajpath.2006.060480<?supplied-pmid 17071602?>17071602 </plain></SENT>
</text></ref><ref id="B101-ijms-19-02072"><text><SENT sid="690" pm="."><plain>101.ChioseaS.JelezcovaE.ChandranU.LuoJ.ManthaG.SobolR.W.DacicS.Overexpression of Dicer in precursor lesions of lung adenocarcinomaCancer Res.2007672345235010.1158/0008-5472.CAN-06-3533<?supplied-pmid 17332367?>17332367 </plain></SENT>
</text></ref><ref id="B102-ijms-19-02072"><text><SENT sid="691" pm="."><plain>102.MuralidharB.WinderD.MurrayM.PalmerR.Barbosa-MoraisN.SainiH.RobertsI.PettM.ColemanN.Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profilesJ. </plain></SENT>
<SENT sid="692" pm="."><plain>Pathol.201122449650710.1002/path.2898<?supplied-pmid 21590768?>21590768 </plain></SENT>
</text></ref><ref id="B103-ijms-19-02072"><text><SENT sid="693" pm="."><plain>103.RakhejaD.ChenK.S.LiuY.ShuklaA.A.SchmidV.ChangT.C.KhokharS.WickiserJ.E.KarandikarN.J.MalterJ.S.Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumoursNat. </plain></SENT>
<SENT sid="694" pm="."><plain>Commun.20142480210.1038/ncomms5802<?supplied-pmid 25190313?>25190313 </plain></SENT>
</text></ref><ref id="B104-ijms-19-02072"><text><SENT sid="695" pm="."><plain>104.HorikawaY.WoodC.G.YangH.ZhaoH.YeY.GuJ.LinJ.HabuchiT.WuX.Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinomaClin. </plain></SENT>
<SENT sid="696" pm="."><plain>Cancer Res.2008147956796210.1158/1078-0432.CCR-08-1199<?supplied-pmid 19047128?>19047128 </plain></SENT>
</text></ref><ref id="B105-ijms-19-02072"><text><SENT sid="697" pm="."><plain>105.LiuS.AnJ.LinJ.LiuY.BaoL.ZhangW.ZhaoJ.J.Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinomaPLoS ONE20149e9279110.1371/journal.pone.0092791<?supplied-pmid 24676133?>24676133 </plain></SENT>
</text></ref><ref id="B106-ijms-19-02072"><text><SENT sid="698" pm="."><plain>106.SunH.L.CuiR.ZhouJ.TengK.Y.HsiaoY.H.NakanishiK.FassanM.LuoZ.ShiG.TiliE.ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5Cancer Cell20163072373610.1016/j.ccell.2016.10.001<?supplied-pmid 27846390?>27846390 </plain></SENT>
</text></ref><ref id="B107-ijms-19-02072"><text><SENT sid="699" pm="."><plain>107.CalinG.A.SevignaniC.DumitruC.D.HyslopT.NochE.YendamuriS.ShimizuM.RattanS.BullrichF.NegriniM.Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancersProc. </plain></SENT>
<SENT sid="700" pm="."><plain>Natl. </plain></SENT>
<SENT sid="701" pm="."><plain>Acad. </plain></SENT>
<SENT sid="702" pm="."><plain>Sci. </plain></SENT>
<SENT sid="703" pm="."><plain>USA20041012999300410.1073/pnas.0307323101<?supplied-pmid 14973191?>14973191 </plain></SENT>
</text></ref><ref id="B108-ijms-19-02072"><text><SENT sid="704" pm="."><plain>108.MemczakS.JensM.ElefsiniotiA.TortiF.KruegerJ.RybakA.MaierL.MackowiakS.D.GregersenL.H.MunschauerM.Circular RNAs are a large class of animal RNAs with regulatory potencyNature201349533333810.1038/nature11928<?supplied-pmid 23446348?>23446348 </plain></SENT>
</text></ref><ref id="B109-ijms-19-02072"><text><SENT sid="705" pm="."><plain>109.JeckW.R.SorrentinoJ.A.WangK.SlevinM.K.BurdC.E.LiuJ.MarzluffW.F.SharplessN.E.Circular RNAs are abundant, conserved, and associated with ALU repeatsRNA20131914115710.1261/rna.035667.112<?supplied-pmid 23249747?>23249747 </plain></SENT>
</text></ref><ref id="B110-ijms-19-02072"><text><SENT sid="706" pm="."><plain>110.SchwanhausserB.BusseD.LiN.DittmarG.SchuchhardtJ.WolfJ.ChenW.SelbachM.Corrigendum: Global quantification of mammalian gene expression controlNature201349512612710.1038/nature11848<?supplied-pmid 23407496?>23407496 </plain></SENT>
</text></ref><ref id="B111-ijms-19-02072"><text><SENT sid="707" pm="."><plain>111.HaqueS.HarriesL.W.Circular RNAs (circRNAs) in Health and DiseaseGenes2017810.3390/genes8120353 </plain></SENT>
</text></ref><ref id="B112-ijms-19-02072"><text><SENT sid="708" pm="."><plain>112.GhosalS.DasS.SenR.BasakP.ChakrabartiJ.Circ2Traits: A comprehensive database for circular RNA potentially associated with disease and traitsFront. </plain></SENT>
<SENT sid="709" pm="."><plain>Genet.2013428310.3389/fgene.2013.00283<?supplied-pmid 24339831?>24339831 </plain></SENT>
</text></ref><ref id="B113-ijms-19-02072"><text><SENT sid="710" pm="."><plain>113.JiangQ.WangY.HaoY.JuanL.TengM.ZhangX.LiM.WangG.LiuY.miR2Disease: A manually curated database for microRNA deregulation in human diseaseNucleic Acids Res.200937D98D10410.1093/nar/gkn714<?supplied-pmid 18927107?>18927107 </plain></SENT>
</text></ref><ref id="B114-ijms-19-02072"><text><SENT sid="711" pm="."><plain>114.ChenX.HanP.ZhouT.GuoX.SongX.LiY.circRNADb: A comprehensive database for human circular RNAs with protein-coding annotationsSci. </plain></SENT>
<SENT sid="712" pm="."><plain>Rep.201663498510.1038/srep34985<?supplied-pmid 27725737?>27725737 </plain></SENT>
</text></ref><ref id="B115-ijms-19-02072"><text><SENT sid="713" pm="."><plain>115.GlazarP.PapavasileiouP.RajewskyN.circBase: A database for circular RNAsRNA2014201666167010.1261/rna.043687.113<?supplied-pmid 25234927?>25234927 </plain></SENT>
</text></ref><ref id="B116-ijms-19-02072"><text><SENT sid="714" pm="."><plain>116.ZhengQ.BaoC.GuoW.LiS.ChenJ.ChenB.LuoY.LyuD.LiY.ShiG.Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAsNat. </plain></SENT>
<SENT sid="715" pm="."><plain>Commun.201671121510.1038/ncomms11215<?supplied-pmid 27050392?>27050392 </plain></SENT>
</text></ref><ref id="B117-ijms-19-02072"><text><SENT sid="716" pm="."><plain>117.BoeckelJ.N.JaeN.HeumullerA.W.ChenW.BoonR.A.StellosK.ZeiherA.M.JohnD.UchidaS.DimmelerS.Identification and Characterization of Hypoxia-Regulated Endothelial Circular RNACirc. </plain></SENT>
<SENT sid="717" pm="."><plain>Res.201511788489010.1161/CIRCRESAHA.115.306319<?supplied-pmid 26377962?>26377962 </plain></SENT>
</text></ref><ref id="B118-ijms-19-02072"><text><SENT sid="718" pm="."><plain>118.FlynnR.A.ChangH.Y.Long noncoding RNAs in cell-fate programming and reprogrammingCell Stem Cell20141475276110.1016/j.stem.2014.05.014<?supplied-pmid 24905165?>24905165 </plain></SENT>
</text></ref><ref id="B119-ijms-19-02072"><text><SENT sid="719" pm="."><plain>119.FaghihiM.A.ModarresiF.KhalilA.M.WoodD.E.SahaganB.G.MorganT.E.FinchC.E.St LaurentG.3rdKennyP.J.WahlestedtC.Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretaseNat. </plain></SENT>
<SENT sid="720" pm="."><plain>Med.20081472373010.1038/nm1784<?supplied-pmid 18587408?>18587408 </plain></SENT>
</text></ref><ref id="B120-ijms-19-02072"><text><SENT sid="721" pm="."><plain>120.GarzonR.VoliniaS.PapaioannouD.NicoletD.KohlschmidtJ.YanP.S.MrozekK.BucciD.CarrollA.J.BaerM.R.Expression and prognostic impact of lncRNAs in acute myeloid leukemiaProc. </plain></SENT>
<SENT sid="722" pm="."><plain>Natl. </plain></SENT>
<SENT sid="723" pm="."><plain>Acad. </plain></SENT>
<SENT sid="724" pm="."><plain>Sci. </plain></SENT>
<SENT sid="725" pm="."><plain>USA2014111186791868410.1073/pnas.1422050112<?supplied-pmid 25512507?>25512507 </plain></SENT>
</text></ref><ref id="B121-ijms-19-02072"><text><SENT sid="726" pm="."><plain>121.SchmittA.M.ChangH.Y.Long Noncoding RNAs in Cancer PathwaysCancer Cell.20162945246310.1016/j.ccell.2016.03.010<?supplied-pmid 27070700?>27070700 </plain></SENT>
</text></ref><ref id="B122-ijms-19-02072"><text><SENT sid="727" pm="."><plain>122.BhanA.SoleimaniM.MandalS.S.Long Noncoding RNA and Cancer: A New ParadigmCancer Res.2017773965398110.1158/0008-5472.CAN-16-2634<?supplied-pmid 28701486?>28701486 </plain></SENT>
</text></ref><ref id="B123-ijms-19-02072"><text><SENT sid="728" pm="."><plain>123.WangK.C.YangY.W.LiuB.SanyalA.Corces-ZimmermanR.ChenY.LajoieB.R.ProtacioA.FlynnR.A.GuptaR.A.A long noncoding RNA maintains active chromatin to coordinate homeotic gene expressionNature201147212012410.1038/nature09819<?supplied-pmid 21423168?>21423168 </plain></SENT>
</text></ref><ref id="B124-ijms-19-02072"><text><SENT sid="729" pm="."><plain>124.FanY.YanT.ChaiY.JiangY.ZhuX.Long noncoding RNA HOTTIP as an independent prognostic marker in cancerClin. </plain></SENT>
<SENT sid="730" pm="."><plain>Chim. </plain></SENT>
<SENT sid="731" pm="."><plain>Acta201710.1016/j.cca.2017.07.031<?supplied-pmid 28778381?>28778381 </plain></SENT>
</text></ref><ref id="B125-ijms-19-02072"><text><SENT sid="732" pm="."><plain>125.XiangJ.F.YinQ.F.ChenT.ZhangY.ZhangX.O.WuZ.ZhangS.WangH.B.GeJ.LuX.Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locusCell Res.20142451353110.1038/cr.2014.35<?supplied-pmid 24662484?>24662484 </plain></SENT>
</text></ref><ref id="B126-ijms-19-02072"><text><SENT sid="733" pm="."><plain>126.DavidovichC.CechT.R.The recruitment of chromatin modifiers by long noncoding RNAs: Lessons from PRC2RNA2015212007202210.1261/rna.053918.115<?supplied-pmid 26574518?>26574518 </plain></SENT>
</text></ref><ref id="B127-ijms-19-02072"><text><SENT sid="734" pm="."><plain>127.HockH.A complex Polycomb issue: The two faces of EZH2 in cancerGenes Dev.20122675175510.1101/gad.191163.112<?supplied-pmid 22508723?>22508723 </plain></SENT>
</text></ref><ref id="B128-ijms-19-02072"><text><SENT sid="735" pm="."><plain>128.HeW.CaiQ.SunF.ZhongG.WangP.LiuH.LuoJ.YuH.HuangJ.LinT.linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancerBiochim. </plain></SENT>
<SENT sid="736" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="737" pm="."><plain>Acta201318321528153710.1016/j.bbadis.2013.05.010<?supplied-pmid 23688781?>23688781 </plain></SENT>
</text></ref><ref id="B129-ijms-19-02072"><text><SENT sid="738" pm="."><plain>129.GuptaR.A.ShahN.WangK.C.KimJ.HorlingsH.M.WongD.J.TsaiM.C.HungT.ArganiP.RinnJ.L.Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasisNature20104641071107610.1038/nature08975<?supplied-pmid 20393566?>20393566 </plain></SENT>
</text></ref><ref id="B130-ijms-19-02072"><text><SENT sid="739" pm="."><plain>130.LeeN.K.LeeJ.H.KimW.K.YunS.YounY.H.ParkC.H.ChoiY.Y.KimH.LeeS.K.Promoter methylation of PCDH10 by HOTAIR regulates the progression of gastrointestinal stromal tumorsOncotarget20167753077531810.18632/oncotarget.12171<?supplied-pmid 27659532?>27659532 </plain></SENT>
</text></ref><ref id="B131-ijms-19-02072"><text><SENT sid="740" pm="."><plain>131.WuL.ZhangL.ZhengS.Role of the long non-coding RNA HOTAIR in hepatocellular carcinomaOncol. </plain></SENT>
<SENT sid="741" pm="."><plain>Lett.2017141233123910.3892/ol.2017.6312<?supplied-pmid 28789338?>28789338 </plain></SENT>
</text></ref><ref id="B132-ijms-19-02072"><text><SENT sid="742" pm="."><plain>132.LeeJ.T.Lessons from X-chromosome inactivation: Long ncRNA as guides and tethers to the epigenomeGenes Dev.2009231831184210.1101/gad.1811209<?supplied-pmid 19684108?>19684108 </plain></SENT>
</text></ref><ref id="B133-ijms-19-02072"><text><SENT sid="743" pm="."><plain>133.YaoY.MaJ.XueY.WangP.LiZ.LiuJ.ChenL.XiZ.TengH.WangZ.Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152Cancer Lett.2015359758610.1016/j.canlet.2014.12.051<?supplied-pmid 25578780?>25578780 </plain></SENT>
</text></ref><ref id="B134-ijms-19-02072"><text><SENT sid="744" pm="."><plain>134.MaL.ZhouY.LuoX.GaoH.DengX.JiangY.Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancerOncotarget201784125413510.18632/oncotarget.13670<?supplied-pmid 27911852?>27911852 </plain></SENT>
</text></ref><ref id="B135-ijms-19-02072"><text><SENT sid="745" pm="."><plain>135.XingY.H.YaoR.W.ZhangY.GuoC.J.JiangS.XuG.DongR.YangL.ChenL.L.SLERT Regulates DDX21 Rings Associated with Pol I TranscriptionCell201716966467810.1016/j.cell.2017.04.011<?supplied-pmid 28475895?>28475895 </plain></SENT>
</text></ref><ref id="B136-ijms-19-02072"><text><SENT sid="746" pm="."><plain>136.Nguyen leX.T.RavalA.GarciaJ.S.MitchellB.S.Regulation of ribosomal gene expression in cancerJ. </plain></SENT>
<SENT sid="747" pm="."><plain>Cell. </plain></SENT>
<SENT sid="748" pm="."><plain>Physiol.20152301181118810.1002/jcp.24854<?supplied-pmid 25336383?>25336383 </plain></SENT>
</text></ref><ref id="B137-ijms-19-02072"><text><SENT sid="749" pm="."><plain>137.GutschnerT.HammerleM.DiederichsS.MALAT1—A paradigm for long noncoding RNA function in cancerJ. </plain></SENT>
<SENT sid="750" pm="."><plain>Mol. </plain></SENT>
<SENT sid="751" pm="."><plain>Med.20139179180110.1007/s00109-013-1028-y<?supplied-pmid 23529762?>23529762 </plain></SENT>
</text></ref><ref id="B138-ijms-19-02072"><text><SENT sid="752" pm="."><plain>138.LiuB.SunL.LiuQ.GongC.YaoY.LvX.LinL.YaoH.SuF.LiD.A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasisCancer Cell20152737038110.1016/j.ccell.2015.02.004<?supplied-pmid 25759022?>25759022 </plain></SENT>
</text></ref><ref id="B139-ijms-19-02072"><text><SENT sid="753" pm="."><plain>139.HuangW.CuiX.ChenJ.FengY.SongE.LiJ.LiuY.Long non-coding RNA NKILA inhibits migration and invasion of tongue squamous cell carcinoma cells via suppressing epithelial-mesenchymal transitionOncotarget20167625206253210.18632/oncotarget.11528<?supplied-pmid 27613832?>27613832 </plain></SENT>
</text></ref><ref id="B140-ijms-19-02072"><text><SENT sid="754" pm="."><plain>140.LuZ.LiY.WangJ.CheY.SunS.HuangJ.ChenZ.HeJ.Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-κB/Snail pathwayJ. </plain></SENT>
<SENT sid="755" pm="."><plain>Exp. </plain></SENT>
<SENT sid="756" pm="."><plain>Clin. </plain></SENT>
<SENT sid="757" pm="."><plain>Cancer Res.2017365410.1186/s13046-017-0518-0<?supplied-pmid 28412955?>28412955 </plain></SENT>
</text></ref><ref id="B141-ijms-19-02072"><text><SENT sid="758" pm="."><plain>141.ZhangY.ShieldsT.CrenshawT.HaoY.MoultonT.TyckoB.Imprinting of human H19: Allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switchingAm. </plain></SENT>
<SENT sid="759" pm="."><plain>J. </plain></SENT>
<SENT sid="760" pm="."><plain>Hum. </plain></SENT>
<SENT sid="761" pm="."><plain>Genet.199353113124<?supplied-pmid 8391213?>8391213 </plain></SENT>
</text></ref><ref id="B142-ijms-19-02072"><text><SENT sid="762" pm="."><plain>142.LuoJ.H.RenB.KeryanovS.TsengG.C.RaoU.N.MongaS.P.StromS.DemetrisA.J.NalesnikM.YuY.P.Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomasHepatology2006441012102410.1002/hep.21328<?supplied-pmid 17006932?>17006932 </plain></SENT>
</text></ref><ref id="B143-ijms-19-02072"><text><SENT sid="763" pm="."><plain>143.De KokJ.B.VerhaeghG.W.RoelofsR.W.HesselsD.KiemeneyL.A.AaldersT.W.SwinkelsD.W.SchalkenJ.A.DD3(PCA3), a very sensitive and specific marker to detect prostate tumorsCancer Res.20026226952698<?supplied-pmid 11980670?>11980670 </plain></SENT>
</text></ref><ref id="B144-ijms-19-02072"><text><SENT sid="764" pm="."><plain>144.MeiD.SongH.WangK.LouY.SunW.LiuZ.DingX.GuoJ.Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical associationMed. </plain></SENT>
<SENT sid="765" pm="."><plain>Oncol.20133070910.1007/s12032-013-0709-2<?supplied-pmid 23996296?>23996296 </plain></SENT>
</text></ref><ref id="B145-ijms-19-02072"><text><SENT sid="766" pm="."><plain>145.ChenL.L.Linking Long Noncoding RNA Localization and FunctionTrends Biochem. </plain></SENT>
<SENT sid="767" pm="."><plain>Sci.20164176177210.1016/j.tibs.2016.07.003<?supplied-pmid 27499234?>27499234 </plain></SENT>
</text></ref><ref id="B146-ijms-19-02072"><text><SENT sid="768" pm="."><plain>146.LiW.JinX.DengX.ZhangG.ZhangB.MaL.The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4EBiochem. </plain></SENT>
<SENT sid="769" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="770" pm="."><plain>Res. </plain></SENT>
<SENT sid="771" pm="."><plain>Commun.201444923524010.1016/j.bbrc.2014.05.011<?supplied-pmid 24845562?>24845562 </plain></SENT>
</text></ref><ref id="B147-ijms-19-02072"><text><SENT sid="772" pm="."><plain>147.WangP.LiuY.H.YaoY.L.LiZ.LiZ.Q.MaJ.XueY.X.Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21Cell. </plain></SENT>
<SENT sid="773" pm="."><plain>Signal.20152727528210.1016/j.cellsig.2014.11.011<?supplied-pmid 25446261?>25446261 </plain></SENT>
</text></ref><ref id="B148-ijms-19-02072"><text><SENT sid="774" pm="."><plain>148.LiuX.H.SunM.NieF.Q.GeY.B.ZhangE.B.YinD.D.KongR.XiaR.LuK.H.LiJ.H.Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancerMol. </plain></SENT>
<SENT sid="775" pm="."><plain>Cancer2014139210.1186/1476-4598-13-92<?supplied-pmid 24775712?>24775712 </plain></SENT>
</text></ref><ref id="B149-ijms-19-02072"><text><SENT sid="776" pm="."><plain>149.LiuQ.HuangJ.ZhouN.ZhangZ.ZhangA.LuZ.WuF.MoY.Y.LncRNA loc285194 is a p53-regulated tumor suppressorNucleic Acids Res.2013414976498710.1093/nar/gkt182<?supplied-pmid 23558749?>23558749 </plain></SENT>
</text></ref><ref id="B150-ijms-19-02072"><text><SENT sid="777" pm="."><plain>150.LiW.ZhaoW.LuZ.ZhangW.YangX.Long non-coding RNA GAS5 promotes proliferation, migration and invasion by regulation of miR-301a in esophageal cancerOncol. </plain></SENT>
<SENT sid="778" pm="."><plain>Res.201810.3727/096504018X15166193231711<?supplied-pmid 29386089?>29386089 </plain></SENT>
</text></ref><ref id="B151-ijms-19-02072"><text><SENT sid="779" pm="."><plain>151.SunY.HuB.WangQ.YeM.QiuQ.ZhouY.ZengF.ZhangX.GuoY.GuoL.Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216aCell Death Dis.201898510.1038/s41419-017-0113-5<?supplied-pmid 29367594?>29367594 </plain></SENT>
</text></ref><ref id="B152-ijms-19-02072"><text><SENT sid="780" pm="."><plain>152.YangY.WenL.ZhuH.Unveiling the hidden function of long non-coding RNA by identifying its major partner-proteinCell Biosci.201555910.1186/s13578-015-0050-x<?supplied-pmid 26500759?>26500759 </plain></SENT>
</text></ref><ref id="B153-ijms-19-02072"><text><SENT sid="781" pm="."><plain>153.HungT.WangY.LinM.F.KoegelA.K.KotakeY.GrantG.D.HorlingsH.M.ShahN.UmbrichtC.WangP.Extensive and coordinated transcription of noncoding RNAs within cell-cycle promotersNat. </plain></SENT>
<SENT sid="782" pm="."><plain>Genet.20114362162910.1038/ng.848<?supplied-pmid 21642992?>21642992 </plain></SENT>
</text></ref><ref id="B154-ijms-19-02072"><text><SENT sid="783" pm="."><plain>154.JacqC.MillerJ.R.BrownleeG.G.A pseudogene structure in 5S DNA of Xenopus laevisCell19771210912010.1016/0092-8674(77)90189-1561661 </plain></SENT>
</text></ref><ref id="B155-ijms-19-02072"><text><SENT sid="784" pm="."><plain>155.MilliganM.J.LipovichL.Pseudogene-derived lncRNAs: Emerging regulators of gene expressionFront. </plain></SENT>
<SENT sid="785" pm="."><plain>Genet.2014547610.3389/fgene.2014.00476<?supplied-pmid 25699073?>25699073 </plain></SENT>
</text></ref><ref id="B156-ijms-19-02072"><text><SENT sid="786" pm="."><plain>156.PolisenoL.SalmenaL.ZhangJ.CarverB.HavemanW.J.PandolfiP.P.A coding-independent function of gene and pseudogene mRNAs regulates tumour biologyNature20104651033103810.1038/nature09144<?supplied-pmid 20577206?>20577206 </plain></SENT>
</text></ref><ref id="B157-ijms-19-02072"><text><SENT sid="787" pm="."><plain>157.JohnssonP.AckleyA.VidarsdottirL.LuiW.O.CorcoranM.GranderD.MorrisK.V.A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cellsNat. </plain></SENT>
<SENT sid="788" pm="."><plain>Struct. </plain></SENT>
<SENT sid="789" pm="."><plain>Mol. </plain></SENT>
<SENT sid="790" pm="."><plain>Biol.20132044044610.1038/nsmb.2516<?supplied-pmid 23435381?>23435381 </plain></SENT>
</text></ref><ref id="B158-ijms-19-02072"><text><SENT sid="791" pm="."><plain>158.MaH.W.XieM.SunM.ChenT.Y.JinR.R.MaT.S.ChenQ.N.ZhangE.B.HeX.Z.DeW.The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expressionOncotarget20178522115222410.18632/oncotarget.11075<?supplied-pmid 28881724?>28881724 </plain></SENT>
</text></ref><ref id="B159-ijms-19-02072"><text><SENT sid="792" pm="."><plain>159.LianY.XuY.XiaoC.XiaR.GongH.YangP.ChenT.WuD.CaiZ.ZhangJ.The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTENSci. </plain></SENT>
<SENT sid="793" pm="."><plain>Rep.20177731210.1038/s41598-017-07954-7<?supplied-pmid 28779166?>28779166 </plain></SENT>
</text></ref><ref id="B160-ijms-19-02072"><text><SENT sid="794" pm="."><plain>160.HansenT.B.JensenT.I.ClausenB.H.BramsenJ.B.FinsenB.DamgaardC.K.KjemsJ.Natural RNA circles function as efficient microRNA spongesNature201349538438810.1038/nature11993<?supplied-pmid 23446346?>23446346 </plain></SENT>
</text></ref><ref id="B161-ijms-19-02072"><text><SENT sid="795" pm="."><plain>161.HansenT.B.WiklundE.D.BramsenJ.B.VilladsenS.B.StathamA.L.ClarkS.J.KjemsJ.miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNAEMBO J.2011304414442210.1038/emboj.2011.359<?supplied-pmid 21964070?>21964070 </plain></SENT>
</text></ref><ref id="B162-ijms-19-02072"><text><SENT sid="796" pm="."><plain>162.HansenT.B.KjemsJ.DamgaardC.K.Circular RNA and miR-7 in cancerCancer Res.2013735609561210.1158/0008-5472.CAN-13-1568<?supplied-pmid 24014594?>24014594 </plain></SENT>
</text></ref><ref id="B163-ijms-19-02072"><text><SENT sid="797" pm="."><plain>163.GuoJ.U.AgarwalV.GuoH.BartelD.P.Expanded identification and characterization of mammalian circular RNAsGenome Biol.20141540910.1186/s13059-014-0409-z<?supplied-pmid 25070500?>25070500 </plain></SENT>
</text></ref><ref id="B164-ijms-19-02072"><text><SENT sid="798" pm="."><plain>164.LiF.ZhangL.LiW.DengJ.ZhengJ.AnM.LuJ.ZhouY.Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/beta-catenin pathwayOncotarget201566001601310.18632/oncotarget.3469<?supplied-pmid 25749389?>25749389 </plain></SENT>
</text></ref><ref id="B165-ijms-19-02072"><text><SENT sid="799" pm="."><plain>165.LiF.MaK.SunM.ShiS.Identification of the tumor-suppressive function of circular RNA ITCH in glioma cells through sponging miR-214 and promoting linear ITCH expressionAm. </plain></SENT>
<SENT sid="800" pm="."><plain>J. </plain></SENT>
<SENT sid="801" pm="."><plain>Transl. </plain></SENT>
<SENT sid="802" pm="."><plain>Res.20181013731386<?supplied-pmid 29887952?>29887952 </plain></SENT>
</text></ref><ref id="B166-ijms-19-02072"><text><SENT sid="803" pm="."><plain>166.DuW.W.YangW.LiuE.YangZ.DhaliwalP.YangB.B.Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2Nucleic Acids Res.2016442846285810.1093/nar/gkw027<?supplied-pmid 26861625?>26861625 </plain></SENT>
</text></ref><ref id="B167-ijms-19-02072"><text><SENT sid="804" pm="."><plain>167.YangW.DuW.W.LiX.YeeA.J.YangB.B.Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesisOncogene2016353919393110.1038/onc.2015.460<?supplied-pmid 26657152?>26657152 </plain></SENT>
</text></ref><ref id="B168-ijms-19-02072"><text><SENT sid="805" pm="."><plain>168.LuW.Y.Roles of the circular RNA circ-Foxo3 in breast cancer progressionCell Cycle20171658959010.1080/15384101.2017.1278935<?supplied-pmid 28278047?>28278047 </plain></SENT>
</text></ref><ref id="B169-ijms-19-02072"><text><SENT sid="806" pm="."><plain>169.LiY.ZhengQ.BaoC.LiS.GuoW.ZhaoJ.ChenD.GuJ.HeX.HuangS.Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosisCell Res.20152598198410.1038/cr.2015.82<?supplied-pmid 26138677?>26138677 </plain></SENT>
</text></ref><ref id="B170-ijms-19-02072"><text><SENT sid="807" pm="."><plain>170.DuP.WangL.SlizP.GregoryR.I.A Biogenesis Step Upstream of Microprocessor Controls miR-17 approximately 92 ExpressionCell201516288589910.1016/j.cell.2015.07.008<?supplied-pmid 26255770?>26255770 </plain></SENT>
</text></ref><ref id="B171-ijms-19-02072"><text><SENT sid="808" pm="."><plain>171.OliveV.SabioE.BennettM.J.De JongC.S.BitonA.McGannJ.C.GreaneyS.K.SodirN.M.ZhouA.Y.BalakrishnanA.A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosisElife20132e0082210.7554/eLife.00822<?supplied-pmid 24137534?>24137534 </plain></SENT>
</text></ref><ref id="B172-ijms-19-02072"><text><SENT sid="809" pm="."><plain>172.NishikuraK.A-to-I editing of coding and non-coding RNAs by ADARsNat. </plain></SENT>
<SENT sid="810" pm="."><plain>Rev. </plain></SENT>
<SENT sid="811" pm="."><plain>Mol. </plain></SENT>
<SENT sid="812" pm="."><plain>Cell Biol.201617839610.1038/nrm.2015.4<?supplied-pmid 26648264?>26648264 </plain></SENT>
</text></ref><ref id="B173-ijms-19-02072"><text><SENT sid="813" pm="."><plain>173.FumagalliD.GacquerD.RotheF.LefortA.LibertF.BrownD.KheddoumiN.ShlienA.KonopkaT.SalgadoR.Principles Governing A-to-I RNA Editing in the Breast Cancer TranscriptomeCell Rep.20151327728910.1016/j.celrep.2015.09.032<?supplied-pmid 26440892?>26440892 </plain></SENT>
</text></ref><ref id="B174-ijms-19-02072"><text><SENT sid="814" pm="."><plain>174.KimD.D.KimT.T.WalshT.KobayashiY.MatiseT.C.BuyskeS.GabrielA.Widespread RNA editing of embedded alu elements in the human transcriptomeGenome Res.2004141719172510.1101/gr.2855504<?supplied-pmid 15342557?>15342557 </plain></SENT>
</text></ref><ref id="B175-ijms-19-02072"><text><SENT sid="815" pm="."><plain>175.DanielC.LagergrenJ.OhmanM.RNA editing of non-coding RNA and its role in gene regulationBiochimie2015117222710.1016/j.biochi.2015.05.020<?supplied-pmid 26051678?>26051678 </plain></SENT>
</text></ref><ref id="B176-ijms-19-02072"><text><SENT sid="816" pm="."><plain>176.VeroniC.MarnettoF.GranieriL.BertolottoA.BalleriniC.RepiceA.M.SchirruL.CogheG.CoccoE.AnastasiadouE.Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosisJ. </plain></SENT>
<SENT sid="817" pm="."><plain>Neuroinflamm.20151213210.1186/s12974-015-0353-1<?supplied-pmid 26169064?>26169064 </plain></SENT>
</text></ref><ref id="B177-ijms-19-02072"><text><SENT sid="818" pm="."><plain>177.OtaH.SakuraiM.GuptaR.ValenteL.WulffB.E.AriyoshiK.IizasaH.DavuluriR.V.NishikuraK.ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencingCell201315357558910.1016/j.cell.2013.03.024<?supplied-pmid 23622242?>23622242 </plain></SENT>
</text></ref><ref id="B178-ijms-19-02072"><text><SENT sid="819" pm="."><plain>178.TomaselliS.GaleanoF.AlonS.RahoS.GalardiS.PolitoV.A.PresuttiC.VincentiS.EisenbergE.LocatelliF.Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastomaGenome Biol.201516510.1186/s13059-014-0575-z<?supplied-pmid 25582055?>25582055 </plain></SENT>
</text></ref><ref id="B179-ijms-19-02072"><text><SENT sid="820" pm="."><plain>179.NemlichY.GreenbergE.OrtenbergR.BesserM.J.BarshackI.Jacob-HirschJ.JacobyE.EyalE.RivkinL.PrietoV.G.MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growthJ. </plain></SENT>
<SENT sid="821" pm="."><plain>Clin. </plain></SENT>
<SENT sid="822" pm="."><plain>Investig.20131232703271810.1172/JCI62980<?supplied-pmid 23728176?>23728176 </plain></SENT>
</text></ref><ref id="B180-ijms-19-02072"><text><SENT sid="823" pm="."><plain>180.ShoshanE.MobleyA.K.BraeuerR.R.KamiyaT.HuangL.VasquezM.E.SalamehA.LeeH.J.KimS.J.IvanC.Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasisNat. </plain></SENT>
<SENT sid="824" pm="."><plain>Cell Biol.20151731132110.1038/ncb3110<?supplied-pmid 25686251?>25686251 </plain></SENT>
</text></ref><ref id="B181-ijms-19-02072"><text><SENT sid="825" pm="."><plain>181.KuangL.LvG.WangB.LiL.DaiY.LiY.Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR125a and miR10a expressionMol. </plain></SENT>
<SENT sid="826" pm="."><plain>Med. </plain></SENT>
<SENT sid="827" pm="."><plain>Rep.201512939810.3892/mmr.2015.3341<?supplied-pmid 25673044?>25673044 </plain></SENT>
</text></ref><ref id="B182-ijms-19-02072"><text><SENT sid="828" pm="."><plain>182.EstellerM.Epigenetics in cancerN. </plain></SENT>
<SENT sid="829" pm="."><plain>Engl. </plain></SENT>
<SENT sid="830" pm="."><plain>J. </plain></SENT>
<SENT sid="831" pm="."><plain>Med.20083581148115910.1056/NEJMra072067<?supplied-pmid 18337604?>18337604 </plain></SENT>
</text></ref><ref id="B183-ijms-19-02072"><text><SENT sid="832" pm="."><plain>183.SaitoY.LiangG.EggerG.FriedmanJ.M.ChuangJ.C.CoetzeeG.A.JonesP.A.Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cellsCancer Cell2006943544310.1016/j.ccr.2006.04.020<?supplied-pmid 16766263?>16766263 </plain></SENT>
</text></ref><ref id="B184-ijms-19-02072"><text><SENT sid="833" pm="."><plain>184.WadaT.KikuchiJ.FurukawaY.Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8EMBO Rep.20121314214910.1038/embor.2011.247<?supplied-pmid 22222205?>22222205 </plain></SENT>
</text></ref><ref id="B185-ijms-19-02072"><text><SENT sid="834" pm="."><plain>185.PhanR.T.Dalla-FaveraR.The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cellsNature200443263563910.1038/nature03147<?supplied-pmid 15577913?>15577913 </plain></SENT>
</text></ref><ref id="B186-ijms-19-02072"><text><SENT sid="835" pm="."><plain>186.LujambioA.CalinG.A.VillanuevaA.RoperoS.Sánchez-CéspedesM.BlancoD.MontuengaL.M.RossiS.NicolosoM.S.FallerW.J.A microRNA DNA methylation signature for human cancer metastasisProc. </plain></SENT>
<SENT sid="836" pm="."><plain>Natl. </plain></SENT>
<SENT sid="837" pm="."><plain>Acad. </plain></SENT>
<SENT sid="838" pm="."><plain>Sci. </plain></SENT>
<SENT sid="839" pm="."><plain>USA2008105135561356110.1073/pnas.0803055105<?supplied-pmid 18768788?>18768788 </plain></SENT>
</text></ref><ref id="B187-ijms-19-02072"><text><SENT sid="840" pm="."><plain>187.HeD.X.GuF.GaoF.HaoJ.J.GongD.GuX.T.MaoA.Q.JinJ.FuL.MaX.Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancerSci. </plain></SENT>
<SENT sid="841" pm="."><plain>Rep.201662470610.1038/srep24706<?supplied-pmid 27094684?>27094684 </plain></SENT>
</text></ref><ref id="B188-ijms-19-02072"><text><SENT sid="842" pm="."><plain>188.AmeresS.L.HorwichM.D.HungJ.H.XuJ.GhildiyalM.WengZ.ZamoreP.D.Target RNA-directed trimming and tailing of small silencing RNAsScience20103281534153910.1126/science.1187058<?supplied-pmid 20558712?>20558712 </plain></SENT>
</text></ref><ref id="B189-ijms-19-02072"><text><SENT sid="843" pm="."><plain>189.MullenT.E.MarzluffW.F.Degradation of histone mRNA requires oligouridylation followed by decapping and simultaneous degradation of the mRNA both 5′ to 3′ and 3′ to 5′Genes Dev.200822506510.1101/gad.1622708<?supplied-pmid 18172165?>18172165 </plain></SENT>
</text></ref><ref id="B190-ijms-19-02072"><text><SENT sid="844" pm="."><plain>190.LundE.DahlbergJ.E.Cyclic 2′,3′-phosphates and nontemplated nucleotides at the 3′-end of spliceosomal U6 small nuclear RNA’sScience199225532733010.1126/science.1549778<?supplied-pmid 1549778?>1549778 </plain></SENT>
</text></ref><ref id="B191-ijms-19-02072"><text><SENT sid="845" pm="."><plain>191.NorburyC.J.3′ Uridylation and the regulation of RNA function in the cytoplasmBiochem. </plain></SENT>
<SENT sid="846" pm="."><plain>Soc. </plain></SENT>
<SENT sid="847" pm="."><plain>Trans.2010381150115310.1042/BST0381150<?supplied-pmid 20659020?>20659020 </plain></SENT>
</text></ref><ref id="B192-ijms-19-02072"><text><SENT sid="848" pm="."><plain>192.ChoiY.S.PatenaW.LeavittA.D.McManusM.T.Widespread RNA 3′-end oligouridylation in mammalsRNA20121839440110.1261/rna.029306.111<?supplied-pmid 22291204?>22291204 </plain></SENT>
</text></ref><ref id="B193-ijms-19-02072"><text><SENT sid="849" pm="."><plain>193.NewmanM.A.ManiV.HammondS.M.Deep sequencing of microRNA precursors reveals extensive 3′-end modificationRNA2011171795180310.1261/rna.2713611<?supplied-pmid 21849429?>21849429 </plain></SENT>
</text></ref><ref id="B194-ijms-19-02072"><text><SENT sid="850" pm="."><plain>194.HeoI.JooC.KimY.K.HaM.YoonM.J.ChoJ.YeomK.H.HanJ.KimV.N.TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylationCell200913869670810.1016/j.cell.2009.08.002<?supplied-pmid 19703396?>19703396 </plain></SENT>
</text></ref><ref id="B195-ijms-19-02072"><text><SENT sid="851" pm="."><plain>195.UstianenkoD.HrossovaD.PotesilD.ChalupnikovaK.HrazdilovaK.PachernikJ.CetkovskaK.UldrijanS.ZdrahalZ.VanacovaS.Mammalian DIS3L2 exoribonuclease targets the uridylated precursors of let-7 miRNAsRNA2013191632163810.1261/rna.040055.113<?supplied-pmid 24141620?>24141620 </plain></SENT>
</text></ref><ref id="B196-ijms-19-02072"><text><SENT sid="852" pm="."><plain>196.LiuQ.GreimannJ.C.LimaC.D.Reconstitution, activities, and structure of the eukaryotic RNA exosomeCell20061271223123710.1016/j.cell.2006.10.037<?supplied-pmid 17174896?>17174896 </plain></SENT>
</text></ref><ref id="B197-ijms-19-02072"><text><SENT sid="853" pm="."><plain>197.ChangH.M.TribouletR.ThorntonJ.E.GregoryR.I.A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathwayNature201349724424810.1038/nature12119<?supplied-pmid 23594738?>23594738 </plain></SENT>
</text></ref><ref id="B198-ijms-19-02072"><text><SENT sid="854" pm="."><plain>198.PirouzM.DuP.MunafòM.GregoryR.I.Dis3l2-Mediated Decay Is a Quality Control Pathway for Noncoding RNAsCell Rep.2016161861187310.1016/j.celrep.2016.07.025<?supplied-pmid 27498873?>27498873 </plain></SENT>
</text></ref><ref id="B199-ijms-19-02072"><text><SENT sid="855" pm="."><plain>199.ThorntonJ.E.GregoryR.I.How does Lin28 let-7 control development and disease?Trends Cell. </plain></SENT>
<SENT sid="856" pm="."><plain>Biol.20122247448210.1016/j.tcb.2012.06.001<?supplied-pmid 22784697?>22784697 </plain></SENT>
</text></ref><ref id="B200-ijms-19-02072"><text><SENT sid="857" pm="."><plain>200.SalzmanD.W.NakamuraK.NallurS.DookwahM.T.MetheetrairutC.SlackF.J.WeidhaasJ.B.miR-34 activity is modulated through 5′-end phosphorylation in response to DNA damageNat. </plain></SENT>
<SENT sid="858" pm="."><plain>Commun.201671095410.1038/ncomms10954<?supplied-pmid 26996824?>26996824 </plain></SENT>
</text></ref><ref id="B201-ijms-19-02072"><text><SENT sid="859" pm="."><plain>201.WelchC.ChenY.StallingsR.L.MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cellsOncogene2007265017502210.1038/sj.onc.1210293<?supplied-pmid 17297439?>17297439 </plain></SENT>
</text></ref><ref id="B202-ijms-19-02072"><text><SENT sid="860" pm="."><plain>202.HeL.HeX.LimL.P.de StanchinaE.XuanZ.LiangY.XueW.ZenderL.MagnusJ.RidzonD.A microRNA component of the p53 tumour suppressor networkNature20074471130113410.1038/nature05939<?supplied-pmid 17554337?>17554337 </plain></SENT>
</text></ref><ref id="B203-ijms-19-02072"><text><SENT sid="861" pm="."><plain>203.ProudfootN.J.Ending the message: Poly(A) signals then and nowGenes Dev.2011251770178210.1101/gad.17268411<?supplied-pmid 21896654?>21896654 </plain></SENT>
</text></ref><ref id="B204-ijms-19-02072"><text><SENT sid="862" pm="."><plain>204.MajorosW.H.OhlerU.Spatial preferences of microRNA targets in 3′ untranslated regionsBMC Genom.2007815210.1186/1471-2164-8-152<?supplied-pmid 17555584?>17555584 </plain></SENT>
</text></ref><ref id="B205-ijms-19-02072"><text><SENT sid="863" pm="."><plain>205.MayrC.BartelD.P.Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cellsCell200913867310.1016/j.cell.2009.06.016<?supplied-pmid 19703394?>19703394 </plain></SENT>
</text></ref><ref id="B206-ijms-19-02072"><text><SENT sid="864" pm="."><plain>206.WiluszC.J.WormingtonM.PeltzS.W.The cap-to-tail guide to mRNA turnoverNat. </plain></SENT>
<SENT sid="865" pm="."><plain>Rev. </plain></SENT>
<SENT sid="866" pm="."><plain>Mol. </plain></SENT>
<SENT sid="867" pm="."><plain>Cell Biol.2001223724610.1038/35067025<?supplied-pmid 11283721?>11283721 </plain></SENT>
</text></ref><ref id="B207-ijms-19-02072"><text><SENT sid="868" pm="."><plain>207.VasudevanS.TongY.SteitzJ.A.Switching from repression to activation: MicroRNAs can up-regulate translationScience20073181931193410.1126/science.1149460<?supplied-pmid 18048652?>18048652 </plain></SENT>
</text></ref><ref id="B208-ijms-19-02072"><text><SENT sid="869" pm="."><plain>208.LinC.C.LiuL.Z.AddisonJ.B.WonderlinW.F.IvanovA.V.RuppertJ.M.A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell contextMol. </plain></SENT>
<SENT sid="870" pm="."><plain>Cell. </plain></SENT>
<SENT sid="871" pm="."><plain>Biol.2011312513252710.1128/MCB.01189-10<?supplied-pmid 21518959?>21518959 </plain></SENT>
</text></ref><ref id="B209-ijms-19-02072"><text><SENT sid="872" pm="."><plain>209.MooreM.J.From birth to death: The complex lives of eukaryotic mRNAsScience20053091514151810.1126/science.1111443<?supplied-pmid 16141059?>16141059 </plain></SENT>
</text></ref><ref id="B210-ijms-19-02072"><text><SENT sid="873" pm="."><plain>210.KimM.KoganN.SlackF.J.Cis-acting elements in its 3′UTR mediate post-transcriptional regulation of KRASOncotarget20167117701178410.18632/oncotarget.7599<?supplied-pmid 26930719?>26930719 </plain></SENT>
</text></ref><ref id="B211-ijms-19-02072"><text><SENT sid="874" pm="."><plain>211.BarrettL.W.FletcherS.WiltonS.D.Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elementsCell. </plain></SENT>
<SENT sid="875" pm="."><plain>Mol. </plain></SENT>
<SENT sid="876" pm="."><plain>Life Sci.2012693613363410.1007/s00018-012-0990-9<?supplied-pmid 22538991?>22538991 </plain></SENT>
</text></ref><ref id="B212-ijms-19-02072"><text><SENT sid="877" pm="."><plain>212.MaW.J.FurneauxH.Localization of the human HuR gene to chromosome 19p13.2Hum. </plain></SENT>
<SENT sid="878" pm="."><plain>Genet.199799323310.1007/s004390050305<?supplied-pmid 9003489?>9003489 </plain></SENT>
</text></ref><ref id="B213-ijms-19-02072"><text><SENT sid="879" pm="."><plain>213.FanX.C.SteitzJ.A.Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAsEMBO J.1998173448346010.1093/emboj/17.12.3448<?supplied-pmid 9628880?>9628880 </plain></SENT>
</text></ref><ref id="B214-ijms-19-02072"><text><SENT sid="880" pm="."><plain>214.QuenaultT.LithgowT.TravenA.PUF proteins: Repression, activation and mRNA localizationTrends Cell Biol.20112110411210.1016/j.tcb.2010.09.013<?supplied-pmid 21115348?>21115348 </plain></SENT>
</text></ref><ref id="B215-ijms-19-02072"><text><SENT sid="881" pm="."><plain>215.KeddeM.van KouwenhoveM.ZwartW.Oude VrielinkJ.A.ElkonR.AgamiR.A Pumilio-induced RNA structure switch in p27-3′UTR controls miR-221 and miR-222 accessibilityNat. </plain></SENT>
<SENT sid="882" pm="."><plain>Cell Biol.2010121014102010.1038/ncb2105<?supplied-pmid 20818387?>20818387 </plain></SENT>
</text></ref><ref id="B216-ijms-19-02072"><text><SENT sid="883" pm="."><plain>216.MilesW.O.TschopK.HerrA.JiJ.Y.DysonN.J.Pumilio facilitates miRNA regulation of the E2F3 oncogeneGenes Dev.20122635636810.1101/gad.182568.111<?supplied-pmid 22345517?>22345517 </plain></SENT>
</text></ref><ref id="B217-ijms-19-02072"><text><SENT sid="884" pm="."><plain>217.ChenH.Z.TsaiS.Y.LeoneG.Emerging roles of E2Fs in cancer: An exit from cell cycle controlNat. </plain></SENT>
<SENT sid="885" pm="."><plain>Rev. </plain></SENT>
<SENT sid="886" pm="."><plain>Cancer2009978579710.1038/nrc2696<?supplied-pmid 19851314?>19851314 </plain></SENT>
</text></ref><ref id="B218-ijms-19-02072"><text><SENT sid="887" pm="."><plain>218.KeddeM.StrasserM.J.BoldajipourB.Oude VrielinkJ.A.SlanchevK.le SageC.NagelR.VoorhoeveP.M.van DuijseJ.OromU.A.RNA-binding protein Dnd1 inhibits microRNA access to target mRNACell20071311273128610.1016/j.cell.2007.11.034<?supplied-pmid 18155131?>18155131 </plain></SENT>
</text></ref><ref id="B219-ijms-19-02072"><text><SENT sid="888" pm="."><plain>219.LeeY.S.DuttaA.The tumor suppressor microRNA let-7 represses the HMGA2 oncogeneGenes Dev.2007211025103010.1101/gad.1540407<?supplied-pmid 17437991?>17437991 </plain></SENT>
</text></ref><ref id="B220-ijms-19-02072"><text><SENT sid="889" pm="."><plain>220.PreskillC.WeidhaasJ.B.SNPs in microRNA Binding Sites as Prognostic and Predictive Cancer BiomarkersCrit. </plain></SENT>
<SENT sid="890" pm="."><plain>Rev. </plain></SENT>
<SENT sid="891" pm="."><plain>Oncog.20131832734010.1615/CritRevOncog.2013007254<?supplied-pmid 23614619?>23614619 </plain></SENT>
</text></ref><ref id="B221-ijms-19-02072"><text><SENT sid="892" pm="."><plain>221.YuZ.LiZ.JolicoeurN.ZhangL.FortinY.WangE.WuM.ShenS.H.Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancersNucleic Acids Res.2007354535454110.1093/nar/gkm480<?supplied-pmid 17584784?>17584784 </plain></SENT>
</text></ref><ref id="B222-ijms-19-02072"><text><SENT sid="893" pm="."><plain>222.ChinL.J.RatnerE.LengS.ZhaiR.NallurS.BabarI.MullerR.U.StrakaE.SuL.BurkiE.A.A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer riskCancer Res.2008688535854010.1158/0008-5472.CAN-08-2129<?supplied-pmid 18922928?>18922928 </plain></SENT>
</text></ref><ref id="B223-ijms-19-02072"><text><SENT sid="894" pm="."><plain>223.WynendaeleJ.BohnkeA.LeucciE.NielsenS.J.LambertzI.HammerS.SbrzesnyN.KubitzaD.WolfA.GradhandE.An illegitimate microRNA target site within the 3′UTR of MDM4 affects ovarian cancer progression and chemosensitivityCancer Res.2010709641964910.1158/0008-5472.CAN-10-0527<?supplied-pmid 21084273?>21084273 </plain></SENT>
</text></ref><ref id="B224-ijms-19-02072"><text><SENT sid="895" pm="."><plain>224.NicolosoM.S.SunH.SpizzoR.KimH.WickramasingheP.ShimizuM.WojcikS.E.FerdinJ.KunejT.XiaoL.Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibilityCancer Res.2010702789279810.1158/0008-5472.CAN-09-3541<?supplied-pmid 20332227?>20332227 </plain></SENT>
</text></ref><ref id="B225-ijms-19-02072"><text><SENT sid="896" pm="."><plain>225.GuarnerioJ.BezziM.JeongJ.C.PaffenholzS.V.BerryK.NaldiniM.M.Lo-CocoF.TayY.BeckA.H.PandolfiP.P.Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal TranslocationsCell20161661055105610.1016/j.cell.2016.07.035<?supplied-pmid 27518567?>27518567 </plain></SENT>
</text></ref><ref id="B226-ijms-19-02072"><text><SENT sid="897" pm="."><plain>226.dos SantosG.A.KatsL.PandolfiP.P.Synergy against PML-RARa: Targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemiaJ. </plain></SENT>
<SENT sid="898" pm="."><plain>Exp. </plain></SENT>
<SENT sid="899" pm="."><plain>Med.20132102793280210.1084/jem.20131121<?supplied-pmid 24344243?>24344243 </plain></SENT>
</text></ref><ref id="B227-ijms-19-02072"><text><SENT sid="900" pm="."><plain>227.MartelliM.P.SozziG.HernandezL.PettirossiV.NavarroA.ConteD.GaspariniP.PerroneF.ModenaP.PastorinoU.EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissuesAm. </plain></SENT>
<SENT sid="901" pm="."><plain>J. </plain></SENT>
<SENT sid="902" pm="."><plain>Pathol.200917466167010.2353/ajpath.2009.080755<?supplied-pmid 19147828?>19147828 </plain></SENT>
</text></ref><ref id="B228-ijms-19-02072"><text><SENT sid="903" pm="."><plain>228.GuoW.DongZ.ShiY.LiuS.LiangJ.GuoY.GuoX.ShenS.ShanB.Aberrant methylation-mediated downregulation of long noncoding RNA LOC100130476 correlates with malignant progression of esophageal squamous cell carcinomaDig. </plain></SENT>
<SENT sid="904" pm="."><plain>Liver Dis.20164896196910.1016/j.dld.2016.05.010<?supplied-pmid 27338851?>27338851 </plain></SENT>
</text></ref><ref id="B229-ijms-19-02072"><text><SENT sid="905" pm="."><plain>229.GuoW.LiuS.DongZ.GuoY.DingC.ShenS.LiangJ.ShanB.Aberrant methylation-mediated silencing of lncRNA CTC-276P9.1 is associated with malignant progression of esophageal squamous cell carcinomaClin. </plain></SENT>
<SENT sid="906" pm="."><plain>Exp. </plain></SENT>
<SENT sid="907" pm="."><plain>Metastasis201835536810.1007/s10585-018-9881-2<?supplied-pmid 29524086?>29524086 </plain></SENT>
</text></ref><ref id="B230-ijms-19-02072"><text><SENT sid="908" pm="."><plain>230.DongZ.ZhangA.LiuS.LuF.GuoY.ZhangG.XuF.ShiY.ShenS.LiangJ.Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal CancerMol. </plain></SENT>
<SENT sid="909" pm="."><plain>Cancer Res.20171580081010.1158/1541-7786.MCR-16-0385<?supplied-pmid 28539329?>28539329 </plain></SENT>
</text></ref><ref id="B231-ijms-19-02072"><text><SENT sid="910" pm="."><plain>231.GeY.Polymorphisms in lncRNA PTENP1 and the Risk of Gastric Cancer in a Chinese PopulationDis. </plain></SENT>
<SENT sid="911" pm="."><plain>Markers20172017680745210.1155/2017/6807452<?supplied-pmid 28931965?>28931965 </plain></SENT>
</text></ref><ref id="B232-ijms-19-02072"><text><SENT sid="912" pm="."><plain>232.YangC.TangR.MaX.WangY.LuoD.XuZ.ZhuY.YangL.Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han populationOncotarget20156153111532010.18632/oncotarget.3840<?supplied-pmid 25944697?>25944697 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="ijms-19-02072-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="913" pm="."><plain>An overview of biogenesis of (A): miRNAs, (B): circular RNAs and (C): lncRNAs. </plain></SENT>
<SENT sid="914" pm="."><plain>NcRNAs are first generated in the nucleus, transcribed by polymerase II giving rise to a long, sometimes hundreds of kilobases 5′ capped and 3′ polyadenylated transcripts. </plain></SENT>
<SENT sid="915" pm="."><plain>(A): Canonical miRNA: DGCR8 and Drosha bind and cleave the basal stem of pri-miRNAs to liberate the stem-loop pre-miRNA that enters the cytoplasm by Exportin 5 (EXP5) where the pre-miRNA loop is cleaved by the RNase III Dicer and HIV-1 TAR RNA binding protein (TRBP) to form a mature RNA duplex. </plain></SENT>
<SENT sid="916" pm="."><plain>One of the two strands, the guide strand, is selected by one of the four Argonaute (AGO) proteins and loaded together with the passenger strand in the RNA induced silencing complex (RISC). </plain></SENT>
<SENT sid="917" pm="."><plain>The passenger strand is degraded while the guide strand will become the mature miRNA. </plain></SENT>
<SENT sid="918" pm="."><plain>Non-canonical miRNAs: mirtrons: reside in introns at the exon junction site of the pre-mRNA, are spliceosome-dependent and have their own processing mechanism, which is independent from microprocessor complex. </plain></SENT>
<SENT sid="919" pm="."><plain>Mirtrons form lariats which are debranched under the action of lariat debranching enzymes (LDE) to fold into the pre-miRNA hairpin and proceed through the canonical miRNA pathway maturation. </plain></SENT>
<SENT sid="920" pm="."><plain>(B): Circular RNAs: The canonical spliceosomal machinery produces 3′-5′ backspliced circular pre-mRNA transcripts that are composed of exons (exonic circRNAs), or 2′-5′ lariats (intronic RNAs, ciRNAs) and exon-intron circRNAs (EIciRNAs). </plain></SENT>
<SENT sid="921" pm="."><plain>CiRNAs and ElciRNAs remain in the nucleus in contrast to the circRNAs, which are transported in the cytoplasm. </plain></SENT>
<SENT sid="922" pm="."><plain>(C): LncRNAs: Based on their location in the genome, lncRNAs may be long intergenic (lincRNAs), between two adjacent genes or intronic or within the intron of a protein-coding gene. </plain></SENT>
<SENT sid="923" pm="."><plain>Antisense lncRNAs as uaRNAs or eRNAs are transcribed in an opposite direction from the host gene. </plain></SENT>
<SENT sid="924" pm="."><plain>Intergenic and intronic lncRNAs are spliced from the pre-mRNA, through the spliceosomal machinery and can be polyadenylated or not. </plain></SENT>
<SENT sid="925" pm="."><plain>One of the functions of lncRNAs is to decoy miRNAs. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-19-02072-g001"/></fig></SecTag><SecTag type="FIG"><fig id="ijms-19-02072-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="926" pm="."><plain>Interactions of ncRNAs in cancer. </plain></SENT>
<SENT sid="927" pm="."><plain>(A): LncRNA, CCAT1-L, interacts with the chromatin binding factor, CTCF. </plain></SENT>
<SENT sid="928" pm="."><plain>CCAT1-L is transcribed upstream of the oncogene MYC enhancer region, promotes chromosome looping that brings into proximity the super enhancer to the MYC promoter and induces enhanced transcription of MYC in colorectal cancer. </plain></SENT>
<SENT sid="929" pm="."><plain>(B): LncRNAs (XIST, HOTAIR, HOTTIP) compete with the binding of miRNA target genes. </plain></SENT>
<SENT sid="930" pm="."><plain>Each color corresponds to a lncRNA-oncogene-miRNA interaction. </plain></SENT>
<SENT sid="931" pm="."><plain>Tumor suppressor miRNAs cannot bind to their target oncogenes because they are sequestered by lncRNAs. </plain></SENT>
<SENT sid="932" pm="."><plain>(C): PANDA antisense transcription is induced by p53, counteracts CDKN1 inhibitory effect on the cell cycle and decoys the transcription factor NF-YA. </plain></SENT>
<SENT sid="933" pm="."><plain>The latter cannot bind anymore to the promoter of apoptotic activators such as APAF1, BIK, FAS. </plain></SENT>
<SENT sid="934" pm="."><plain>(TSS: transcriptional start site). </plain></SENT>
<SENT sid="935" pm="."><plain>(D): CDR1 decoys the tumor suppressor miR-7, which cannot bind to its oncogene targets. </plain></SENT>
<SENT sid="936" pm="."><plain>miR-671 cleaves CDR1 and alleviates miR-7 decoying. </plain></SENT>
<SENT sid="937" pm="."><plain>The latter is now able to suppress its targets. </plain></SENT>
<SENT sid="938" pm="."><plain>(E): Circ-Foxo3 forms a ternary complex with two cell cycle regulatory proteins, p21 and CDK2 to block the cell cycle progression. </plain></SENT>
<SENT sid="939" pm="."><plain>Foxo3 and circ-Foxo3 in a breast cancer cell line decreased cell proliferation and induced extensive cell death due to apoptosis in tumors formed by the same cell line in nude mice. </plain></SENT>
<SENT sid="940" pm="."><plain>(F): Chromosomal translocations of the oncogenes MLL/AF9 in AML produce the fusion of the due oncogenes to form fusion (f)-circM9 and a fusion protein. </plain></SENT>
<SENT sid="941" pm="."><plain>Both, f-circM9 together with the f-protein induced leukemia in vivo and resistance to chemotherapy. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-19-02072-g002"/></fig></SecTag><SecTag type="FIG"><fig id="ijms-19-02072-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="942" pm="."><plain>Disruption of ncRNA Networks in Cancer. </plain></SENT>
<SENT sid="943" pm="."><plain>(A): miRNA editing: in glioblastoma, ADAR2 edit the precursors of miR-222/221 and miR-21 and decrease expression of the corresponding oncomiRs in vitro and in vivo, (B): Epigenetic regulation: Methylation and deacetylation of miR-127 promoter suppresses expression of the tumor suppressor miRNA. </plain></SENT>
<SENT sid="944" pm="."><plain>Consequently, BCL6 oncogene expression increases. </plain></SENT>
<SENT sid="945" pm="."><plain>(C): Uridylation of miRNA and lncRNA: the enzyme TUTase adds Uridine groups at the 3′-end of pre-let-7 and the lncRNA Rmrp. </plain></SENT>
<SENT sid="946" pm="."><plain>Degradation of oligo-Uridine tails through the exonuclease Dis3L2 unified in the DMD pathway may explain the reduced expression of let-7 and other tumor suppressor miRNAs as well as lncRNAs deregulation in cancer. </plain></SENT>
<SENT sid="947" pm="."><plain>(D): 3′UTR regulatory sequences, ARES: ARES interact with micro-ribonucleoproteins (microRNPs) such as AGO2 as a complex with other proteins to regulate the stability and translation of mRNAs in response to external or internal stimuli. </plain></SENT>
<SENT sid="948" pm="."><plain>miR-369-3 binds ARES, AGO2 and fragile X mental retardation-related protein 1 (FXR1) complex to induce translation of TNFα, in serum starved HEK293 and HeLa cell lines. </plain></SENT>
<SENT sid="949" pm="."><plain>When cells start to proliferate, miR-369-3 inhibits TNFα. </plain></SENT>
<SENT sid="950" pm="."><plain>(E): RBPs of 3′UTR, Pumilio: Bladder carcinomas selectively down-regulate miRNAs that cooperate with Pumilio to target E2F3, and multiple tumor cell lines shorten the 3′-end of the E2F3 mRNA, removing the Pumilio regulatory elements. </plain></SENT>
<SENT sid="951" pm="."><plain>(F): 3′UTR alterations SNPs: A somatic SNP in the 3′UTR of the oncogene MDM4 created a new binding site for miR-191. </plain></SENT>
<SENT sid="952" pm="."><plain>This miRNA suppressed only the oncogene MDM4-C allelic variant expression and retarded ovarian cancer progression and the tumor became chemosensitive. </plain></SENT>
<SENT sid="953" pm="."><plain>(G): LncRNA modifications: (1) Methylation: tumor suppressor, lncRNA MEG3, has binding sites for onco-miR-9, so that it does not bind its targets, FOXO1 and E-cadherin, in ESCC human cell lines. </plain></SENT>
<SENT sid="954" pm="."><plain>Promoter of lncRNA MEG3 is usually methylated in ESCC and cannot sequester miR-9 and this induces to proliferation of cancer cells. </plain></SENT>
<SENT sid="955" pm="."><plain>(2) SNPs: lncRNA PTENP1 polymorphism rs7853346 in GC, change the local folding structure of lncRNAPTENP1. </plain></SENT>
<SENT sid="956" pm="."><plain>The latter is not able to exert its decoying effect on miR-106b and miR-93, with a consequent reduction of the tumor suppressor PTEN gene expression. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-19-02072-g003"/></fig></SecTag></floats-group></article>
